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STELLINGEN BEHORENDE BIJ HET PROEFSCHRIFT: 
Integration of Multi-Omics in Type 2 Diabetes and Related 
Disorders Research
1. DNA differential methylation explains at least 16.9% of the association between obesity and 
insulin. (this thesis)
2. Among the low risk populations, a multi-metabolite risk prediction model predicts future 
type 2 diabetes better than fasting glucose. (this thesis)
3. Large high-density-lipoprotein (HDL) particles and small HDL particles have distinct causal 
associations with glucose. (this thesis)
4. The blood pressure-related phosphatidylethanolamines (PE) 38:3, PE 38:4 and 
Phosphatidylcholines (PC) 40:5 are under control of fatty acid desaturase pathways which 
links them to lipoproteins, blood cell counts (white, red and platelet) and pulse rate. (this 
thesis)
5. The metabolic atlas shows a link between proton pump inhibitors, the gut microbiome, 
circulating metabolites and liver function. (this thesis)
6. Omics studies, by their nature, rely on large numbers of comparisons, tailored statistical 
analyses, and a considerable investment of time, skilled manpower, and money. (Hasin, et 
al., Genome Biology, 2017)
7. It is important to understand which “at-risk” individuals are most likely to progress to overt 
disease. (Wang, et al., Nat Med, 2011)
8. The tens of thousands of small molecules circulating in the blood can reflect many causal 
chains of events between genes, traits, and critically, the environment. (Edward Lau, et al., 
Circulation Research, 2018)
9. The focus of metabolomic studies is shifting from cataloguing chemical structures to finding 
biological stories. (Baker M., Nat Methods, 2011)
10. It is now possible to define metabolic signatures of drug exposure that can identify 
pathways involved in both drug efficacy and adverse drug reactions. (Kaddurah-Daouk, et 
al., Clin Pharmacol Ther, 2014)
11. A man should look for what is, and not for what he thinks should be. (Albert Einstein) 
                                                                                                                           Jun Liu
17 January, 2020
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Abstract 
Despite existing reports on differential DNA methylation in type 2 diabetes (T2D) and 
obesity, our understanding of its functional relevance remains limited. Here we show the 
effect of differential methylation in the early phases of T2D pathology by a blood-based 
epigenome-wide association study of 4,808 non-diabetic Europeans in the discovery phase 
and 11,750 individuals in the replication. We identify CpGs in LETM1, RBM20, IRS2, MAN2A2
and the 1q25.3 region associated with fasting insulin, and in FCRL6, SLAMF1, APOBEC3H and 
the 15q26.1 region with fasting glucose. In silico cross-omics analyses highlight the role of 
differential methylation in the crosstalk between the adaptive immune system and glucose 
homeostasis. The differential methylation explains at least 16.9% of the association 
between obesity and insulin. Our study sheds light on the biological interactions between 
genetic variants driving differential methylation and gene expression in the early 
pathogenesis of T2D.  
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Introduction 
Type 2 diabetes (T2D) is a common metabolic disease, characterized by 
disturbances in glucose and insulin metabolism. The pathogenesis of T2D is driven by 
inherited and environmental factors1. There is increasing interest in differential DNA 
methylation in the development of T2D as well as with glucose and insulin metabolism2, 3, 4, 
5, 6. Depending on the region, DNA methylation may result in gene silencing and thus 
regulate gene expression and subsequent cellular functions7. Differential methylation in the 
circulation may predict the development of future T2D beyond traditional risk factors such 
as age and obesity3, 8, but it may also be part of the biological mechanism that links age 
and/or obesity to glucose, insulin metabolism and/or T2D. A recent longitudinal study with 
multiple visits reported that most DNA methylation changes occur 80–90 days before 
detectable glucose elevation9, suggesting that differential DNA methylation evokes changes 
in glucose and is involved in the early stage(s) of diabetes. Differential DNA methylation is 
further associated with obesity, which is an important driver of the T2D risk and also 
precedes the increase in glucose and insulin level in persons developing T2D8. A key 
question to answer is whether the differential methylation associated with glucose and 
insulin metabolism is an irrelevant epiphenomenon that is related to obesity acting as a 
statistical confounder or whether there are functional effects of the differential methylation 
relevant of obesity that is associated to metabolic pathology.  
Here, we determine the relation of differential DNA methylation and fasting 
glucose and insulin metabolism as markers of early stages of diabetes pathology in non-
diabetic subjects, accounting for obesity measured as body mass index (BMI). We identify 
and replicate nine CpG sites associated with fasting glucose (in FCRL6, SLAMF1, APOBEC3H
and the 15q26.1 region) and insulin (in LETM1, RBM20, IRS2, MAN2A2 and the 1q25.3 
region). Using cross-omics analyses, we present in silico evidence supporting the functional 
relevance of the CpG sites on the development and progression of diabetes, in terms of 
their effect on expression paths and elucidate the genetic networks involved.  
Results 
Epigenome-wide association analysis and replication 
In the discovery phase, we performed a blood-based epigenome-wide association 
study (EWAS) meta-analysis of four cohorts including 4,808 non-diabetic individuals of 
European ancestry (Supplementary Data 1), which revealed differential DNA methylation at 
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28 unique CpG sites in either the baseline model without BMI adjustment or in the second 
model with BMI adjustment (Table 1 and Supplementary Table 1). The summary statistic 
results of the EWAS are provided as a Source Data file. These include three CpG sites 
associated with both insulin and glucose, eight CpG sites associated with fasting glucose 
only and 17 with fasting insulin (P-value < 1.3 × 10-7 in meta-analysis). Of these 28 CpG sites, 
13 were identified by earlier EWAS studies of either T2D or related traits, including glucose, 
insulin, hemoglobin A1c (HbA1c), and homeostatic model assessment-insulin resistance 
(HOMA-IR)2, 3, 4, 5, 8, 10, 11 (Supplementary Table 1). The known CpG sites include three sites 
located in SLC7A11, CPT1A and SREBF1 that are associated with both glucose and insulin. 
The remaining ten CpG sites, located in DHCR24, CPT1A, RNF145, ASAM, KDM2B, MYO5C,
TMEM49, ABCG1 (harboring two CpG sites) and the 4p15.33 region, are associated with 
insulin only. All of the previously reported CpG sites with glycemic traits are also associated 
with BMI in previous EWAS8, 10, 12, 13, 14, 15 (Supplementary Table 1).  
The 15 novel CpG sites were tested using the same statistical models in 11 
independent cohorts including 11,750 non-diabetic participants from the Cohorts for Heart 
and Aging Research in Genomic Epidemiology (CHARGE) consortium (Supplementary Data 
1). Nine unique CpG-trait associations were replicated when correcting for multiple testing 
using Bonferroni (15 tests, P-value threshold for significance < 3.3 × 10-3) and were 
investigated in the further analyses (Table 2). These include five sites (in LETM1, RBM20, 
IRS2, MAN2A2 and the 1q25.3 region) associated with fasting insulin and one site (in FCRL6) 
associated with fasting glucose in the baseline model without adjusting for BMI, and three 
(in SLAMF1, APOBEC3H and the 15q26.1 region, all associated with fasting glucose) 
emerging in the BMI-adjusted model. Of note, no locus was found to be associated with 
fasting insulin in the BMI-adjusted model. 
Because the replication cohorts also included individuals of African ancestry (AA, n 
= 4,355) and Hispanic ancestry (HA, n = 577), we also performed the replication stratified 
by ancestry (Supplementary Data 2). Two CpG sites (cg13222915 and cg18247172) were 
replicated in the AA population when corrected by the number of tests and two 
(cg00936728 and cg06229674) replicated with nominal significance. In the HA population, 
cg20507228 was replicated at nominal significance. Two CpG sites (cg18881723 and 
cg13222915) show the opposite direction for the effect estimate in HA ancestry population 
as compared to the other two populations. However, the estimates of effect size are not 
significantly different from zero (P-value = 0.63 in cg18881723 and P-value = 0.092 in 
cg13222915).  
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Glycemic differential DNA methylation and transcriptomics 
To determine whether the differential DNA methylation has functional effects on 
gene expression and subsequent cellular functions, we conducted three series of analyses. 
Figure 1 shows the overview of the cross-omics analyses. First, we explored the Genotype-
Tissue Expression (GTEx)16 database for the expression levels of the genes which annotated 
to the novel CpG sites. We found that the genes are expressed in a wide range of tissues, 
including whole blood and spleen (in particular MAN2A2 and RBM20), but also other tissues 
relevant for glucose and insulin metabolism such as adipose subcutaneous, adipose visceral 
omentum, liver (in particular SLAMF1, APOBEC3H, FCRL6 and RBM20), pancreas and 
skeletal muscle (in particular SLAMF1, APOBEC3H, FCRL6 and MAN2A2) and small intestine 
terminal ileum (in particular MAN2A2, RBM20, FCRL6 and APOBEC3H; Supplementary 
Figure 1). 
Table1 CpG sites associated with glycemic traits in discovery phase. 
Novel epigenome-wide significant results in the discovery phase (n = 4,808) are shown. ǂ Significant results (P-value 
< 1.3 × 10-7). Model 1 (M1) indicates inverse variance-weighted fixed effect meta-analysis of effect estimates in four 
cohorts. Each cohort performed a regression model adjusting for age, sex, technical covariates, white blood cell, 
and smoking status, and accounting for family structure in family-based cohorts. Model 2 (M2) indicates the meta-
analysis of the same studies, adjusting for body mass index (BMI) additionally. Locus: the cytogenetic location or 
the gene symbol of the CpG sites from Illumina annotation. Beta: effect estimate of the meta-analysis. P-value 
shown is genomic controlled after meta-analysis. The effect refers to the increase/ decrease in fasting glucose/ 
insulin as the outcome in the model. 
Locus CpG Chr: Pos Trait BetaM1 P-valueM1 BetaM2 P-valueM2
FCRL6 cg00936728 1:159772194 Glucose -1.79 9.1 × 10-8ǂ -1.60 1.9 × 10-7
SLAMF1 cg18881723 1: 160616870 Glucose 1.16 7.5 × 10-8ǂ 1.25 3.4 × 10-10ǂ
1q25.3 cg13222915 1: 184598594 Insulin -1.69 2.6 × 10-9ǂ -1.06 4.1 × 10-6
BRE cg20657709 2: 28509570 Glucose -1.42 2.7 × 10-6 -1.53 4.1 × 10-8ǂ
LRPPRC cg01913188 2: 44223249 Glucose 1.18 9.4 × 10-6 1.38 5.7 × 10-9ǂ
IRAK2 cg14527942 3: 10276383 Insulin 2.44 3.4 × 10-10ǂ 2.14 2.9 × 10-11ǂ
LETM1 cg13729116 4: 1859262 Insulin 2.38 4.3 × 10-8ǂ 1.64 4.5 × 10-6
RBM20 cg15880704 10: 112546110 Insulin 2.50 3.8 × 10-9ǂ 1.38 6.7 × 10-5
IRS2 cg25924746 13: 110432935 Insulin 2.11 3.0 × 10-9ǂ 1.32 4.9 × 10-6
SPTB cg07119168 14: 65225253 Glucose -1.64 4.4 × 10-7 -1.63 4.9 × 10-8ǂ
15q26.1 cg18247172 15: 91370233 Glucose -1.05 4.9 × 10-6 -1.18 2.8 × 10-8ǂ
MAN2A2 cg20507228 15: 91460071 Insulin 1.18 5.5 × 10-8ǂ 0.87 9.0 × 10-7
FAM92B cg06709610 16: 85143924 Insulin 6.22 6.5 × 10-9ǂ 6.30 5.8 × 10-13ǂ
CD300A cg08087047 17: 72461209 Glucose -1.35 5.9 × 10-6 -1.45 1.1 × 10-7ǂ
APOBEC3H cg06229674 22: 39492189 Glucose -1.62 1.8 × 10-6 -1.70 4.7 × 10-8ǂ
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Table2 CpG sites associated with glycemic traits in replication.
Novel epigenome-wide significant results in the replication (n = 11,750) are shown. ǂ Significant results (P-value < 
3.3 × 10-3). Replication was not performed in the non-significant associated model or trait (NP). Model 1 (M1) 
indicates inverse variance-weighted fixed effect meta-analysis of effect estimates in 11 cohorts. Each study 
performed a regression model adjusting for age, sex, technical covariates, white blood cell, and smoking status, 
and accounting for family structure in family-based cohorts. Model 2 (M2) indicates the meta-analysis of the same 
studies, adjusting for body mass index (BMI) additionally. Locus: the cytogenetic location or the gene symbol of 
the CpG sites from Illumina annotation. Beta: effect estimate of the meta-analysis. The effect refers to the 
increase/ decrease in methylation as the outcome in the model. 
Locus CpG Chr: Pos Trait BetaM1 P-valueM1 BetaM2 P-valueM2
FCRL6 cg00936728 1:159772194 Glucose 
-1.55 × 
10-3
9.6 × 10-5ǂ NP NP 
SLAMF1 cg18881723 1: 160616870 Glucose 
1.17 × 
10-3
7.7 × 10-3
1.48 × 
10-3
1.2 × 10-3ǂ
1q25.3 cg13222915 1: 184598594 Insulin 
-3.77 × 
10-3
3.3 × 10-16ǂ NP NP 
BRE cg20657709 2: 28509570 Glucose NP NP 
-9.40 × 
10-4
0.036 
LRPPRC cg01913188 2: 44223249 Glucose NP NP 
1.64 × 
10-5
0.90 
IRAK2 cg14527942 3: 10276383 Insulin 
-6.49 × 
10-5
0.48 
-7.72 × 
10-5
0.45 
LETM1 cg13729116 4: 1859262 Insulin 
1.92 × 
10-3
7.0 × 10-7ǂ NP NP 
RBM20 cg15880704 
10: 
112546110 
Insulin 
3.05 × 
10-3
8.6 × 10-12ǂ NP NP 
IRS2 cg25924746 
13: 
110432935 
Insulin 
3.38 × 
10-3
3.0 × 10-11ǂ NP NP 
SPTB cg07119168 14: 65225253 Glucose NP NP 
-7.18 × 
10-4
0.070 
15q26.1 cg18247172 15: 91370233 Glucose NP NP 
-1.77 × 
10-3
5.1 × 10-4ǂ
MAN2A2 cg20507228 15: 91460071 Insulin 
6.11 × 
10-3
2.3 × 10-15ǂ NP NP 
FAM92B cg06709610 16: 85143924 Insulin 
2.08 × 
10-5
0.81 
5.37 × 
10-5
0.59 
CD300A cg08087047 17: 72461209 Glucose NP NP 
-4.92 × 
10-4
0.28 
APOBEC3H cg06229674 22: 39492189 Glucose NP NP 
-2.09 × 
10-3
1.4 × 10-6ǂ
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Figure 1 Overview of the cross-omics analysis. 1. Methylation quantitative trait loci (meQTL). 2. Expression 
quantitative trait loci (eQTL). 3. Expression quantitative trait methylation (eQTM). 4. Epigenome-wide association 
study (EWAS) and Mendelian randomization (MR). 5. Genome-wide association study (GWAS). 6. The association 
of gene expression expressed in the glucose or insulin metabolism related tissues and glycemic traits. Results in 1, 
2, 3 were extracted from the summary statistics from Biobank-based Integrative Omics Study (BIOS) database (n = 
3,814). Results in 4 was the results in the current EWAS (discovery phase, n = 4,808, replication phase, n = 11,750) 
and the two-sample Mendelian randomization based on the BIOS database (n = 3,814) and GWAS results of Meta-
Analyses of Glucose and Insulin-related traits Consortium (MAGIC). Results in 5 was from the GWAS results of 
MAGIC or the DIAbetes Genetics Replication And Meta-analysis consortium (DIAGRAM, n = 96,496 ~ 452,244). 
Results in 6 was based on the summary statistics of Genotype-Tissue Expression project (GTEx) and MAGIC or 
DIAGRAM (n = 153 ~ 491).
 Second, the effect on gene expression in blood of the previously identified 11 
independent CpG sites (cg00574958 in CPT1A and cg06500161 in ABCG1 were used) and 
the nine novel sites from our current study was examined in the Biobank-based Integrative 
Omics Study (BIOS) database that is part of the Biobanking and BioMolecular Infrastructure 
of the Netherlands (BBMRI-NL)17 (indicated in Figure 2 in the orange boxes). We found that 
five CpG sites, i.e. cg00936728 (FCRL6), cg18881723 (SLAMF1), cg00574958 (CPT1A), 
cg11024682 (SREBF1) and cg06500161 (ABCG1), are expression quantitative trait 
methylations (eQTMs), i.e. there is correlation between gene expression and methylation18. 
In most cases, the differential methylation levels are associated with the expression 
(indicated in Figure 2 in the yellow boxes) of their respective genes. Cg18881723 (SLAMF1)
is also associated with the expression of two other genes near SLAMF1, i.e. SLAMF7 and
CD244 (Supplementary Table 2).  
Third, we investigated whether the genetically regulated expression of the 
annotated genes in specific tissues is altered in T2D or related traits, such as glucose, insulin 
and HbA1c. To answer this question, we mined in the MetaXcan database for genome-wide 
association studies (GWAS) of T2D, fasting glucose, HbA1c, insulin and HOMA-IR19, 20, 21, 22, 23
as a genetic proxy for the traits24. No association was found between glycemic traits and the 
DNA expression in adipose subcutaneous, adipose visceral omentum and small intestine 
terminal ileum. Supplementary Table 3 gives the significant findings for tissues known to be 
implicated in glucose and insulin metabolism including blood, liver, pancreas and skeletal 
muscle (P-value < 0.05 for MetaXcan). As described earlier, we associated the increased 
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expression of SREBF1 with decreased risk of T2D and decreased HbA1c levels in the whole 
blood25. The increased expression in the whole blood of ABOBEC3H, a methylation locus we 
identified in the present study, is associated with increased HOMA-IR level, a measure of 
insulin resistance. In skeletal muscle, the increased fasting glucose is associated with the 
increased expression of KDM2B and decreased expression of MAN2A2. Moreover, we 
discovered that increased hepatic expression of FCRL6, which was annotated to the 
methylation locus associated with fasting glucose in the present study, is associated with 
the risk of T2D. In the pancreas, the increased expression of the methylation loci MYO5C
and RBM20 are associated with increased fasting glucose levels. 
Figure 2 Significant associations of the cross-omics integration. The effect allele is standardized across all 
associations. Only the significant associations which passed the specific P-value threshold in each association step 
and the direction of effects consistent were shown in the figure. FG: fasting glucose. FI: fasting insulin. T2D: type 2 
diabetes. HbA1c: hemoglobin A1c. 
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Glycemic differential DNA methylation and genomics 
Although differential DNA methylation may be the result of environmental 
exposures, the process is often (partly) heritable with genetic variants (co-)determining the 
process26. Therefore, we next set out to find whether the differential methylation 
associated with fasting glucose and insulin levels is driven by genetic variants which referred 
to as methylation quantitative trait loci (meQTLs). Using the BIOS database (blood-based 
data)17, we were able to study 18 out of the 20 unique CpG sites in this respect. We 
associated 2,991 single-nucleotide polymorphisms (SNPs) in 29 unique meQTLs (indicated 
in Figure 2 in the blue boxes) with differential methylation either in cis or trans (for details 
see Supplementary Data 3). Six of these meQTLs (4 cis and 2 trans-acting) are also associated 
with T2D, fasting glucose, fasting Insulin, or HbA1c in earlier studies21, 22, 27, 28, 29, and the 
directions of the effect between the SNP, methylation and glycemic traits are consistent 
(shown in Figure 2 in the pink boxes, for details see Supplementary Table 4). A genetic locus 
near TMEM61 is a common genetic driver affecting the differential methylation at nearby 
CpG cg17901584 (DHCR24) in our study and fasting glucose levels in an earlier study22. 
Further, the RNF145 locus was found to be a common driver affecting the differential 
methylation at cg26403843 (RNF145) and fasting insulin levels21. The KDM2B locus affects 
differential methylation at cg13708645 (KDM2B) and fasting glucose levels22, and the 
TOM1L2/RAI1 locus affects the differential methylation at cg11024682 (SREBF1) as well as 
HbA1c and T2D27, 28. Two trans-acting loci involve a genetic locus in CCDC162P that is 
affecting differential methylation at cg20507228 (MAN2A2) and HbA1c27 and the genetic 
locus in RP11-16L9.4 affecting the differential methylation at cg11024682 (SREBF1) and 
HbA1c27.  
We next explored if these genetic variants associated with differential methylation 
(meQTLs) are also associated with gene expression, i.e. quantitative trait loci (eQTLs; see 
the integrated outline of analyses in Figure 2 and detailed in Supplementary Table 5). We 
searched specifically for expression profiles earlier associated with glycemic CpG sites in 
blood (listed in Supplementary Table 2). We associated three genetic variants with both 
differential methylation and gene expression in blood. These include that: 1) rs11265282 in 
FCRL6 is positively associated with the differential methylation at cg00936728 (FCRL6) and 
decreased the expression of FCRL6 in blood, 2) rs1577544 near SLAMF1 is associated with 
decreased differential methylation at cg18881723 (SLAMF1) and decreased SLAMF1
expression in blood, and 3) rs6502629 in TOM1L2 is associated with increased differential 
methylation at cg11024682 (SREBF1) and decreased SREBF1 expression in blood.  
As we observed that the genes driving glycemic CpG sites overlapped with genetic 
determinants of T2D or related traits, we studied the causal effect of differential 
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methylation on glucose and insulin metabolism with a generalized summary statistic-based 
Mendelian randomization (MR) test30. Up to eight independent genetic variants include in 
the genetic risk score were used as the instrumental variable for each CpG. Thirteen CpG 
sites out of the initial 20 met the present MR criteria and were tested by MR (Supplementary 
Data 4). No significant association was detected when adjusting for multiple testing 
accounting for 13 independent tests (P-value threshold for significance < 3.8 × 10-3). The 
genetic risk score for cg15880704 (RBM20) methylation levels is nominally significantly 
associated with fasting insulin levels (P-value = 0.04), and the genetic risk score for 
cg18881723 (SLAMF1) levels is nominally associated with fasting glucose levels (P-value = 
0.05) in the MR tests.  
Multi-omics integration and functional annotation  
To understand the biological relevance of our findings, we first integrated the 
cascade of associations into genomics, epigenomics, transcriptomics and glycemic traits 
through EWAS, eQTM, meQTL and eQTL. There are three pathways emerging when 
considering the consistency of the direction of the effects between the associations. One 
pathway involves SREBF1 which in part was reported earlier3, 25, 31 but substantially 
extended in the current report. The other two involve differential methylation of FCRL6 and 
SLAMF1 (Figure 3). The C allele of rs11265282 in FCRL6 is associated with increased 
methylation, which turns down the FCRL6 expression in blood. In addition, the genetically 
decreased FCRL6 expression in the liver is also associated with a decreased risk of T2D. The 
T allele of rs1577544 near SLAMF1 increases the differential methylation levels in the blood, 
which decreases SLAMF1 expression in the circulation, consistent with the negative 
association between the genetic variant and gene expression levels.  
To understand the correlation of the findings, we clustered the normalized 
differential methylation values of the nine novel CpG sites including those not annotated to 
a gene. Two clusters emerge, one including IRS2, MAN2A2, 1q25.3 locus (intergenic), 
RBM20, LETM1 and SLAMF1 and the second one including FCRL6, 15q26.1 (intergenic) and 
APOBEC3H (Figure 4 and Supplementary Table 6). Four CpGs in FCRL6, 15q26.1 (intergenic), 
APOBEC3H and SLAMF1 are highly correlated with each other, in which the absolute 
correlation coefficients are bigger than 0.6, while they are located in different 
chromosomes, suggesting a common biological mechanism: SLAMF1 and FCRL6 from 
chromosome 1, APOBEC3H from chromosome 22 and 15q26.1 from chromosome 15. We 
next performed gene set enrichment analysis in different pathway databases, including 
KEGG pathways32, Reactome Pathway Knowledgebase33 and Gene Ontology (GO) biological 
process classification34. We found that the genes in the first cluster are highly enriched 
together in multiple pathways, including regulation of leukocyte proliferation, protein 
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secretion and cell activation (SLAMF1 and IRS2), hexose, monosaccharide and carbohydrate 
metabolism (IRS2 and MAN2A2). Further, SLAMF1 (cluster 1) and APOBEC3H (cluster 2) are 
both enriched in immune effector processes and innate immune response (Supplementary 
Table 7).  
Figure 3 The cross-omics integration of CpGs in SREBF1 (a), FCRL6 (b) and SLAMF1 (c). Cascading associations 
cross multi-omics were integrated in the network. * The association happens in the FCRL6 expression in liver. All 
other differential methylation or gene expression was measured in blood. FG: fasting glucose. FI: fasting insulin. 
T2D: type 2 diabetes. HbA1c: hemoglobin A1c.
BMI in the association of methylation and glycemic traits  
Of note, among the 20 methylation loci associated with glycemic metabolism in the 
present analyses, 11 are associated with BMI in the previous EWAS8, 10, 12, 13, 14, 15. These 11 
loci are all associated with insulin metabolism (Supplementary Table 1). Based on the bi-
direction MR findings performed as part of the previous EWAS of BMI8, we found that BMI 
appears to drive methylation for cg06500161 (ABCG1, P-value = 6.4 × 10-5), a CpG that we 
associated with insulin levels. Using a marginal P-value of 0.05 in their MR results, the 
differential methylation appears to be a consequence of obesity rather than a cause for 
three other CpG sites: cg110244682 (SREBF1; P-value = 4.1 × 10-3), cg17901584 (DHCR24; P-
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value = 4.1 × 10-3) and cg26403843 (RNF145; P-value = 0.011)8. Taken together 
(Supplementary Table 1), our results raise the question whether BMI is driving differential 
methylation, which subsequently raises insulin level in the circulation. Such a pathway 
would predict that the association between BMI and insulin changes when adjusting for 
differential methylation at ABCG1, SREBF1, DHCR24 and RNF145. We tested this hypothesis 
in the non-diabetic individuals of the Rotterdam Study by comparing the relationship 
between BMI and fasting insulin with and without adjusting for the methylation levels at 
the four CpG sites. The variance explained (R2) by the linear regression model improves 
significantly from 0.40 to 0.43 (P-value = 1.2 × 10-13 by analysis of variance (ANOVA) testing) 
when adjusting for the CpG effect, while the effect estimates for BMI decrease by 9.2% 
(beta: 0.065, standard error (SE): 0.003, P-value = 1.2 × 10-82 for the model without CpG 
adjustment compared to beta: 0.059, SE: 0.003, P-value = 2.9 × 10-70 adjusting for the four 
CpGs). When we extended the adjustment to the 16 independent CpG sites associated with 
circulating insulin levels, the variance explained by the model improves further (R2=0.46, P-
value = 2.1 × 10-18) and the beta for BMI reduces further by 16.9% (beta: 0.054, SE: 0.003, 
P-value = 4.6 × 10-58 for the model adjusting for 16 CpG sites). 
Figure 4 Clustered correlation of the nine novel glycemic CpGs. The correlation of the novel CpG sites was checked 
by Pearson's correlation test (n = 1,544). The hierarchical cluster analysis was used in the clustering.
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Discussion 
The current large-scale EWAS identify and replicate nine CpG sites associated with 
fasting glucose (in FCRL6, SLAMF1, APOBEC3H and the 15q26.1 region) or insulin (in LETM1,
RBM20, IRS2, MAN2A2 and the 1q25.3 region). When we adjust for BMI as a potential 
confounder, three CpG sites (in SLAMF1, APOBEC3H and the 15q26.1 region) are associated 
with fasting glucose only after adjustment for BMI. We validate 13 previously reported CpG 
sites from 11 independent genetic loci2, 3, 4, 5, 6, 8, 10, 12, 13, 14, 15 and complement the 
understanding on why these CpG sites are associated with T2D and/or glycemic traits based 
on comprehensive cross-omics analyses. We present in silico evidence supporting the 
functional relevance of the CpG sites, in terms of their effect on expression paths and 
elucidate the genetic networks involved.
Our data shows that differential methylation plays a key role in understanding the 
immunological changes observed in glucose metabolism35. SLAMF1 and APOBC3H are both 
enriched in immune function and the innate immune response. The differential methylation 
level at FCRL6, 15q26.1 (intergenic), APOBEC3H and SLAMF1 were highly correlated though 
they on three different chromosomes. This finding suggests a common pathway. SLAMF1 
belongs to the immunoglobulin gene superfamily and is involved in T-cell stimulation36. 
APOBEC3H proteins are part of an intrinsic immune defense that has potent activity against 
a variety of retroelements36 and its expression in whole blood is positively associated with 
HOMA-IR from the current study. FCRL6 is a distinct indicator of cytotoxic effector T-
lymphocytes that is upregulated in diseases characterized by chronic immune stimulation36. 
Meanwhile, we show that decreased FCRL6 differential methylation increased expression 
of FCRL6 and fasting glucose in the blood. A key finding that links FCRL6 to glucose 
metabolism is that the genetically determined FCRL6 expression in the liver is also 
associated with decreased risk of T2D. In line with a role in immune relation and pathology37, 
38, the HLA region (6p22.1 region) is a key meQTLs of FCRL6 (rs2523946), 15q26.1 
(rs3129055 and rs4324798) and SLAMF1 (rs3129055). Of interest is that in the population 
of non-diabetic individuals, we found strong signals of the immune system particularly when 
we adjust the effects attributed to BMI. Remarkably, three out of the four methylation loci 
at SLAMF1, APOBEC3H and the 15q26.1 region emerged in the BMI-adjusted model, 
suggesting that these associations were masked by confounding noise of BMI on 
methylation in opposite effects to that of insulin.  
We studied the interplay between BMI, fasting glucose and insulin levels and 
differential methylation in the circulation. On the one hand, we find evidence that the 
differential methylation of the insulin-related CpG sites together explained up to 16.9% of 
the association between obesity and insulin levels. These findings are in line with the Nature 
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paper on the EWAS of BMI that found that the methylation patterns in blood predict future 
diabetes8. Our study reveals that insulin is a key player underlying the association reported 
earlier8. On the other hand, we find evidence that the association between differential 
methylation and insulin metabolism is attenuated up to 62%, e.g. CpG sites in SREBF1 (62%), 
ASAM (56%), CPT1A (54%) and TMEM49 (52%), when BMI is accounted for in the model, 
suggesting that the interplay between BMI, differential methylation and insulin metabolism 
is extremely complex and differs across CpG sites. BMI may be a confounder of associations 
for some CpGs but may be in the causal pathway for others.  
To our knowledge, we report for the first time that in blood, differential 
methylation of IRS2 was associated with fasting insulin level. Expression level of IRS2 (insulin 
receptor substrate 2) in β-cells in the pancreas are associated with the onset of diabetes39, 
40, 41. Though the expression level of IRS2 is low in blood, we find its blood-based differential 
methylation was associated with fasting insulin. We also find an insulin-related genetic locus, 
MAN2A2 (mannosidase alpha class 2A member 2) in our EWAS. MAN2A2 encodes an 
enzyme that forms intermediate asparagine-linked carbohydrates (N-glycans)42. It is related 
to the hexose/monosaccharide metabolism. In addition, the expression of MAN2A2 in 
skeletal muscle is negatively associated with fasting glucose level and the meQTL 
(rs9374080) of MAN2A2 associates with HbA1c27. Together, these findings suggest that 
regulating the differential methylation level or expression level of MAN2A2 may be relevant 
to the development of insulin resistance. Another interesting gene that emerged is the 
familial cardiomyopathy related gene RBM20, which may play a role in cardiovascular 
complications of diabetes via mediating insulin damage in cardiac tissues43. The expression 
of RBM20 in the pancreas is also associated with fasting glucose. The meQTL for RBM20 is 
associated with pulse rate (P-value = 4.6 × 10-5) in UKBIOBANK GWAS44, and its mRNA is 
highly expressed in cardiac tissues45.  
One limitation of our study is that the main findings are based on data from blood 
which was the only accessible tissue in our epidemiological studies and may not be 
representative of more disease-relevant tissues. However, the concordance of differential 
methylation between blood and adipose is high for certain pathways46. DNA methylation 
globally is considered a relatively stable epigenetic mark that can be inherited through 
multiple cell divisions47, 48. However, some changes can be dynamic reflected by recent 
environmental exposures. This phenomenon could be site-specific. While our study 
provides a snapshot of associations specific to the fasting state, instant methylation of 
different CpG sites in the vicinity of IRS2 and KDM2B have been reported earlier49. Such 
effects may also occur at the loci presented in the present study. Our present MR analyses 
yield no evidence for the causal effects of CpG sites on fasting glucose or insulin. One 
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limitation in the interpretation of the findings is that low power of the MR due to the fact 
we lack insight in the genes driving differential methylation. For instance, seven of the 13 
performed CpG sites have instrumental variables which explain less than 5% of the 
exposure. Further studies are needed to include additional biologically relevant tissues and 
perform MR based on the tissue-specific meQLTs. Last but not least, cg19693031 in TXNIP
has been repeatedly associated with type 2 diabetes case-control status earlier3, 50, 51. 
Although it did not pass our predefined EWAS significance threshold, TXNIP is associated 
with fasting glucose in the non-diabetic population (P-value = 7.6 × 10-7 in the BMI 
adjustment model) if we take the current study aiming to replicate earlier findings. Of note 
is that cg19693031 is not associated with fasting insulin (in BMI unadjusted model, p-value 
= 0.30; in the BMI adjusted model, p-value = 0.37). 
In conclusion, our large-scale EWAS and replication identifies nine differentially 
methylated sites associated with fasting glucose or insulin, and shows that differential 
methylation explains part of the association between obesity and insulin metabolism. The 
integrative in silico cross-omics analyses provide insights of glycemic loci into the genetics, 
epigenetics and transcriptomics pathways. We also highlight that differential methylation 
is a key point in the involvement of the adaptive immune system in glucose homeostasis. 
Further studies in the future will benefit from tissue-specific methylation and meQTL 
databases which are currently the missing piece of the in silico data integration framework.  
Methods 
Study population 
The discovery samples consisted of 4,808 European individuals without diabetes 
from four non-overlapped cohorts, recruited by Rotterdam Study III-1 (RS III-1, n = 626), 
Rotterdam Study II-3 and Rotterdam Study III-2 (called as RS-BIOS, n = 705), Netherlands 
Twin Register (NTR, n = 2,753) and UK adult Twin registry (TwinsUK, n = 724). The replication 
sets contained up to 11,750 individuals from 11 independent cohorts from CHARGE, 
including up to 6,818 individuals from European ancestry, 4,355 from African ancestry and 
577 from Hispanic ancestry (Supplementary Data 1). They are from Atherosclerosis Risk in 
Communities (ARIC) Study, Baltimore Longitudinal Study of Aging (BLSA), Cardiovascular 
Health Study (CHS), Framingham Heart Study Cohort (FHS), The Genetic Epidemiology 
Network of Arteriopathy (GENOA), Genetics of Lipid Lowering Drugs and Diet Network 
(GOLDN), Hypertension Genetic Epidemiology Network (HyperGEN), Invecchiare in Chianti 
Study (InCHIANTI), Kooperative Gesundheitsforschung in der Region Augsburg (KORA), 
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Women’s Health Initiative - Broad Agency Award 23 (WHI-BAA23) and Women’s Health 
Initiative - Epigenetic Mechanisms of PM-Mediated CVD (WHI-EMPC). We excluded 
individuals with known diabetes and/or fasting glucose ≥ 7mmol/l and/or those on anti-
diabetic treatment. All studies were approved by their respective Institutional Review 
Boards, and all participants provided written informed consent. Details about the studies 
have been reported previously, and the key references as well as the summary of the design 
of each study are reported in Supplementary Note 1. 
Glycemic traits and covariates 
Venous blood samples were obtained after an overnight fast in all discovery and 
replication cohorts. BMI was calculated as weight over height squared (kg m-2) based on 
clinical examinations. Smoking status was divided into current, former and never, based on 
questionnaires. White blood cell counts were quantified using standard laboratory 
techniques or predicted from methylation data using the Houseman method52. The cohort 
specific measurement of glycemic traits and covariates are shown inSupplementary Note 1. 
DNA methylation quantification 
The Illumina© Human Methylation450 array was used in all discovery and 
replication cohorts to quantify genome-wide DNA methylation in blood samples. We 
obtained DNA methylation levels reported as β values, which represents the cellular 
average methylation level ranging from 0 (fully unmethylated) to 1 (fully methylated). 
Study-specific details regarding DNA methylation quantification, normalization and quality 
control procedures are provided in the Supplementary Note 1. 
Epigenome-wide association analysis and replication 
All statistical analyses were performed using R statistical software and the two-
tailed test was considered. Insulin was natural log transformed. In the discovery analysis, 
we first performed EWAS in each cohort separately. Linear regression analysis was used to 
test the association between glucose and insulin with each CpG site in the Rotterdam Study 
samples. Linear mixed models were used in NTR and TwinsUK accounting for the family 
structure. We fitted two models for each cohort: 1) the baseline model adjusting for age, 
sex, technical covariates (chip array number and position on the array), white blood cell 
counts (lymphocytes, monocytes, and granulocytes) and smoking status, and 2) a second 
model additionally adjusting for BMI. We removed probes that have evidence of multiple 
mapping or contain a genetic variant in the CpG site53. All cohort-specific EWAS results for 
each model were then meta-analysed using inverse variance-weighted fixed effect meta-
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analysis as implemented in the metafor R package54. In total, we meta-analysed 393,183 
CpG sites that passed quality control in all four discovery cohorts. The details of the quality 
control for each cohort could be found in the Supplementary Note 1. The association was 
later corrected by the genomic control factor (λ) in each meta-EWAS55. We produced 
quantile-quantile (QQ) plots of the -log10 (P) to evaluate inflation in the test statistic 
(Supplementary Figure 2). A Bonferroni correction was used to correct for multiple testing 
and identify epigenome-wide significant results (P < 1.3 × 10-7). We did not correct the 
number of glycemic traits and models, as they are highly correlated and not independent. 
The genome coordinates were provided by Illumina (GRCh37/hg19). The CpG sites were 
annotated to genes using Infinium HumanMethylation 450 BeadChip annotation resources. 
The correlation of the CpG sites located in the same gene was further checked in the overall 
RS III-1 and RS-BIOS samples by Pearson's correlation test (n = 1,544) to find the 
independent top CpG sites.  
For the associations discovered in the meta-EWAS that have not been reported 
previously, we attempted replication in independent samples using the same traits and 
regression models as in the discovery analyses. Study-specific details of replication cohorts 
are provided in Supplementary Data 1 and Supplementary Note 1. Results from each 
replication cohort were meta-analysed using the same methods as in the discovery 
analyses. Bonferroni P-value < 3.3 × 10-3 (0.05 corrected by 15 loci tested for associations) 
was considered significant.  
Glycemic differential DNA methylation and transcriptomics 
To explore whether the differential CpG sites were associated with gene expression 
level in blood, we explored eQTMs17 from the European blood-based BIOS database17 from 
BBMRI-NL which captured meQTLs, eQTLs and eQTMs from genome-wide database of 
3,841 Dutch blood samples (See resources of the database in URLs). The associated gene 
expression probes of the known and replicated CpG sites were searched. We then tested 
whether the expression of the genes that harbor the identified methylation sites was 
associated with T2D and related traits in glucose metabolism-related tissues (adipose 
subcutaneous, adipose visceral omentum, liver, whole blood, pancreas, skeletal muscle and 
small intestine terminal ileum) using MetaXcan package24, 56. MetaXcan associates the 
expression of the genes with the phenotype by integrating functional data generated by 
large-scale efforts, e.g. GTEx project16 with that of the GWAS of the trait. MetaXcan is 
trained on transcriptome models in 44 human tissues from GTEx and is able to estimate 
their tissue-specific effect on phenotypes from GWAS. For this study we used the GWAS 
studies of T2D19, fasting glucose traits21, 22, fasting insulin22, HbA1c23 and HOMA-IR20. We 
used the nominal P-value threshold (P-value threshold for significance < 0.05) as we had 
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separate assumptions for each terminal pathway between gene expressions and phenotype. 
The associations with genes in low prediction performance were excluded, i.e. the 
association of the tissue model's correlation to the gene's measured transcriptome is not 
significant (P-value > 0.05).  
Glycemic differential DNA methylation and genomics 
We identified the genetic determinants of the significant CpG sites known or 
replicated through the current EWAS using the results of the cis and trans meQTLs from the 
European blood-based BIOS database17 (See resources of the database in URLs). All the 
reported SNPs with P-value adjusted for false discovery rate (FDR) less than 0.05 in the 
database were treated as the target genetic variants in the present study. The SNPs were 
annotated based on the information in the BIOS study17 or the nearest protein-coding gene 
list from SNPnexus57 on GRCh37/hg19. We also explored the associations of these DNA 
methylation-related genetic variants with T2D or related traits, i.e. fasting glucose, insulin, 
HbA1c and HOMA-IR, based on public GWAS datasets in European ancestry20, 21, 22, 27, 28, 29. 
Meanwhile, we checked the effect direction consistency of the association between the 
SNPs, CpG sites and T2D or related traits. That is the direction of the association between 
SNP and T2D or related traits should be a combination of the direction of SNP with CpG sites 
and CpG sites with T2D or related traits. A multiple-testing correction was performed by 
Bonferroni adjustment (P-value significant threshold < 1.8 × 10-3, 0.05 corrected by the 29 
genetic loci shown in Supplementary Data 3). The associations of the DNA methylation-
related genetic variants and the gene expression were also looked up in the BIOS database17. 
This is limited to the expression profiles earlier associated with glycemic CpG sites in blood.  
For the significant CpG sites known or replicated through EWAS, we attempted to 
evaluate the causality effect of CpG sites on their significant traits, either fasting glucose or 
fasting insulin, using two-sample MR approach as described in detail before by Dastani et 
al30, 58 based on the summary statistic GWAS results from the BIOS database and the Meta-
Analyses of Glucose and Insulin-related traits Consortium (MAGIC) database17, 21
(Supplementary Figure 3). Briefly, we constructed a weighted genetic risk score for 
individual CpG on phenotype using independent SNPs as the instrument variables of the 
CpG, implemented in the R-package gtx. The effect of each score on phenotype was 
calculated as 
 ℎ   =  ∑  (        ) ⁄
∑  (       ⁄ ) 
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, where     is the effect of the CpG-increasing alleles on phenotype, s  its corresponding 
standard error and    the SNP effect on the respective CpG. Because the genetic variants 
might be close (cis) or far (trans) from the methylated site, we also performed MR test in 
the cis only SNPs if the CpG has both cis and trans genetic markers. All SNPs were mapped 
to the human genome build hg19. For each test (one CpG with one trait), we extracted all 
the genetic markers of the CpG in the fasting glucose or insulin GWAS from the MAGIC 
dataset (n = 96,496)21 with their effect estimate and standard error on fasting glucose or 
insulin. Within the overlapped SNPs, we removed SNPs in potential linkage disequilibrium 
(LD, pairwise R2 ≥ 0.05) in 1-Mbp window based on the 1000 Genome imputed genotype 
dataset from the general population: Rotterdam Study I (RS I, n = 6,291)59. We managed to 
exclude the genetic loci which were genome-wide associated with glycemic traits, but none 
of the genetic loci meet this exclusion criterion. The instrumental variables that explain 
more than 1% of the variance in exposure (DNA methylation) were taken forward for MR 
test. The Bonferroni P-value threshold was used to correct for the 13 CpG sites available for 
MR (P-value < 3.8 × 10-3).  
Functional annotation 
Further, we integrated the cascade of associations as above among the results of 
EWAS, eQTM, meQTL and eQTL and showed in Figure 3. We checked the effect direction 
consistency of the association between the SNPs, CpG sites, gene expression in blood and 
glycemic traits. The correlation of the novel CpG sites was checked in the overall RS III-1 and 
RS-BIOS samples by Pearson's correlation test (n = 1,544). The hierarchical cluster analysis 
was used in the clustering. Gene set enrichment analyses were performed in the genes of 
new CpG sites60. We tested if genes of interest were overrepresented in any of the pre-
defined gene sets from KEGG pathway database32, Reactome Pathway Knowledgebase33
and GO biological process34. Multiple test correction was performed in the tests. Gene sets 
of KEGG pathway database, Reactome Pathway Knowledgebase were obtained from 
Molecular Signatures Database (MsigDB) c2 and GO biological process was obtained from 
MsigDB c560. We used the platform of Functional Mapping and Annotation of Genome-wide 
Association Studies (FUMA GWAS)61 and GENE2FUNC function to perform the gene set 
enrichment analysis and the tissue-specific gene expression patterns based on GTEx v616. 
Besides, the tools Ensembl Human Genes62 (see URLs) and UCSC GRCh37/hg1963 (see URLs) 
were also used in interpreting genetic determinants, CpG sites and genes.  
BMI in the association of methylation and glycemic traits  
We used linear regression to check the effect of CpGs on the relationship between 
BMI and fasting insulin in the non-diabetic individuals in Rotterdam study. The initial model 
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used BMI as the independent variable and the natural log transformed insulin as the 
dependent variable. The covariates included age, sex, technical covariates (chip array 
number and position on the array), white blood cell counts, smoking status and dataset (RS 
III-1 and RS-BIOS). The normalized differential methylation values of CpG sites were added 
as covariates in the advanced model. The differences of the models were compared by 
ANOVA testing using anova function in R (P-value < 0.05).  
URLs. BIOS database, https://genenetwork.nl/biosqtlbrowser/; SNPnexus, http://snp-
nexus.org/index.html ; GWAS database of glycemic traits, 
https://www.magicinvestigators.org/ ; GWAS database of T2D, http://diagram-
consortium.org/ ; MetaXcan, https://s3.amazonaws.com/imlab-
open/Data/MetaXcan/results/metaxcan_results_database_v0.1.tar.gz; NHGRI-EBI Catalog, 
https://www.ebi.ac.uk/gwas/ ; Ensembl, 
https://www.ensembl.org/Homo_sapiens/Info/Index; FUMA, http://fuma.ctglab.nl; UCSC, 
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Abstract 
Background The growing field of metabolomics has opened up new opportunities for 
prediction of type 2 diabetes (T2D) going beyond the classical biochemistry assays.  
Objectives We aimed to identify markers from different pathways which represent early 
metabolic changes and test their predictive performance for T2D, as compared to the 
performance of traditional risk factors (TRF). 
Methods We analyzed 2,776 participants from the Erasmus Rucphen Family study from 
which 1,571 disease free individuals were followed up to 14-years. The targeted 
metabolomics measurements at baseline were performed by three different platforms using 
either nuclear magnetic resonance spectroscopy or mass spectrometry. We selected 24 T2D 
markers by using Least Absolute Shrinkage and Selection operator (LASSO) regression and 
tested their association to incidence of disease during follow-up. 
Results The 24 markers i.e. high-density, low-density and very low-density lipoprotein sub-
fractions, certain triglycerides, amino acids, and small intermediate compounds predicted 
future T2D with an area under the curve (AUC) of 0.81. The performance of the metabolic 
markers compared to glucose was significantly higher among the young (age < 50 years) 
(0.86 vs 0.77, p-value < 0.0001), the female (0.88 vs 0.84, p-value = 0.009), and the lean (BMI 
< 25 kg/m2) (0.85 vs 0.80, p-value = 0.003). The full model with fasting glucose, TRFs, and 
metabolic markers yielded the best prediction model (AUC = 0.89). 
Conclusions Our novel prediction model increases the long-term prediction performance in 
combination with classical measurements, brings a higher resolution over the complexity of 
the lipoprotein component, increasing the specificity for individuals in the low risk group. 
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Introduction 
Early lifestyle intervention is a cost-effective recommendation to reduce the 
incidence of type 2 diabetes1, 2, 3, asking for informative, sensitive and specific markers. 
Although the standard laboratory tests, such as fasting glucose, 2-hour postprandial 
glucose, and glycated hemoglobin A1c (HbA1c), provide strong evidence for the risk of type 
2 diabetes4, 5, 6, these predictors emerge after years of subclinical metabolic dysfunction7. 
Traditional risk factors (TRFs) such as age, sex, body mass index (BMI), and waist 
circumference also explain considerable part of future risk8, 9, but fail to capture the full 
complexity of the etiology and their predictive performance vary between different risk 
groups10. BMI has been put forward as the modifiable risk factor but, there are also 
metabolically unhealthy normal weight (MUHNW) as well as metabolically healthy obese 
(MHO) individuals, raising the question to what extent BMI explain the mechanisms of the 
underlying metabolic disease11. Therefore, there is an increasing interest in finding 
informative markers that indicate the particular metabolic dysfunctions before the 
manifestation of the disease. Hence, people identified at high risk would be able to take 
preventive lifestyle interventions or treatments targeted to their individual molecular 
profile, eventually personalizing their health care. 
High throughput metabolomics offers an opportunity to test multiple metabolic 
markers in large settings. Such approach led to the discovery of five amino acids by the 
prospective Framingham Heart Study (FHS) using a 12-year follow-up12. Branched chain 
amino acids (BCAA) from this panel were previously pointed out in a case-control setting 13
and later in a follow-up study of limited size 14, 15. Other metabolites including phospholipids, 
triglycerides, acyl-carnitines, organic acids and small molecular weight compounds were 
also added to the list of metabolomics based predictors 13, 14, 15, 16, 17, 18, covering the glucose 
and phospholipid metabolism. However, lipoprotein metabolism, which is one of the key 
components of metabolic dysfunction, has not been addressed.  
In the present study, we aimed to identify novel metabolic markers using a total of 261 
metabolic features measured by either targeted mass spectrometry (MS) or by targeted 
nuclear magnetic resonance (NMR). The chemical classes of tested molecules include sub-
fractions of lipoproteins, triglycerides, phospholipids, amino acids, and small intermediate 
compounds. We estimated the predictive performance of the selected marker set in 
comparison to other well-known predictors, including fasting glucose, TRFs, and the 
validated panel of amino acids.  
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Research Design and Methods 
Study population 
The Erasmus Rucphen Family genetic isolate study (ERF) is a prospective family 
based study located in Southwest of the Netherlands. This young genetic isolate was 
founded in the mid-eighteenth century and minimal immigration and marriages occurred 
between surrounding settlements due to social and religious reasons. The ERF study 
population includes 3,465 individuals that are living descendants of 22 couples with at least 
six children baptized. Informed consent has been obtained from patients where appropriate. 
The study protocol was approved by the medical ethics board of the Erasmus Medical 
Center Rotterdam, the Netherlands19.
The baseline demographic data and measurements of the ERF participants were 
collected around 2002 to 2006. All the participants filled out questionnaires on socio-
demographics, diseases and medical history and lifestyle factors, and were invited to the 
research center for an interview and blood collection for biochemistry and physical 
examinations including blood pressure and anthropometric measurements have been 
performed. The participants were asked to bring all their current medications for 
registration during the interview. Venous blood samples were collected after at least eight 
hours fasting. Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic 
blood pressure ≥ 90 mmHg or treatment for hypertension. The family history was coded as 
0, 1, 2 based on no first-degree relatives has type 2 diabetes, one has type 2 diabetes and 
more than one have type 2 diabetes. Baseline type 2 diabetes was defined according to the 
fasting plasma glucose ≥ 7.0 mmol/L and/or anti-diabetic treatment, yielding 212 cases and 
2,564 controls, totaling up to 2,776. The follow-up data collection of the ERF study took 
place from March 2015 to May 2016 (9 to 14 years after baseline visit). During the follow 
up a total of 1,935 participants' records were scanned for incidence of type 2 diabetes in 
general practitioner’s databases. Additionally, a questionnaire on type 2 diabetes 
medication surveyed on 1,232 participants in June 2010 (4 to 8 years after baseline visit) 
was referred if a participant were not included in May 2016 follow-up. This effort yielded 
the inclusion of 18 otherwise missed extra cases. To summarize, out of the 2,564 controls 
at baseline, 1,571 were followed-up for a mean 11.3 years (inter quartile range: 11.0 - 12.2). 
Among those, 137 developed type 2 diabetes, whereas 1,434 did not, comprising together 
the analytical sample for prediction analysis.
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Metabolomics measurements 
In total 261 metabolic marker molecules including sub-fractions of lipoproteins, 
triglycerides, phospholipids, amino acids and small intermediate compounds, which 
throughout this article will be referred as “metabolites”, were measured by three different 
targeted platforms, either by NMR spectrometry or MS at baseline. The samples included 
in metabolomics measurements were not selected based on any disease. The platforms 
used in this research are: (1) Liquid Chromatography-MS (LC-MS, 116 positively charged 
lipids, comprising of 39 triglycerides (TG), 47 phosphatidylcholines (PC), 8 
phosphatidylethanolamines (PE), 20 sphingolipids (SM), and 2 ceramides (Cer), available in 
up to 2,638 participants) measured in Netherlands Metabolomics Center, Leiden using the 
method described before20, (2) small molecular compounds window based NMR 
spectroscopy (NMR-COMP, 41 molecules comprising of 29 low-molecular weight molecules 
and 12 amino acids available in up to 2,639 participants) measured in Center for Proteomics 
and Metabolomics, Leiden University Medical Center21, 22, (3) lipoprotein window based 
NMR spectroscopy (NMR-LIPO, 104 lipoprotein particles size sub-fractions comprising of 28 
very low-density lipoprotein (VLDL) components, 30 high-density lipoprotein (HDL) 
components, 35 low-density lipoprotein (LDL) components, 5 IDL components and 6 plasma 
totals, available in up to 2,609 participants) measured in Proteomics and Metabolomics, 
Leiden University Medical Center and lipoprotein sub-fraction concentrations were 
determined by the Bruker algorithm (Bruker BioSpin GmbH, Germany) details were given 
previously23. Details over the quality control of samples in these platforms can be found in 
the Supplementary Information. The laboratories had no access to phenotype information 
and the data pre-filtering and quality control for measurement errors were based on 
internal controls and duplicates.  
Metabolite identification 
The compounds measured by LC-MS and NMR-COMP were identified according to 
the metabolomics standards initiative (MSI) level 1 using information coming from at least 
2 different sources 24. The available ChEBI ID were shown in Supplementary Table 1. 
For metabolites measured by LC-MS, the identities of the lipids were assigned on 
the basis of accurate mass, fragmentation pattern, and retention times matched to 
authentic standards where available. The detail of the metabolite identification can be 
found in previous publications25. 
For metabolites measured by NMR-COMP, the identities of the small components 
and molecules were assigned by the peaks which are annotated using the combined 
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information from chemical shift databases, spiking experiments, and correlation behaviors. 
The detail of the metabolite identification can be found in the methodological paper22. 
For lipoproteins measured by NMR-LIPO, the method is based on the analysis of 
signals in the 1H-NMR spectrum which are related to the lipoproteins. Differences in 
lipoprotein composition, size and density translate into respective signal line shape 
differences, which can be used to extract information on lipoprotein main- and subclasses. 
As these are not real metabolites, the MSI criteria do not apply. 
Statistical methods 
The distributions of individual metabolites were checked for non-normality by eye 
and outlying values that were more than four times standard deviation away from the mean 
were excluded from analysis. Non-normally distributed measurements were natural 
logarithm transformed, or rank transformed. Figure 1 shows the procedure that we 
followed for the selection of metabolites.  
Firstly, we tested the association between the 261 individual metabolites and 
prevalent type 2 diabetes using a logistic regression model adjusting for age, sex, and lipid-
lowering medication. Residuals from the polygenic model (using “polygenic” function in the 
R package GenABEL), were used in all analysis to account for family relations among the ERF 
participants26. To control for multiple testing, we applied a Bonferroni correction based on 
the effect number of independent vectors in the data which were estimated to be 81 
independent equivalents using Matrix Spectral Decomposition (MSD)27. Thus, a p-value less 
than 6.18  10-4 (0.05/81) was used as the threshold for metabolome-wide significance. We 
repeated analysis stratifying the cases into medicated and non-medicated cases to test if 
the associations were attributed to the effect of anti-diabetic medication. Metabolites that 
did not differentiate (p-value > 0.05) between non-medicated diabetics (n = 68) vs controls 
(n = 2,564) were not taken forward. These metabolite levels were assumed to be different 
due to the post medication metabolic changes in the diabetics. The remaining metabolites 
(n = 88, the list is given in Supplementary Table 1) and the TRFs (age, sex, family history, 
BMI, waist circumference, hypertension, HDL-cholesterol, and triglycerides) with scaled 
around 0 and standard deviation as 1 were included in the prior to LASSO (Least Absolute 
Shrinkage and Selection Operator) regression to select the set of predictors that maximize 
the prediction performance. The LASSO regression was performed using glmnet package in 
R28. We imputed these missing data points (i.e. 9.6% ~ 18.5% missing values) before 
selecting the independent predictors by LASSO regression which requires all the variables 
to be complete measurements. In order to select the best imputation method suitable for 
our data, we first generated a training dataset with 20% missing values at random and 
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compared three methods: (1) deterministic imputation, (2) random regression imputation, 
(3) multiple imputation with R package “mice”29. After comparing the results to the initial 
correlation with glucose and the means between the imputed values and real values for 
each method, multiple imputation was selected. The sum of predicted values from the 
multiple random regression model divided by the number of imputations (n = 20) was used 
to replace the missing data. The outliers more or less than four times standard deviation 
were removed after imputation. With the selected independent type 2 diabetes metabolic 
predictors, we assessed their associations with fasting glucose by linear regression analysis 
in the non-diabetic participants at baseline. To account for multiple testing in these 24 linear 
regression sets, a p-value less than 0.003 (0.05/16) was used as the threshold after MSD of 
the 24 metabolites that yielded 16 independent components. 
Figure 1 Flow chart of the metabolite selection. 
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Prediction of incident type 2 diabetes  
The metabolites selected from the baseline population were tested to predict the 
incidence of type 2 diabetes during the follow-up time. Area under the receiver operator 
characteristics (ROC) curve (AUC) of logistic regression together with continuous Net 
Reclassification Improvement (NRI) was performed to estimate the discrimination and 
reclassification in different models30. The models compared were: ERF metabolite model
(the metabolites those selected in the current study only), FHS metabolite model, (the 
amino acids reported by the FHS research: isoleucine, leucine, valine, tyrosine, and 
phenylalanine), and the TRF model (age, sex, family history, BMI, waist circumference, 
hypertension, HDL-cholesterol, and triglycerides) and glucose only model (fasting plasma 
glucose measured at baseline) and combination of those. As some of the previous studies 
showed the association between metabolites and covariates, i.e. age, sex and BMI31, 32, we 
also tested the models in subgroups of sex, age (< 50 y vs ≥ 50 y), and BMI (< 25 kg/m2 vs ≥ 
25 kg/m2). A p-value < 0.05 here was used as a cut off for significance improvement across 
the models. Meanwhile, the specificity with fixed 80% sensitivity in different prediction 
models is compared. Analyses were conducted using R (version 3.2.3). 
Results 
Table 1 displays the baseline characteristics of the participants stratified by 
prevalent cases at baseline and incident cases in the follow-up. Compared to the participants 
who did not develop type 2 diabetes, those with type 2 diabetes were older, more often had 
a family history of the disease, suffered from hypertension, and have been using lipid-
lowering medication. They had higher levels of BMI, waist circumference, blood pressure, 
triglycerides, fasting glucose, and lower levels of HDL-cholesterol. The participants with 
incident type 2 diabetes had higher fasting glucose at baseline compared to the individuals 
who did not develop type 2 diabetes during the follow up.
Metabolites associated with type 2 diabetes at baseline 
We identified 24 independent metabolites together with five TRFs (age, sex, family 
history, waist circumference, and HDL-cholesterol) from LASSO regression maximizing the 
discrimination at baseline. These metabolites and their associations with prevalent and 
incident type 2 diabetes, as well as fasting glucose at baseline are listed in Table 2. Four of 
them (i.e. PC(O-34:2), L-HDL-free cholesterol, XXL-LDL-phospholipids and L-LDL-cholesterol) 
are associated with decreased risk of type 2 diabetes, whereas twenty of them associated 
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with increased risk; including three triglycerides, seven lipoprotein particles, three amino 
acids, and seven small intermediate compounds. Among the seven lipoprotein particles, 
two are sub-fractions of HDL, two are of LDL, and three are of VLDL (See details in Table 2). 
Out of the 24 metabolites, PC(O-34:2), XXL-LDL-triglycerides, HDL-triglycerides, L-HDL-
ApoA2, and M-HDL-ApoA2 are not associated with fasting glucose in the non-diabetic 
population at baseline and incident type 2 diabetes.  
Table 1 Characteristics of the study population. 
Baseline (n=2,776) Follow-up (n=1,571) 
Controls Cases Controls Cases 
(n = 2,564) (n = 212) (n = 1,434) (n = 137) 
Male [n (%)] 1132 (44.1) 108 (50.9) 595 (41.5) 78 (56.9) *
Age (years) 48.2 ± 14.3 59.8 ± 11.8* 47.7 ± 13.9 57 ± 10.7*
Diabetes in first-degree relatives 
    0 individuals [n (%)] 1711 (76.6) 71 (55.0) 966 (76.4) 63 (53.8) 
    1 individual [n (%)] 428 (19.2) 37 (28.7) 248 (19.6) 38 (32.5) 
    ≥ 2 individuals [n (%)] 95 (4.3) 21 (16.3) * 50 (4.0) 16 (13.7) *
Body mass index (kg/m2) 26.7 ± 4.6 30.0 ± 5.9* 26.6 ± 4.4 30.1 ± 5.1*
Waist circumference (cm) 86.7 ± 13.1 99.3 ± 14.2* 86.2 ± 12.8 98.9 ± 13.4*
Systolic blood pressure (mmHg) 139 ± 20 154 ± 21* 137.7 ± 19.6 152.4 ± 21.8*
Diastolic blood pressure (mmHg) 80.3 ± 10.0 82.9 ± 9.9 79.7 ± 9.6 84.8 ± 9.8*
Hypertension [n (%)] 1282 (50) 170 (80.2) * 674 (47.0) 111 (81.0) *
HDL-cholesterol (mmol/l) 1.3 ± 0.4 1.1 ± 0.3* 1.3 ± 0.4 1.1 ± 0.3*
Triglycerides (mmol/l) 1.2 (0.8, 1.6) 1.6 (1.1, 1.9) * 1.2 (0.8, 1.6) 1.7 (1.1, 2.1) *
Fasting glucose (mmol/l) 4.5 ± 0.7 7.4 ± 2.2* 4.4 ± 0.6 5.3 ± 0.7*
Lipid-lowering medication [n (%)] 265 (10.3) 99 (46.7) * 136 (9.5) 42 (30.9) *
Data are means ± standard deviations (SD), medians (inter-quartile range), or n (%). Triglycerides were natural 
logarithm transformed prior to analysis. * P-value < 0.05 after adjusting age, sex and/or lipid-lowering medication. 
Predicting incident type 2 diabetes 
Figure 2 shows the AUC comparisons across the different prediction models. The 
ERF metabolites discriminate future type 2 diabetes with an AUC [95% confidence interval] 
of 0.81 [0.77, 0.85]. The AUC of the ERF metabolite model was significantly higher than of 
the FHS metabolite model (AUC 0.81 [0.77, 0.85] vs 0.77 [0.73, 0.81], NRI = 0.42, p-value < 
0.0001). It is of note that tyrosine and isoleucine, which were previously selected by FHS, 
were also selected in the ERF metabolite model. The AUC for the model including both ERF 
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and FHS metabolites together was significantly higher than the AUC for models with either 
set of predictors (AUC 0.83 [0.79, 0.86] vs 0.77 [0.73, 0.81], NRI = 0.67, p-value < 0.0001 for 
ERF and FHS metabolites vs only FHS metabolites; AUC 0.83 [0.79, 0.86] vs 0.81 [0.77, 0.85], 
NRI = 0.29, p-value = 0.0015 for ERF and FHS metabolites vs only ERF metabolites). The AUC 
of the ERF and FHS combined metabolite model did not differ from that of fasting glucose 
(AUC 0.83 [0.79, 0.86] vs 0.84 [0.81, 0.88], p-value = 0.45). However, combining the ERF 
metabolites and fasting glucose together in a model improved the predictive performance 
significantly over the performance of fasting glucose (AUC 0.88 [0.84, 0.91] vs 0.84 [0.81, 
0.88], NRI = 0.66, p-value < 0.0001). Adding TRFs to fasting glucose and metabolite model 
maximized the AUC to 0.89 [0.86, 0.92]. The specificity with fixed 80% sensitivity increases 
from 70% to 80% when metabolites are added to the glucose only model (Supplementary 
Figure 1).  
Figure 2 AUC comparisons in different prediction models. Continuous Net Reclassification Improvement (NRI) 
indices were performed to compare different prediction models. FG: fasting glucose. TRFs: all traditional risk 
factors: age, sex, family history, BMI, waist circumference, hypertension, HDL-cholesterol, triglycerides. 
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Table 2 Association of LASSO regression selected metabolites with type 2 diabetes and fasting glucose.
Prevalent cases vs controls Incident cases vs controls Fasting glucose 
Metabolites ChEBI ID OR [95%CI] P-value OR [95%CI] P-value Effect P-value 
PC(O-34:2) CHEBI:64544 0.6 [0.5, 0.7] 1.3×10-7 0.9 [0.7, 1.1] 0.19 -0.01 0.28 
Isoleucine CHEBI:24898 2.4 [2.0, 2.9] 2.7×10-20 2.0 [1.6, 2.5] 4.4×10-9 0.09 3.6×10-8
Methionine CHEBI:16811 1.4 [1.2, 1.6] 1.2×10-4 1.3 [1.1, 1.6] 7.4×10-3 0.05 2.6×10-4
Tyrosine CHEBI:18186 1.5 [1.2, 1.7] 1.6×10-5 2.0 [1.6, 2.5] 5.3×10-10 0.13 6.0×10-18
2-hydroxybutyrate CHEBI:64552 2.0 [1.7, 2.5] 2.5×10-13 2.0 [1.6, 2.6] 2.6×10-10 0.15 2.8×10-27
1,5-AG CHEBI:16070 2.3 [1.9, 2.7] 5.0×10-19 1.5 [1.2, 1.8] 3.3×10-4 0.09 4.5×10-10
2-oxoglutaric acid CHEBI:30915 1.5 [1.3, 1.8] 2.70×10-6 1.8 [1.4, 2.2] 6.0×10-7 0.13 8.9×10-20
Glycine betaine CHEBI:17750 2.2 [1.8, 2.6] 2.50×10-17 1.5 [1.2, 1.9] 2.3×10-4 0.12 1.8×10-14
Glycerol CHEBI:17754 2.3 [1.8, 2.8] 2.1×10-14 1.7 [1.3, 2.1] 1.5×10-5 0.13 9.1×10-18
Lactate CHEBI:24996 1.7 [1.4, 1.9] 4.9×10-11 1.5 [1.2, 1.7] 3.1×10-5 0.11 3.1×10-15
Pyruvate CHEBI:15361 1.6 [1.4, 1.8] 3.0×10-9 1.5 [1.3, 1.8] 3.3×10-6 0.14 1.3×10-25
TG (48:0) CHEBI:85870 1.4 [1.2, 1.6] 2.3×10-5 1.6 [1.3, 1.9] 9.3×10-7 0.08 2.0×10-8
TG (48:1) CHEBI:85726 1.4 [1.2, 1.6] 1.3×10-4 1.5 [1.3, 1.9] 8.0×10-6 0.07 5.1×10-8
TG (50:5) CHEBI:90301 1.3 [1.1, 1.4] 2.3 ×10-3 1.5 [1.2, 1.7] 6.5 ×10-6 0.06 1.4 ×10-5
VLDL-free 
cholesterol 
- 
1.4 [1.2, 1.7] 7.2×10-7 1.6 [1.4, 1.9] 8.2×10-8 0.08 1.7×10-9
XXL-VLDL-
cholesterol 
- 
1.3 [1.1, 1.5] 4.9 ×10-4 1.5 [1.3, 1.7] 2.9 ×10-6 0.08 1.1 ×10-8
VLDL-triglycerides - 1.4 [1.2, 1.6] 3.2×10-6 1.5 [1.3, 1.8] 1.0×10-6 0.09 3.3×10-10
XXL-LDL-
phospholipids 
- 
0.6 [0.5, 0.7] 4.4 ×10-9 0.7 [0.6, 0.9] 2.9 ×10-3 -0.06 6.4 ×10-5
XXL-LDL-
triglycerides 
- 
1.4 [1.2, 1.6] 2.4 ×10-4 0.9 [0.7, 1.1] 0.16 0.01 0.34 
L-LDL-cholesterol - 0.5 [0.5, 0.6] 8.1×10-14 0.7 [0.6, 0.9] 1.7×10-3 -0.05 1.9×10-4
XS-LDL-ApoB - 1.4 [1.2, 1.7] 3.6×10-6 1.6 [1.3, 1.9] 3.7×10-7 0.05 2.2×10-4
L-HDL-ApoA2 - 1.4 [1.2, 1.6] 2.1×10-4 1.0 [0.8, 1.2] 0.94 0.02 0.14 
L-HDL-free 
cholesterol 
- 
0.5 [0.4, 0.6] 3.9×10-12 0.7 [0.5, 0.8] 1.5×10-4 -0.09 3.2×10-10
M-HDL-ApoA2 - 1.4 [1.2, 1.7] 5.8×10-5 1.1 [0.9, 1.3] 0.61 0.04 4.1×10-3
Odds ratio (OR) and 95% confidence interval (CI) estimates provided from logistic regression and Effect from linear 
regression with age- sex- and lipid-lowering medication-adjusted in the standardized metabolite variables. 
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Predicting incident type 2 diabetes in different baseline risk groups 
The AUC of the combined ERF, and FHS metabolite models and of fasting glucose 
model in subpopulations stratified by age, sex, and BMI is shown in Figure 3. In the group 
with age < 50 years, the AUC of the combined metabolite model is significantly higher than 
that of fasting glucose model (AUC 0.86 [0.78, 0.94] vs 0.77 [0.67, 0.87], NRI = 0.72, p-value 
< 0.0001), whereas the AUCs of these two models are not statistically different in the elderly 
group (AUC 0.83 [0.78, 0.87] vs 0.84 [0.80, 0.88], p-value = 0.06). The AUC of the metabolite 
model is significantly higher than that of fasting glucose in the female group (AUC 0.88 [0.83, 
0.92] vs 0.84 [0.79, 0.90], NRI = 0.44, p-value = 0.001), whereas in the male group there is 
an opposite trend (0.78 [0.72, 0.84] vs 0.83 [0.79, 0.88], NRI = -0.40, p-value = 0.001). 
Similarly, in the group with normal BMI, the AUC of metabolite model is significantly higher 
than that of fasting glucose model (AUC 0.85 [0.75, 0.95] vs 0.80 [0.66, 0.93], NRI = 0.49, p-
value = 0.04). In the overweight and obese group, the trend is opposite but not significantly 
different (AUC 0.81 [0.76, 0.85] vs 0.83 [0.79, 0.87], p-value = 0.13). When the sensitivity is 
fixed to 80%, the specificity rises from 59% (glucose only model) to 87% (glucose and 
metabolite model) in the young (age < 50y), which is much higher increase than in the old 
(age ≥ 50y, from 66% to 82%). The specificity also grows when we add metabolites or TRFs 
to the prediction model. (Supplementary Figure 1) The ROC curves for the models and 
subgroups are given in the Supplementary Figure 2 and Supplementary Figure 3. The 
separation shown by time to event curves across different risk groups are given in 
Supplementary Figure 4. 
Figure 3 AUC comparisons in different subgroups. Continuous Net Reclassification Improvement (NRI) indices 
were performed to compare different prediction models. Black bars: metabolite model; white bars: fasting glucose 
model. (/): Number of controls and incident cases analyzed in the follow-up. 
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Discussion 
In the present study, we showed that the combined effect of 24 metabolites 
including ten lipoprotein sub-fractions yield a powerful discrimination model for predicting 
future type 2 diabetes. The ERF metabolite model significantly improved the prediction 
performance of FHS metabolite model and fasting glucose. We showed that combined 
metabolite model predicts future type 2 diabetes better than fasting glucose in the 
population who are female, younger than 50 years, or those with normal weight. In 
addition, we confirmed the conclusion from the FHS that isoleucine and tyrosine are 
predictors of type 2 diabetes independent of other factors12.  
The ERF metabolite model includes molecules from five classes: triglycerides, 
amino acids, lipoproteins, phospholipids and small intermediate compounds. Among those, 
metabolites such as 1,5-anhydro-D-glucitol (1,5-AG), 2-hydroxybutyrate, pyruvate, 
phosphatidylcholines, betaine, some triglycerides, and BCAA have been previously reported 
to be potential predictive and diagnostic markers for type 2 diabetes3, 12, 18, 33, 34, 35. Despite 
the fact that LASSO regression method is used to select independent components of our 
model, various metabolites from the same biochemical class were selected, supporting the 
view that the sub-fractions of some classical measurements play independent functions in 
the pathogenesis of type 2 diabetes36. In line with this, the ERF metabolite model points out 
lipid perturbations evident in the very early stage of the disease. For example, levels of 
different triglycerides (e.g. TG (48:0), TG (48:1)) show independent effects. Our results on 
HDL and LDL sub-fractions are particularly interesting. We found them associated with both 
increased and decreased risk. L-HDL-ApoA2, M-HDL-ApoA2, XS-LDL-ApoB and XXL-LDL-
triglycerides are associated with increased risk of type 2 diabetes, whereas L-HDL-free 
cholesterol, XXL-LDL-phospholipids and L-LDL-cholesterol are associated with decreased 
risk of type 2 diabetes. This suggests different roles for HDL and LDL particles and their 
content. Our results highlight the importance of reclassifying lipoproteins of clinical value 
into sub-fractions of HDL, LDL and VLDL, as the measurement techniques develop in the 
coming decade.  
We also demonstrated that PC(O-34:2) is inversely associated with type 2 diabetes, 
which is in line with a recent study performed in the population based KORA study that 
showed decrease in PC(O-34:2) levels in patients with impaired glucose tolerance18. 
Phosphatidylcholine is a key element in lipoproteins34. Elevated plasma levels of choline and 
betaine mark cardiovascular risk in diabetes37, while increased level of isoleucine was 
significantly associated with an increased risk of hypertriglyceridemia38. 2-hydroxybutyrate 
appears to be useful as an early indicator of insulin resistance in non-diabetic subjects39, 
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and its elevated serum levels have recently been indicated to predict worsening of glucose 
tolerance40.  
Among the other ERF metabolites, our results on two (1,5-AG and glycerol) are 
inconsistent with the previous studies in terms of direction of association: Suhre et al. 
studied on 40 diabetes cases and 60 healthy male controls in the German population13; Lu 
J. et al.'s study included 22 Chinese cases and 22 healthy controls41, and the study by 
Shaham O. et al. was done in 47 healthy academic students 42. Considering the larger sample 
size, our study should have yielded more reliable estimates compared to the above studies. 
It has been shown that levels of 1,5-AG metabolite reflect glycemic changes, and recent 
clinical studies demonstrated significant differences in 1,5-AG levels between diabetic 
patients receiving different treatments, consistent with their individual glucose profiles43, 44. 
As shown in Table 2, all metabolites are associated with prevalent diabetes, but 
some are not associated with incident case control status. We kept those in the ERF 
prediction model as this could be due to their small effect sizes which need more sample 
size (power) to be detected since the effect estimates were in the expected direction. 
Another explanation could be that some metabolite levels change depending on the 
duration and progression of the disease that we cannot control for in the statistical model. 
A third explanation is that it could as well be due to anti-diabetic medication effect but we 
have already filtered the associations controlling for that. The addition of ERF metabolites 
can complement the type 2 diabetes prediction by fasting glucose and TRFs, yielding the 
best model when combined. This is partly a result of our selection approach performed 
independently of TRFs but may also be due to the assumption that high resolution 
metabolites reflect different possible etiologies of type 2 diabetes. Thus, improvement of 
predictive performance with additional metabolites implies that potential metabolic 
ramifications may extend far beyond and prior to impaired glucose metabolism. It is of note 
that each metabolite contributed equally to the improvement of the AUC except tyrosine, 
exclusion of which dropped the AUC significantly. The AUC of the model without tyrosine is 
0.79, and is significantly lower than the AUC of ERF metabolite model which is 0.81 (NRI = 
0.38, p-value < 0.0001), suggesting that tyrosine is an important component of the model.  
In the present study, we found a higher AUC of the metabolite model in lower risk 
population as female, younger, or leaner subgroups. For the optimum cut-off value of the 
ROC curve, we observed the biggest difference in specificity especially in the young age 
group, such that if the sensitivity of the prediction model is set to 80%, the metabolite only 
model yielded a specificity of 0.82, whereas the glucose model is as low as 0.59. This 
suggests that the metabolomics information may have better utility for type 2 diabetes 
prediction specifically in those without the risk condition, which is in agreement with 
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previous study from Walford et al17. Interestingly, low risk population that develop type 2 
diabetes were reported to have higher risk of mortality45, raising the importance of more 
specific predictors suited for different underlying mechanisms. Markers which reflect the 
metabolic condition both dependent and independent of BMI that may partially help to 
address the different active pathways underlying to the MUHNW and MHO phenotypes11.  
Two additional platforms measured among subsets of the ERF population which 
were not included in our main analysis due to sample size restrictions gave us the 
opportunity to compare some of the associations using these different measurement 
methods. These were electrospray-Ionization MS, measured in 878 participants, using the 
method described before46 and AbsoluteIDQTM p150 Kit of Biocrates Life Sciences AG 
measured in 989 participants as details mentioned before47. Supplementary Figure 5 shows 
the x-y plots of the effect estimates per standard error (i.e. Z score) in the 62 lipids and 9 
amino acids that were measured in duplication. The Z scores between these platforms are 
strongly correlated with correlation coefficients ranging from 0.74 to 0.87.  
The present study has a strong design such that the new cases develop among the 
control group in the baseline. However, due to the wide metabolite spectrum in the present 
study, validation of the full model in an external sample is not available yet. One limitation 
can be that in the present study, 46.7 % of the type 2 diabetes patients at baseline took 
lipid-lowering medication compared 10.3 % in the non-diabetics. To reduce the bias, all the 
participants were fasted overnight before taking the blood sample and we adjusted for lipid-
lowering medication in each step of statistical analysis. It also needs mentioning that the 
metabolite set that predicts type 2 diabetes is assumed to point out the biochemical 
pathways disrupted before the disease onset. However, these metabolites may not be 
necessarily in the causal pathway. We have previously shown that most these metabolites 
are partially heritable21, 23, 47 and our increasing knowledge about their genetic determinants 
opens up new opportunities for testing causal inference using Mendelian randomization23.  
Conducting a 14-years prospective study with comparably large sample size and 
wide metabolite spectrum, we developed a novel prediction model which includes 
informative markers of dyslipidemia, and which also increases the specificity for the young 
individuals. Importantly, this model has a high potential to result with better understanding 
of the biological mechanisms leading to glycemic deterioration in prediabetes and diabetes. 
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Abstract  
Mendelian randomization (MR) provides us the opportunity to investigate the causal paths 
of metabolites in type 2 diabetes and glucose homeostasis. We developed and tested an 
MR approach based on genetic risk scoring for plasma metabolite levels, utilizing a 
pathway-based sensitivity analysis to control for non-specific effects. We focused on 124 
circulating metabolites which correlate with fasting glucose in the Erasmus Rucphen Family 
study (n = 2,564) and tested the possible causal effect of each metabolite with glucose and 
type 2 diabetes and vice versa. We detected fourteen paths with potential causal effects 
by MR, following pathway based sensitivity analysis. Our results suggest that elevated 
plasma triglycerides might be partially responsible for increased glucose level and type 2 
diabetes risk, which is consistent with previous reports. Additionally, elevated high-density 
lipoprotein (HDL) components i.e. S-HDL-triglycerides might have a causal role of elevating 
glucose levels. In contrast, large (L) and extra-large (XL) HDL lipid components i.e. XL-HDL-
cholesterol, XL-HDL-free cholesterol, XL-HDL-phospholipids, L-HDL-cholesterol and L-HDL-
free cholesterol as well as HDL-cholesterol seem to be protective against increasing fasting 
glucose, but not against type 2 diabetes. Finally, we demonstrate that genetic 
predisposition to type 2 diabetes associates with increased levels of alanine, and decreased 
levels of phosphatidylcholine alkyl-acyl C42:5 and phosphatidylcholine alkyl-acyl C44:4. Our 
MR results provide novel insight into promising causal paths to and from glucose and type 
2 diabetes and underline the value of additional information from high-resolution 
metabolomics over classical biochemistry. 
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Introduction
Type 2 diabetes is a progressive metabolic disease characterized by hyperglycemia, 
initially as a result of insulin resistance and in later stages also as a result of insulin 
insufficiency. Type 2 diabetes is also associated with dyslipidemia, including higher 
circulating concentrations of triglycerides and lower concentrations of high-density 
lipoprotein (HDL) cholesterol. In addition, several circulating molecules have previously 
been shown to be dysregulated in type 2 diabetes, including phospholipids, branched-chain 
amino acids, keto-acid metabolites and other metabolites such as acyl-carnitines1, 2, 3. 
However, the causal paths between these metabolites and glucose/type 2 diabetes in 
human remain unclear from observational studies, and require randomized controlled trials 
that are difficult to conduct. 
As an alternative, Mendelian randomization (MR) is an instrumental variable 
method that has gained in popularity over the last decade, to investigate causal effects of 
traits using genetic predictors. MR uses the principle that the allocation of genetic variants 
that affect a specific trait, from parents to offspring is random and unrelated to factors other 
than the trait 4. Furthermore, associations between the genotype and the outcome will not 
be affected by reverse causation because disease will occur after the meiosis. MR has 
previously been used to determine whether metabolic markers such as classical blood lipids 
are causally involved in type 2 diabetes5, 6, 7, 8, 9, 10, 11 and has yielded contradicting results. 
One reason for this could be that these studies are affected by the heterogeneous nature 
of the metabolic markers chosen, such as in the example of total HDL cholesterol, which in 
reality consists of a collection of different sized HDL particles possibly with different 
functions. This may dilute the causal effects of SNPs when only combined (total) HDL is 
considered. However, false signals may also be due to pleiotropic effects of the chosen 
genetic variants leading to possibly invalid instrumental variables. As high-throughput 
analyses techniques improve, the quantification of circulating molecules is becoming ever 
more detailed and precise. For instance, instead of LDL-cholesterol, HDL-cholesterol and 
total triglycerides (TG) determined by routine clinical biochemistry, lipoprotein particle size 
distribution and content as well as tens of biochemical components can now be measured 
using Nuclear Magnetic Resonance (NMR) spectroscopy and Mass Spectrometry (MS) based 
approaches12, 13. These additional measures offer an opportunity to gain novel insight into 
the pathogenesis of diseases like type 2 diabetes. With the knowledge of genetic 
determinants of metabolites gained from genome-wide association studies (GWAS)14, 15, 16, 
one can use MR for causal inference given the specific conditions encoded in Figure 1. In 
the present study, with the aim of unraveling potentially causal metabolic paths that 
underlie the observed associations, we used genetic predictors from published metabolite 
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GWAS, guided by pathway-based evidence to select instrumental variables, and performed 
MR between selected metabolic markers and glucose/type 2 diabetes. 
Figure 1 Overview of the Mendelian randomization process. 
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Materials and Methods
Study population 
The observational associations between metabolites and fasting glucose/type 2 
diabetes were tested in the Erasmus Rucphen Family (ERF) study which is a prospective 
family based study with 3,465 individuals in the Southwest of the Netherlands. The study 
protocol for ERF was approved by the medical ethics board of the Erasmus Medical Center 
Rotterdam, the Netherlands17. The baseline demographic data and measurements of the 
ERF participants were collected between 2002 and 2006. Venous blood samples were 
collected after at least eight hours fasting. The detailed description of the ERF study and 
related measurements were reported previously17. Type 2 diabetes was defined according 
to a fasting plasma glucose ≥ 7·0 mmol/L and/or anti-diabetic treatment. The analytical 
sample included 2,564 non-diabetic and 212 diabetic participants.  
Metabolite measurements 
Metabolic markers were measured by five different metabolomics platforms using 
the methods which have been described in earlier publications15, 16, 18, 19. In total 562 
metabolic markers including sub-fractions of lipoproteins, triglycerides, phospholipids, 
ceramides, amino acids, acyl-carnitines and small intermediate compounds, which 
throughout this article will be referred as “metabolites”, were measured either by NMR 
spectrometry or by MS. The platforms used in this research are: (1) Liquid Chromatography-
MS (LC-MS, 116 positively charged lipids, comprising of 39 triglycerides, 47 
phosphatidylcholines, 8 phosphatidylethanolamines, 20 sphingolipids, and 2 ceramides, 
available in up to 2,638 participants) measured in the Netherlands Metabolomics Center, 
Leiden using the method described before18; (2) Electrospray-Ionization MS (ESI-MS, in total 
148 phospholipids and sphingolipids comprising of 16 plasmologens, 72 
phosphatidylcholines, 27 phosphatidylethanolamines, 24 sphingolipids, 9 ceramides, 
available in up to 878 participants), measured in the Institute for Clinical Chemistry and 
Laboratory Medicine, University Hospital Regensburg, Germany using the method 
described previously14; (3) Small molecular compounds window based NMR spectroscopy 
(NMR-COMP, 41 molecules comprising of 29 low-molecular weight molecules and 12 amino 
acids available in up to 2,639 participants) measured in the Center for Proteomics and 
Metabolomics, Leiden University Medical Center19, 20; (4) Lipoprotein window-based NMR 
spectroscopy (NMR-LIPO, 104 lipoprotein particles size sub-fractions comprising of 28 VLDL 
components, 30 HDL components, 35 LDL components, 5 IDL components and 6 plasma 
totals, available in up to 2,609 participants) measured in the Center for Proteomics and 
Metabolomics, Leiden University Medical Center and lipoprotein sub-fraction 
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concentrations were determined by the Bruker algorithm (Bruker BioSpin GmbH, Germany) 
as detailed in Kettunen et al16; (5) AbsoluteIDQTM p150 Kit of Biocrates Life Sciences AG 
(153 molecules comprising of 14 amino acids, 91 phospholipids, 14 sphingolipids, 33 acyl-
carnitines and hexose available in up to 989 participants) measured as detailed in 
publication from Draisma et al15 and the experiments were carried out at the Metabolomics 
Platform of the Genome Analysis Center at the Helmholtz Zentrum München, Germany as 
per the manufacturer’s instructions. The laboratories had no access to phenotype 
information.  
Statistical methods 
We assessed the pairwise partial correlation between each metabolite and each 
glycemic trait (i.e. fasting glucose, fasting insulin, HOMA-IR, BMI and WHR) in the non-
diabetic participants group. We included age, sex and lipid lowering medication as 
covariates. Bonferroni correction was applied based on the number of independent vectors 
in the data. By the Matrix Spectral Decomposition (MSD) method21, we estimated 191 
independent vectors using the pairwise bivariate correlation matrix of the 562 metabolites. 
A P-value < 5.24  10-5 (0.05/191/5) adjusted by number of independent vectors and 
number of outcomes was used as the threshold for metabolome-wide significance. The 
metabolites associated with glucose in the ERF study were taken forward (n = 124) as 
candidates for MR. In this set of 124 metabolites, we also tested the association with type 
2 diabetes using logistic regression.  
Mendelian randomization  
For each metabolite associated with glucose, we performed two-sample bi-
directional MR. The same method on two-sample MR has been performed in the previous 
MR studies on type 2 diabetes6, 9, 22. We tested if genetically varying levels of a particular 
metabolite affect the risk for elevated glucose and type 2 diabetes (we call this the forward
approach) and if genetically increased risk of type 2 diabetes or elevated glucose is 
associated with circulating levels of a particular metabolite (we call this the backward
approach). The associations between the instrumental variables and the exposure and the 
outcome are estimated from different studies, either the metabolite GWAS14, 15, 16, 19 or 
fasting glucose/type 2 diabetes GWAS published by MAGIC and DIAGRAM consortium23, 24, 
using the genetic risk score method. The effect of the genetic risk score was constructed by 
summing up the weighted effects of genome wide significant SNPs on the exposure variable, 
in relation to their effects on the outcome, as detailed in a previous publication6. This was 
performed using summary statistics level data utilizing the method described by Dastani et 
al25 and implemented in the R-package “gtx”. Figure 2 shows the overview of the 
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instrumental variable construction. All SNPs were mapped to human genome build hg19. 
Given that MR assumes no pleiotropic effect beyond that on the risk factor of interest (i.e. 
exposure), we excluded the top SNPs from previously published body-mass index (BMI) and 
WHR GWAS26, 27, and any SNPs within a 1 Mbp window distance of these, from the genetic 
score. We additionally excluded the genetic loci (1 Mbp window) of glucose, type 2 diabetes, 
insulin and HOMA-IR extracted from previous publications23, 24, 28 in the forward MR and the 
genetic loci (1 Mbp window) of the particular metabolite of interest, using the published 
GWAS information in the backwards MR (see Supplemental Table 1 for list of genetic loci 
excluded at this stage). We restricted the SNP lists to a set of independent SNPs in low 
linkage disequilibrium (pairwise R2 < 0.05) for each test29 based on the genotype data in ERF. 
SNPs with disproportionate effects in the risk score were excluded to reduce pleiotropy (see 
Supplemental Table 2 for list of SNPs excluded at this stage). Genetic risk scores comprising > 
5 SNPs which explain > 1% of variance in exposure were taken forward. This effort yielded 
20 metabolite-glucose/type 2 diabetes sets in the forward MR and 76 glucose-metabolite 
sets and 79 type 2 diabetes-metabolite sets in the backward MR. A false discovery rate (FDR) 
of 0.05 was used as the significance threshold for the four series (i.e. metabolite-glucose, 
metabolite-type 2 diabetes, glucose-metabolite and type 2 diabetes-metabolite series). 
Pathway-based sensitivity analysis 
Although we applied several restrictions on the SNPs in the genetic risk scores as explained 
above, the instrumental variable assumption that the locus is associated with the outcome 
only via the association with the exposure (Figure 1) is still hard to justify in practice. We 
harnessed the extensive background biological knowledge available to make the additional 
semi parametric assumption to get the MR estimates of the causal effect. That is, for each 
set, we evaluated whether we could identify the gene in proximity to the locus that could 
explain the change in exposure levels. If a gene codes for an enzyme that catalyzes the 
exposure or a related compound, or if it is present in a signaling cascade that affects the 
exposure, we assumed that the link between the instrumental variable and the exposure 
was direct and not mediated by the outcome. For the forward approach, we checked the 
biological link between the locus and the target metabolite and for the backward approach 
the link with glucose. As the pathway in the disease type 2 diabetes is complex, we did not 
check the biological link with type 2 diabetes in the backward approach. If the gene directly 
links to the exposure, the related SNPs are taken forward to calculate the genetic risk score. 
Then, MR is performed for any genetic risk score (comprising > 5 SNPs) which explains > 1% 
of variance in exposure. To explore potential mechanistic links between the locus and the 
exposure, we used an automated workflow that was developed in house to gather gene-
specific knowledge of all genes in proximity to each locus. In detail, we downloaded a 
number of online databases from the respective ftp servers and integrated them offline in 
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Matlab®. Subsequently, for each SNP we selected genes within a window of 100kbp, with 
coordinates based on the dbSNP30, and NCBI Gene (http://www.ncbi.nlm.nih.gov/gene; 
GRCh37), and genes whose expression is affected by the locus (GTEx-eQTL). Then, for each 
gene we gathered protein-related knowledge from UniProtKB31 and affected pathways from 
ConsensusPathDB32. Finally, for each protein we investigated metabolic activity by checking 
if it concerned a transporter protein in TCDB33, or enzyme in ExPASy34, and, if so, what the 
catalyzed metabolic reaction was in the KEGG database35. For the KEGG database the last 
freely available version was used. The database integration pipeline generated one HTML 
file for each locus, containing gene-specific knowledge and hyperlinks to the original 
database entries, which was then inspected for finding a mechanistic link with the exposure. 
The strength of this approach is that it identifies loci for which the instrumental variable 
assumption can be validated using genetic and biochemical evidence from online databases. 
We have successfully applied this workflow in earlier studies19, 36, 37, 38. Heemskerk et al gives 
the best example of the power of our method37, where we re-analyzed published results of 
a GWAS on metabolite levels39 and confirmed the annotation by an in vitro experiment.
Results 
Observed associations 
Characteristics of the present study population are given in Table 1. Participants 
with type 2 diabetes were older, tended to be more often male, and more likely to be on 
lipid-lowering medication. They had higher BMI, WHR, systolic blood pressure, triglycerides, 
fasting glucose, insulin, HOMA-IR, and lower HDL-cholesterol, adiponectin and LDL-
cholesterol. 
We identified 124 metabolites that observationally associate with fasting glucose 
in the control population with P-value < 5.24  10-5 (Figure 3). These consisted of 36 
phospholipids (Figure 3A), 20 triglycerides (Figure 3B), 24 small molecular compounds 
(Figure 3C) and 44 lipoprotein particle sub-fractions (Figure 3D). Correlation coefficients, P-
values as well as the overlap with previous research for all 124 metabolites are given in 
Supplemental Table 3. A clustered heatmap of correlation structure in-between the 124 
selected metabolites are shown in Supplemental Figure 1. Among the 124, 112 of them also 
associated with type 2 diabetes (P < 0.05), and their associations with type 2 diabetes and 
glucose were in the same direction. In addition to that, their associations with BMI, WHR, 
fasting insulin and HOMA-IR were in line with the direction of their associations with glucose. 
Out of the 124 metabolites, 90 of them correlated positively and 34 correlated negatively 
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with fasting glucose. We observed negative correlation between glucose and alkyl-acyl and 
diacyl phosphatidylcholines, mostly of the poly-unsaturated type, lysophosphatidylcholines, 
mostly of the saturated type and parts of the lipoprotein sub-fractions from LDL and HDL. 
These lipoprotein sub-fractions particularly consisted of lipid components of extra-large (XL) 
and large (L) LDL particles, XL-HDL and L-HDL particles as well as total HDL measurements. 
The second cluster of metabolites which we observed to correlate positively with glucose 
included several phospholipids; phosphatidylethanolamines, and lysophosphatidylcholines. 
Amino acids and low-molecular weight compounds also correlated positively with glucose, 
in addition to lipid side-groups, and triglycerides. Finally, from the lipoprotein sub-fractions, 
small (S), extra-small (XS), medium (M) and XL-VLDL particles, as well as the total VLDL 
components, followed by IDL and LDL-triglycerides, XS-LDL to M-LDL particle components, 
as well as the ApoA1 and triglyceride content of S-HDL particles were correlated positively 
with fasting glucose in the non-diabetic population. 
Table 1 Characteristics of the study population. 
Controls  
n=2,564 
Cases 
n=212 P-value P-value*
Male [n (%)] 1132 (44.1) 108 (50.9) 0.059 0.20 
Age (years) 48.2 ± 14.3 59.8 ± 11.8 6.4 × 10-32 2.1 × 10-12
Body mass index (kg/m2) 26.7 ± 4.6 30.0 ± 5.9 3.4 × 10-13 3.7 × 10-12
Waist-to-hip ratio 0.86 ± 0.10 0.95 ± 0.10 9.5 × 10-27 2.6 × 10-17
Systolic blood pressure (mmHg) 139 ± 20 154 ± 21 7.3 × 10-19 8.2 × 10-6
Diastolic blood pressure (mmHg) 80.3 ± 10.0 82.9 ± 9.9 4.5 × 10-4 0.11 
LDL-cholesterol (mmol/l) 3.8 ± 1.0 3.2 ± 1.0 4.8 × 10-15 1.0 × 10-9
Triglycerides (mmol/l) 1.2 (0.8, 1.6) 1.6 (1.1, 1.9) 2.0 × 10-10 5.1 × 10-6
HDL-cholesterol (mmol/l) 1.3 ± 0.4 1.1 ± 0.3 2.7 × 10-11 5.6 × 10-8
Fasting glucose (mmol/l) 4.5 ± 0.7 7.4 ± 2.2 9.4 × 10-44 1.5 × 10-54
Fasting insulin (mU/L) 11 (8, 15) 16 (11, 22) 1.2 × 10-7 9.0 × 10-7
HOMA-IR 2.3 (1.6, 3.1) 5.0 (3.7, 7.4) 1.5 × 10-23 2.5 × 10-24
Lipid lowering medication [n (%)] 265 (10.3) 99 (46.7) 7.2 × 10-20 1.5 × 10-22
Data are means ± standard deviations (SD), medians (inter-quartile range) or percentages. Triglycerides, fasting 
insulin, adiponectin, and HOMA-IR were natural logarithm transformed prior to analysis. P-value: T-test and Chi-
squire test were used in continuous variables and categorical variables, respectively. P-value*: Logistic regression 
was used with adjusting age, sex and lipid lowering medication. 
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Mendelian randomization 
Table 2 shows the significant results from the association of the relevant 
metabolites with fasting glucose using MR. Among the 20 eligible metabolite-glucose/type 
2 diabetes sets, genetically decreased levels of eight metabolites associated significantly 
with fasting glucose (FDR < 0.05). These include XL-HDL-cholesterol (FDR = 0.03), XL-HDL-
phospholipids (FDR = 2.76 × 10-3), XS-VLDL-phospholipids (FDR = 0.04), XL-HDL-free 
cholesterol (FDR = 0.01), L-HDL-cholesterol (FDR = 0.01), L-HDL-free cholesterol (FDR = 2.76 
× 10-3), HDL-cholesterol (FDR = 0.04), and IDL-phospholipids (FDR = 0.04). After the pathway-
based subset analysis, a causal role for IDL-phospholipids was not supported (FDR = 0.17). 
At the same time, pathway-based sensitivity analysis revealed possibly causal roles for three 
additional metabolic markers, including S-VLDL-triglycerides (FDR = 0.04), S-HDL-
triglycerides (FDR = 0.04), and plasma-triglycerides (FDR = 0.04). Table 3 shows the 
suggested causal effects of metabolites on type 2 diabetes, i.e. XS-VLDL-phospholipids, IDL-
phospholipids and plasma-triglycerides. Interestingly, the statistical significance for both XS-
VLDL-phospholipids and IDL-phospholipids in the initial results are filtered out after the 
sensitivity analysis (FDR: XS-VLDL-phospholipids 0.03 vs 0.31; IDL-phospholipids 0.01 vs
0.24), while plasma-triglycerides shift to being borderline significant (FDR = 0.07 vs 0.046). 
The results from the full lists of performed forward MR tests are given in Supplemental 
Table 4 and the SNPs included in the all the genetic risk scores are given in Supplemental 
Table 5.  
The significant results of the backward MR are shown in Table 4. We found that 
genetic predisposition to type 2 diabetes is associated with lower levels of 
phosphatidylcholine alkyl-acyl 42:5 (FDR = 0.02) and phosphatidylcholine alkyl-acyl 44:4 
(FDR = 0.02) and higher levels of alanine (FDR = 0.02). The details of all the tested SNP sets 
are shown in Supplemental Table 6 and Supplemental Table 7. No possible causal role for 
glucose was supported. As the genetic risk scores of the glucose explained less than 1% of 
variance, the backward MR with pathway analysis is not performed. Figure 4 displays the 
suggested paths discovered by the MR approach after the pathway-based sensitivity 
analysis. Overall, the associations estimated by MR were in the consistent direction with 
the observed associations in ERF.  
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Table 2 Mendelian randomization of metabolites (exposure) on fasting glucose (outcome). 
Fasting glucose Fasting glucose*
Exposure 
R2 
(%) 
n  FDR
R2 
(%) 
n  FDR 
S-VLDL-triglycerides 4.80 13 0.06 0.08 3.92 10 0.08 0.04 
XS-VLDL-phospholipids 7.97 23 -0.06 0.04 6.30 15 -0.07 0.04 
IDL-phospholipids 7.16 26 -0.06 0.04 4.84 15 -0.05 0.17 
XL-HDL-cholesterol 4.25 10 -0.09 0.03 4.25 10 -0.09 0.03 
XL-HDL-free cholesterol 6.48 16 -0.09 0.01† 6.48 16 -0.09 0.01† 
XL-HDL-phospholipids 10.21 22 -0.08 2.76 × 10-3† 9.61 19 -0.09 1.72 × 10-3† 
L-HDL-cholesterol 7.58 17 -0.08 0.01† 7.41 16 -0.08 0.01† 
L-HDL-free cholesterol 7.58 18 -0.09 2.76 × 10-3† 7.27 16 -0.10 1.72 × 10-3† 
HDL-cholesterol 4.84 10 -0.07 0.04 4.67 9 -0.07 0.04 
S-HDL-triglycerides 3.97 11 0.07 0.08 3.52 9 0.09 0.04 
Plasma-triglycerides 3.93 11 0.07 0.08 2.78 7 0.10 0.04 
The Mendelian randomization sets with FDR < 0.05 with respect to either outcome is shown in this table. R2 (%): 
the percentage of explained variance in the exposure by genetic risk score. n: the number of SNPs in the genetic 
risk score. : the weighted effect of the genetic risk score of exposure on outcome FDR: A false discovery rate on 
the number of Mendelian randomization sets adjusted P-value. * results of pathway-based analysis. † the 
Mendelian randomization sets with P-value < Bonferroni P-value 2.5  10-3 (0.05/20). 
Table 3 Mendelian randomization of metabolites (exposure) on type 2 diabetes (outcome)  
Type 2 diabetes Type 2 diabetes*
Exposure R2 (%) n  FDR  R2 (%) n  FDR 
XS-VLDL-phospholipids 8.02 23 -0.08 0.03 6.34 
1
5 -0.06 0.31 
IDL-phospholipids 7.18 26 -0.09 0.01 4.86 
1
5 -0.07 0.24 
Plasma-triglycerides 4.21 12 0.08 0.07 3.16 8 0.12 0.046† 
The Mendelian randomization sets with either FDR < 0.05 are shown in this table. R2 (%): the percentage of 
explained variance in the exposure by genetic risk score. n: the number of SNPs in the genetic risk score. : the 
weighted effect of the genetic risk score of exposure on outcome. FDR: A false discovery rate on the number of 
Mendelian randomization sets adjusted P-value. * results of pathway-based analysis. † the Mendelian 
randomization sets with P-value < Bonferroni P-value 2.5  10-3 (0.05/20). 
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Figure 3 Metabolites correlated with markers of T2DM and anthropometric risk factors. A: Phosphatidylcholines; 
B: Triglycerides; C: small molecules and amino acids; D: lipoproteins. The associations between metabolites and 
continuous variables were performed by partial correlation in the non-diabetic population. The color in the figure 
displays the value of correlation coefficient. The associations between metabolites and type 2 diabetes status were 
performed by logistic regression. The color in the figure displays the standardized effect of metabolites on type 2 
diabetes. Age, sex and lipid lowering medication are considered as covariates. FG: fasting glucose. FI: fasting insulin. 
HOMA-IR: homeostasis model assessment of insulin resistance. BMI: body mass index. WHR: waist-to-hip ratio. *: 
P-value < 5.24 × 10-5 (0.05/191/5). : P-value < 0.05 and P-value  5.24 × 10-5. (B): Selected measurement is from 
the Biocrates platform when the same metabolite is also captured by the LC-MS/NMR-COMP/NMR-LIPO platform. 
(E): Selected measurement is from the ESI-MS platform when the same metabolite is also captured by the LC-MS 
platform.
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Table 4 Mendelian randomization of fasting glucose/type 2 diabetes (exposure) on metabolites (outcome)  
Outcome 
Fasting glucose Type 2 diabetes 
R2 (%) n  FDR R2 (%) n  FDR 
PC alkyl-acyl C42:5 0.83 13 NP NP 1.51 32 -0.08 0.02† 
PC alkyl-acyl C44:4 1.10 15 0.02 0.95 1.51 32 -0.08 0.02 
Alanine 1.06 14 0.06 0.48 1.48 31 0.08 0.02 
The Mendelian randomization sets with either FDR < 0.05 are shown in this table. PC: Phosphatidylcholine. R2 (%): 
the percentage of explained variance in the exposure by genetic risk score. n: the number of SNPs in the genetic 
risk score. : the weighted effect of the genetic risk score of exposure on outcome. FDR: A false discovery rate on 
the number of Mendelian randomization sets adjusted P-value. NP: Not performed. † the Mendelian 
randomization sets with P-value < Bonferroni P-value 6.33  10-4 (0.05/79).  
Figure 4 Suggested causal paths for glucose homeostasis and type 2 diabetes after pathway-based sensitivity 
analysis. FG: fasting glucose; TG: triglycerides; C: cholesterol; FC: free cholesterol; P: phospholipids; PCae: 
phosphatidylcholine alkyl-acyl. The gene names above the metabolite names indicate the loci where the SNPs used 
in the genetic risk score are located.
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Discussion 
We selected 124 metabolites that are correlated with glucose in the non-diabetic 
population and, using MR, we tested if this metabolic profile points to any causal paths 
involved in glucose level or type 2 diabetes. Combining metabolomics and MR, we detected 
fourteen candidate causal associations; ten metabolites influencing fasting glucose, one 
influencing type 2 diabetes and three influenced by type 2 diabetes.  
Our initial observational association tests yielded correlation estimates within the 
expected range of power calculations for the 124 glucose-associated metabolites. To our 
knowledge, 35 of these metabolites were previously published to be associated with 
glucose or type 2 diabetes, including 31 concordant and 4 discordant results (Supplemental 
Table 3) in studies with very limited sample size40, 41. Our significant results on subfractions 
of lipoproteins yielded resolution on the established association of dyslipidemia, especially 
for the HDL subfractions.  
One of our main findings is that genetically increased cholesterol, free cholesterol 
and phospholipid content of circulating XL-HDL and L-HDL particles together with XS-VLDL-
phospholipids associate with decreased glucose level. Our second finding is that triglyceride 
content of S-HDL and S-VLDL particles as well as total plasma triglycerides seem to have a 
glucose increasing causal effect and considering the total triglycerides, this effect has been 
extended to the outcome type 2 diabetes. Finally, we showed that genetic predisposition 
to type 2 diabetes associates with lower levels of two alkyl-acyl phosphatidylcholines and 
higher level of alanine. Our report is the first one using higher resolution (metabolomics 
driven) lipoprotein based exposure variables. Hence no other study exists for comparison 
except for HDL-cholesterol, LDL-cholesterol and total triglycerides which, from routine 
biochemistry, have been previously studied as exposure variables for MR to understand 
their causal effects on type 2 diabetes and glucose (An overview is given in Table 5). Our 
method is similar to the method of White et al9 and Fall et al6 in terms of the application of 
the genetic risk score function utilizing the DIAGRAM/MAGIC datasets. White et al9 showed 
that high levels of all three blood lipids (HDL-cholesterol, LDL-cholesterol and plasma 
triglycerides) were genetically associated with a lower risk of diabetes, although the results 
for triglycerides were inconsistent. However, the study did not consider the genetic variants 
that might be involved in the confounding phenotypes such as BMI, WHR, nor did they 
exclude the SNPs that are involved in type 2 diabetes directly. Fall et al6 showed that the 
association between total HDL-cholesterol risk score and low fasting glucose was 
attenuated when adjusted for the effects of SNPs on LDL-cholesterol, triglycerides and 
surrogates of adiposity. Different from the two studies mentioned above, current MR was 
done in a broad spectrum of metabolites included a detailed sub-classification of 
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lipoproteins that have not been tested before. Using such high resolution phenotypes, we 
demonstrate that decreasing effect of HDL-cholesterol on fasting glucose is more specific 
to the L-HDL or XL-HDL subclasses, whereas for S-HDL-triglycerides, an increasing effect 
exists. These results advocate that a higher resolution of high density in lipoproteins may 
reveal the observed epidemiological associations or biological functions of HDL-cholesterol 
more accurately and will uncover the mystery of complex lipids such as HDL. Certain HDL 
sub-fractions and characteristics of these sub-fractions may have independent associations 
with glucose, particularly for the small vs large size particles. Such a different role for HDL-
triglycerides and HDL-large fractions occurred upon sleeve gastrectomy of obese patients 
and was associated with reduced insulin resistance and HDL remodeling42. In addition, as 
experimentally shown, HDL indeed may mediate glucose regulation in the pathophysiology 
of T2DM43. Suggested mechanisms include44: (i) Insulin secretion from pancreatic beta cells 
combating cellular lipid accumulation and lipotoxicity45, endoplasmic reticulum stress and 
apoptosis46, 47; (ii) Insulin-independent glucose uptake by muscle via the AMP-activated 
protein kinase48, calcium/calmodulin activated protein kinase49; (iii) and insulin sensitivity50. 
The ILLUMINATE trial51 demonstrated that in a subgroup of diabetic participants statin 
treatment led to increased glucose levels, while this effect was not observed in participants 
treated with combination of statin and CETP-inhibitor torcetrapib, suggesting that CETP 
inhibition and consequent HDL cholesterol elevation may improve glycemic control in 
diabetic patients. It is of note that CETP gene is a major determinant of XL-HDL and was 
included in our MR experiment. 
We have detected three associations potentially pointing out an influence of type 
2 diabetes over the metabolome. The first two are long chain polyunsaturated alkyl-acyl 
phosphatidylcholines which are decreased in type 2 diabetes. This is interesting considering 
our previous report which showed that three shorter chain polyunsaturated alkyl-acyl 
phosphatidylcholines are increased in type 2 diabetes patients and decreased in patients 
using the glucose lowering drug metformin52. The other molecule affected by diabetes was 
alanine, which is a non-essential amino acid and can be synthesized in the body from 
pyruvate and branched chain amino acids such as valine, leucine, and isoleucine. Alanine 
has been previously implicated in glucose response53. The enzyme alanine aminotransferase 
(ALT) catalyzes the conversion of alanine to pyruvate and glutamate and high levels of ALT 
indicate liver damage.  
Our study differs from previous reports in three ways. Firstly, we used a 
bidirectional approach and included a wide range of molecular markers to be tested, using 
high resolution phenotypes, measured by MS or NMR. Secondly, we exploited pathway 
knowledge that was gathered through an automated workflow to perform subset analysis 
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in MR. Statistical methods that deal with pleiotropy in MR analyses, such as the Egger 
regression method9, 54, 55, exist but are still being refined. They all rely on additional strong 
assumptions about the unobserved pleiotropy, such as the InSIDE assumption, and are 
sensitive to violations of these assumptions. They also suffer from a lack of power. However, 
one can harness the available genetic and biological knowledge in online databases in order 
to maximize the uniqueness of the genetic risk score for the exposure variable for this 
purpose and to validate the chosen instruments. It has to be mentioned that although 
powerful for most metabolites, our approach with the genetic and biological knowledge is 
also firstly conservative because it ultimately relies on the comprehensiveness of the 
content of the databases that are included. As a consequence, all loci for which no strong 
evidence is present that a nearby gene directly affects the exposure, e.g. because the 
involved gene is affected through a yet unknown regulatory mechanism, are excluded. 
Considering glucose for which the instrumental strength was initially lower compared to the 
others, the pathway approach yielded lower explained variance in exposure (R2 < 1%). While 
one can argue that this would lead to lack of power, it may also reflect the fact that such 
polygenic traits like glucose may not be the most suitable exposure variables for an MR 
analysis. To limit this, we utilized the large-population-based GWAS of broad-spectrum 
metabolites and fasting glucose/type 2 diabetes with the combined instrument MR 
approach25. We want to point out that although we controlled the pleiotropic effects 
between the outcome and exposure by (1) excluding the known predictors, (2) 
heterogeneity tests and (3) finally by pathway analysis, we cannot exclude a correlation 
between the genetic instruments tested, especially for the HDL subfractions, for which the 
genes coding overlap. Whilst effect alleles were weighted by their original effects estimates 
from each GWAS (of exposure variables), there was strong overlap in the SNPs used for 
different lipid subfractions, meaning the genetic instruments were not highly specific to 
these subfractions. 
In conclusion, using MR, the present study provide evidence for potentially causal metabolic 
paths of glucose homeostasis and type 2 diabetes. Our results indicate that increase of large 
HDL particles might have decreasing effect on glucose, while increase of small HDL particles 
have increasing effect, refining earlier MR findings suggesting a possible causal effect of HDL 
on glucose levels, as well as pointing these particles out as targets for glucose management. 
We further found evidence that type 2 diabetes may alter levels of alkyl-acyl 
phosphatidylcholines and alanine which also here can be translated into prevention of 
disease complications and prognosis. 
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Abstract 
Progress in high-throughput metabolic profiling provides unprecedented opportunities to 
obtain insights into the effects of drugs on human metabolism. The Biobanking 
BioMolecular Research Infrastructure of the Netherlands (BBMRI-NL) has constructed an 
atlas of drug-metabolite associations for 87 commonly prescribed drugs and 150 clinically 
relevant plasma-based metabolites assessed by proton nuclear magnetic resonance (1H-
NMR). The atlas involves a meta-analysis of ten cohorts (18,873 persons) and uncovers 
1,071 drug-metabolite associations after evaluating confounders including co-treatment. 
We show the effect estimates of statins on metabolites from the cross-sectional study are 
comparable to those from intervention and genetic observational studies. Further data 
integration links proton pump inhibitors to circulating metabolites, liver function, hepatic 
steatosis and the gut microbiome. Our atlas provides a tool for targeted experimental 
pharmaceutical research and clinical trials to improve drug efficacy, safety and repurposing. 
We provide a web-based resource for visualization of the atlas 
(http://bbmri.researchlumc.nl/atlas/). 
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In the past decade, metabolomics technology has developed rapidly1, facilitating 
large-scale studies which highlighted the importance of differential molecular dynamics 
captured in a wide range of common complex diseases, including diabetes, cardiovascular 
disease, asthma and dementia2-9. The human metabolome is in part driven by the human 
genome and new genetic drivers of these metabolites continue to be revealed.10-13. The past 
decade has also seen major successes in understanding the relation of the human 
metabolome to the exposome, e.g. lifestyle, nutrition, environment and microbiome14-16. 
Although the use of drugs is recognized to have a major effect on the metabolism, our 
knowledge on the drug-metabolite associations incomplete and limited to the most 
commonly prescribed drugs, e.g. statins, metformin and antihypertensives17-22. In addition, 
even for the commonly prescribed drugs, the metabolic and physiologic effects, including 
on- or off-target effects, are virtually unexplored. Mapping these unexplored drug-
metabolite associations is crucial for pharmaco-epidemiological research and practice as it 
may offer new avenues to improve drug efficacy, enable repurposing of drugs23-25 and 
improve our understanding of the off-target effects of drugs occurring in an individual 
patient26,27. However, pointing out such associations is complicated since confounding may 
occur due to the metabolic changes that are the cause or the consequence of the pathology 
for which the drug is prescribed. Furthermore, many patients are treated with multiple 
drugs for multiple diseases, raising the important question of whether drug-metabolite 
associations are confounded by co-treatment28. Last not but least, longitudinal observations 
are often lacking for relatively rare off-target effects, forcing clinical decision making to be 
based on cross-sectional data. 
The aim of the present study was to develop a comprehensive atlas of the 
associations between a wide range of commonly prescribed drugs (Supplementary Table 1) 
and 150 plasma-based metabolites as measured by proton nuclear magnetic resonance (1H-
NMR) platform of Nightingale Health (Supplementary Table 2). The platform allows rapid 
and cost-effective characterization of metabolites in human blood and it has been 
successfully used globally to discover and validate disease-metabolite associations29, such 
as diabetes30, dementia6, cardiovascular diseases31,32, migraine33, graves’ disease34 and 
mortality35,36. Nightingale Health is now being validated for use in clinical care, which makes 
it timely to develop a pharmacological metabolomics atlas for this platform that can be used 
in research as well as clinical care. The term “metabolite” throughout the manuscript does 
not refer to the products of drug metabolism but to endogenous metabolites that are 
naturally produced by an organism and in this context includes lipoprotein particles as well. 
In the present paper, we work through a series of examples of applications of the atlas, 
including disentangling the disease effect of the drug-metabolite associations and exploring 
in-depth the interaction of metabolites and two drugs, statins and proton pump inhibitors 
(PPIs). 
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Results 
Overall drug-metabolite associations 
We meta-analyzed 12 datasets of ten Dutch cohorts (Supplementary Table 3, 
18,873 individuals) from Biobanking and BioMolecular resources Research Infrastructure of 
the Netherlands (BBMRI-NL). We discovered 2,087 significant associations out of 13,050 
meta-analyzed tests involving 87 drugs and 150 metabolites in model 1 with adjustment for 
age and sex (Bonferroni P-value threshold = 1.9 × 10-5). The number of drug users ranged 
from 3,023 (16.0%, for lipophilic statin) down to 20 (0.11%, for leukotriene receptor 
antagonists). Among the 13,050 tests, 543 (4%) showed heterogeneity across datasets and 
for these we used the random-effect model to pool data across datasets. Supplementary 
Table 4 shows all drug-metabolite associations tested across different models, as well as 
disease-metabolite associations. Over the metabolites studied, effect estimates derived 
from different datasets agreed convincingly (pairwise P-values ranging from 1.67 × 10-11 to 
1.0 × 10-318 of pairwise correlation tests) (Supplementary Figure 1 and Supplementary Table 
5). Figure 1 shows the associations of model 1 for the top 15 drugs that were associated 
with the largest number of metabolites. The 15 drugs belong to five clinical pharmacological 
groups: (1) six antihypertensives, i.e. selective beta-blockers, angiotensin II antagonists, ACE 
inhibitors, high-ceiling diuretics, low-ceiling diuretics and potassium-sparing agents, (2) two 
glucose-lowering drugs, i.e. metformin and sulfonamides-urea derivatives, (3) two lipid-
modifying drugs, i.e. lipophilic statin and hydrophilic statin, (4) three other cardiovascular-
related drugs, i.e. vitamin K antagonists, antithrombotic agents-acetylsalicylic acid and 
digoxin, and (5) two others including PPIs and selective serotonin reuptake inhibitors 
(SSRIs). Thirteen of the top 15 drugs that were associated with the largest number of 
metabolites were cardio-metabolic related drugs, which may be for a large part explained 
by the fact that the numbers of users were large and the current metabolome spectrum 
contains mainly lipids and correlated with each other (Extended Data Figure 1). 
Effects of BMI, smoking and co-treatment as major confounders 
Next, we studied the potential confounding effect of BMI and smoking. In total, 
1,640 of the 2,087 significant associations (78.6%) in model 1 were still significant after the 
adjustment for BMI and smoking in model 2 (Extended Data Figure 2 and Figure 1). The 
drugs for which the evidence for association was most dramatically impacted by adjustment 
for BMI and smoking were SSRIs: 59 of the initial 65 SSRIs-metabolite associations (90.8%) 
were no longer significant after adjustment for BMI and smoking. A major impact of 
adjustment was also seen for two antihypertensives: 56 (60.9%) associations with high-
ceiling-diuretics were no longer significant, and 53 (49.1%) associations with angiotensin-II-
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antagonists lost their significance. After we additionally excluded the confounding of other 
drugs by adjustment for co-treatments (Extended Data Figure 3 and Figure 2), 1,071 
significant associations remained to be investigated. For five out of six antihypertensives, 
the associations with LDL and IDL particles were explained by co-treatments (Figure 2). 
Notably, statin use was correlated with antihypertensives and associated with LDL and IDL 
particles, which leads to a false discovery association of LDL and IDL particles and 
antihypertensives. Most antihypertensives associations disappeared after adjusting for co-
treatment including statins, except for 14.3% of the selective beta-blocker and all of the 
angiotensin II antagonists which remained significantly associated with LDL and IDL 
particles, suggesting that these associations are independent of co-treatments. In our 
epidemiological study, metformin was co-prescribed with hydrophilic statins and both drugs 
were associated to similar circulating metabolites, i.e. there were 85 metabolites associated 
with metformin, and 59 of these were also associated with hydrophilic statins. However, 
none of the metformin-metabolite associations were explained by hydrophilic statins, 
suggesting that metformin and hydrophilic statins are independently associated with the 
metabolites (Figure 2). These results above were confirmed by our sensitivity analysis from 
sub-samples of patients who use one drug only: all significant associations in the sensitivity 
analyses remained significant in the model with co-treatment adjusted for (Extended Data 
Figure 4).  
Examples of applications of the atlas 
Effect of indicated disease: drug-metabolite associations explained by the indication  
First, we tested whether indicated diseases causally related to the drug-related 
metabolites using genetic risk score of the disease as an instrumental variable in Mendelian 
randomization (MR) (Supplementary Table 6, 7). Second, we associated the drug-related 
metabolites with the indicated disease in those who were not receiving the treatment, i.e. 
the on-target-treatment-naive population (Supplementary Table 4). For instance, in the 
current study, metformin use is associated with increasing alanine, but we also know that 
type 2 diabetes (causally by MR) increases alanine levels in the blood4. This finding raises 
the question of whether the disease (type 2 diabetes) or its endophenotype partially or fully 
explain the association of metformin and alanine. This hypothesis was supported by the 
finding that after excluding all metformin users, type 2 diabetes was still associated with 
increasing alanine levels (beta = 0.42, P-value = 8.3 × 10-19). Integration of the findings on 
drug-metabolite and disease-metabolite associations suggests that alanine levels in blood 
are most likely raised by type 2 diabetes effect rather than by metformin effect.  
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Figure 1 Drug-metabolite associations in baseline model versus model 2 with adjustment for BMI and smoking. 
The top 15 drugs that were associated with the largest number of metabolites in the baseline model are ordered 
and shown in the figure. The first letter of the Anatomical Therapeutic Chemical (ATC) code is shown in front of 
the drug names to identify different categories. N: nervous system; C: cardiovascular system; A: alimentary tract 
and metabolism; B: blood and blood forming organs. Sample sizes of the drug users and non-users in the baseline 
model and BMI and smoking adjusted model are shown behind the drug names, respectively. Red: positive 
significant associations in the baseline model (P < 1.9 × 10-5). Light red: positive non-significant associations in the 
baseline model (P ≥ 1.9 × 10-5). Blue: negatively significant associations in the baseline model (P < 1.9 × 10-5). Light 
blue: negatively non-significant associations in the baseline model (P ≥ 1.9 × 10-5). Star in boxes (*): The direction 
and significance status did not change between baseline model and model 2 (P < 1.9 × 10-5).
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Figure 2 Drug-metabolite associations in model 2 versus model 3 with adjustment for co-treatments. The top 15 
drugs that were associated with the largest number of metabolites are ordered and shown in the figure. The first 
letter of the Anatomical Therapeutic Chemical (ATC) code is shown in front of the drug names to identify different 
categories. N: nervous system; C: cardiovascular system; A: alimentary tract and metabolism; B: blood and blood 
forming organs. Sample sizes of the drug users and non-users in model 2 and model 3 are shown behind the drug 
names, respectively. Red: positive significant associations in model 2 (P < 1.9 × 10-5). Light red: positive non-
significant associations in in model 2 (P ≥ 1.9 × 10-5). Blue: negatively significant associations in in model 2 (P < 1.9 
× 10-5). Light blue: negatively non-significant associations in in model 2 (P ≥ 1.9 × 10-5). Star in boxes (*): The 
direction and significance status did not change between model 2 and model 3 (P-value threshold is multiple 
testing corrected per drug).
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Following the line of research outlined above, we noticed that hypertension or high 
blood pressure partially or fully explained the associations of very-low-density lipoprotein 
(VLDL) particles and various triglycerides with beta-blockers and low-ceiling diuretics. 
Depression partially or fully explained the association of estimated degree of unsaturation 
of fatty acids and SSRIs, but not for those high-density lipoprotein (HDL) particles. Notably, 
type 2 diabetes or its endophenotype, fasting glucose, partially or fully explained a 
substantial part of associations, including 98.8% associations with metformin and 100% with 
sulfonamides-urea derivatives, based on a nominal significance level in the disease-
metabolite associations (P-value < 0.05, Figure 3). With such a strict exclusion of effect of 
the indicated disease, we still found acetate was negatively associated with metformin 
effect, and there is no evidence that the relationship is resulted from the effect of type 2 
diabetes or fasting glucose levels.  
Effects of drugs in cross-sectional and longitudinal studies 
We compared our results on statin-metabolite associations in the present cross-
sectional study with that of the longitudinal study published earlier by Wurtz and co-
workers17. In their paper, the changes of metabolite concentrations in blood (two time 
points per individual) were compared between 716 patients who started statin therapy 
during follow-up and 4,874 persistent non-users17. There are 48 metabolites that 
overlapped with our study17, in which metabolite and statin use were assessed at the same 
time in 3,023 individuals who were using lipophilic statin and 15,850 non-users, providing a 
cross-sectional snapshot. Twenty-nine (60%) of the metabolites showed consistently 
significant results between the two studies (Figure 4). We further checked the metabolite 
associations with genetic variant rs12916-T located in gene HMGCR (3-Hydroxy-3-
Methylglutaryl-CoA Reductase). This genetic variant was used as an instrumental variable 
for the effect of statins as the protective T allele results in low functioning HMG-CoA 
reductase, which is one of the pharmacological targeted effects of statins17,37. Figure 4 
shows that 20 of the 29 associations (69.0%) were consistently and significantly associated 
with rs12916-T in both the cross-sectional and longitudinal analyses. The 20 statin-
metabolite associations involved mainly fatty acids (30.0%) and non-HDL cholesterols and 
lipoprotein particles (50.0%). Meanwhile, 15 of the 19 metabolites (80%) that were 
inconsistently associated with statins between our study and the previous study17 were not 
associated with rs12916-T.  
We additionally identified 35 of the tested 55 statin-related metabolites (63.6%) 
associated with rs12916-T in the same direction as with lipophilic statins (Figure 4 and 
Supplementary Table 8). Twenty-five of them are new and complement the findings of the 
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above-mentioned study by Wurtz and co-workers17. The new metabolites emerging, by 
association with rs12916-T in our cross-sectional analyses, involved very small to medium 
VLDL particles, IDL particles, LDL particles and the total phosphatidylcholine and other 
choline.  
Figure 3 Drug-metabolite associations in model 3 versus significance after disentangling the indicated 
disease/endophenotype effect. The drugs in the top 15 drugs that were associated with the largest number of 
metabolites are ordered and shown in the figure. The first letter of the Anatomical Therapeutic Chemical (ATC) 
code is shown in front of the drug names to identify the different categories. N: nervous system; C: cardiovascular 
system; A: alimentary tract and metabolism. Sample size of the drug users and non-users in model 3 and sample 
size of the cases and controls in the disease-metabolite associations are shown behind the drug names, 
respectively. The sample size of the association of fasting glucose and metabolites in the non-diabetes participants 
is 5,871. The sample size of the association of blood pressure and metabolites in the non-hypertension participants 
is 2,263. Red: positive significant associations in model 3. Light red: positive non-significant associations in model 
3. Blue: negatively significant associations in model 3. Light blue: negatively non-significant associations in model 
3. Star in boxes (*): The significant associations confirmed after disentangling the disease/endophenotype effect 
(P < 0.05 in the disease-metabolite associations). Common in boxes (,): The associations confirmed after 
disentangling the disease/endophenotype effect (P-value threshold after multiple testing corrected per disease ≤ 
P < 0.05). 
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Figure 4 Comparison of statin-metabolite associations between cross-sectional study, longitudinal study and 
genetic study. Figure 5A shows the comparison of statin-metabolite associations between the current cross-
sectional study, longitudinal study17 and genetic study. The results of statin-metabolite associations in the 
longitudinal study are shown as the previous study in standard deviation (SD)-scaled metabolite concentration 
units (top axis) and related to the lowering effect on LDL cholesterol (bottom axis). The results of rs12916-T-
metabolite associations in Figure 5A are shown in effect estimate per SD and related to the lowering effect on LDL 
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cholesterol (bottom axis). Figure 5B shows the comparison of significant statin-metabolite associations in the 
cross-sectional study and genetic study. The results of statin-metabolite associations are shown in the effect 
estimate (standardized metabolite concentration unit; bottom axis) and the results of rs12916-T-metabolite 
associations are shown in five times of the effect estimate (standardized metabolite concentration unit; top axis). 
The error bars of the Figure 5 are 95% confidence intervals (CI) which were statistically corrected for multiple 
testing. It means that if the error bar crosses the line zero, the association is not significant at the multiple testing 
significance level. * Statistical data were extracted from the previous longitudinal study17.  
Cross-omics analysis exploring the association of PPIs, circulating metabolites, liver 
function and gut microbiome  
In our study, PPIs were found to be associated with 55 metabolites after 
adjustment of co-treatment (Figure 5A), involving small to extremely large VLDL, large HDL, 
triglycerides particles, monounsaturated fatty acids, isoleucine, creatinine and glycoprotein 
acetyls mainly a1-acid glycoprotein (glycoprotein). These associations were validated by 
drug-dose-metabolite associations. Analysis in the population-based cohort, Rotterdam 
Study (n = 700), shows a high consistency of the association between PPI (yes/no) and 
metabolites and the Defined Daily Dose in PPI users and metabolites (Extended Data Figure 
5).  
PPIs are often used by patients with cirrhosis and in these patients PPIs are 
associated with infections and worsening prognosis38. We next studied in Rotterdam Study 
(n = 3,436) whether the PPI-associated metabolites are also associated to liver function, 
including biochemical variables of liver function test and hepatic steatosis. Figure 5A and 
Figure 5B show a high consistency of the patterns of association between PPIs and 
metabolites and between metabolites and liver function (Supplementary Table 9). The 
consistency of associations in terms of the number of significant associations overlapping is 
for hepatic steatosis 98.2%, gamma-glutamyl transferase (GGT) 80.0% and alanine 
transaminase (ALT) 81.8% (positively associated), and 90.9% for the ratio of aspartate 
transaminase and ALT (AST/ALT) and 69.1% for total bilirubin (inversely associated). Of 
these liver function variables, total bilirubin and GGT were significantly associated with 
reported PPI use in Rotterdam Study (Supplementary Table 10).  
We then studied the PPI-associated metabolites in relation to microbial diversity 
and the abundance of microbiota that are pharmacologically driven by PPI use in 
population39-43. We found that 94.5% of the metabolites associated with PPIs are also 
associated with gut microbial (alpha) diversity in a meta-analyses of 2,305 participants that 
did not use antibiotics (Figure 5C and Supplementary Table 11). Of the 92 gut microbiota of 
which the abundances were associated with PPI use39, 45 were available to test the 
association with metabolites (Supplementary Table 12). We found that three common 
microbiota (phylum Tenericutes, class Mollicutes and family Ruminococcaceae) which 
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showed reduced abundance in PPI users had a consistent metabolite association pattern 
with the PPI-metabolite association pattern but in the opposite direction (Figure 5D and 
Supplementary Table 13). The genera of Scardovia showed an increased abundance in the 
gut of patients using PPIs. Although the genera of Scardovia showed a similar metabolite 
association pattern to PPIs, of note is that only the association to glycoprotein reaches 
statistical significance when adjusted for multiple testing.  
Figure 5 Integrating data of proton pump inhibitors (PPIs), metabolites, liver function measurements and gut 
microbiome. The figure shows the significant results after integrating the directions of the associations of between 
PPIs, metabolites, liver function measurements and gut microbiome. GGT: Gamma-glutamyl transferase. ALT: 
alanine transaminase. AST/ALT: ratio of aspartate transaminase and ALT. Red: positive association. Blue: negative 
association. The depth of red and blue presents the value of effect estimate per standard error. Grey: associations 
were not performed. Star in boxes (*): significance of the associations. 
Discussion 
To our knowledge, we performed the most comprehensive analysis of the 
interaction between 87 commonly prescribed drugs and as many as 150 circulating 
metabolites measured by 1H-NMR in 18,873 individuals. We uncovered 1,071 drug-
metabolite associations after adjustment for age, sex, BMI, smoking and co-treatment, 
covering a wide range of drug-metabolite associations which were not studied before. We 
also demonstrated three examples of applications of the atlas, disentangling disease (e.g. 
type 2 diabetes) and therapy (e.g. metformin) effects, aligning longitudinal and genetic 
analysis with our large-scale cross-sectional findings, and ultimately, linking PPI-metabolite 
interactions to the gut microbiome abundance and liver function. 
Although many of the metabolites cluster strongly in populations (Extended Data 
Figure 1), our analysis shows the direction and significance of drug-metabolite associations 
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are not always the same among different metabolites in the same cluster. This especially 
true for VLDL and HDL particles. This is consistent with previous studies of the role of lipid 
particle profiles and diseases4,6,31-34,44,45. This is also true for amino acids. In the Rotterdam 
Study, histone is clustering strongly with leucine, valine and isoleucine (P-values of 
correlation tests 3.3 × 10-23). But histone is negatively associated with selective beta-blocker 
use (Figure 3), and leucine, valine and isoleucine are positively associated with selective 
beta-blocker use. We showed that BMI is a major confounder of associations with SSRIs. 
The high proportion of elimination in the SSRIs-metabolite associations (90.8%) after 
adjustment for smoking and BMI may be explained by the fact that body weight is a strong 
determinant of circulating metabolites and significant weight loss when not dieting or 
weight gain is part of the diagnostic criteria for depression46. After adjustment for co-
treatment, the similar significant association patterns between different drugs (e.g. 
angiotensin II antagonists and metformin) may imply that drug-metabolite associations are 
independently associated with a similar shift in metabolism, but this is only true if the 
pathology for which the two drugs are prescribed does not explain the drug-metabolite 
association. For instance, if metabolic syndrome is associated with a shift in circulating 
metabolites, this may result in a false discovery association with drugs often prescribed to 
these patients (e.g. statins, antihypertensives and metformin). This type of confounding was 
further addressed by investigating whether drug-metabolite associations are related to the 
pathology (e.g. diabetes, hypertension, dyslipidemia) that indicated prescription. As a 
typical metabolic disorder, evidences show that type 2 diabetes explains a substantial 
glucose-lowering-drug-metabolite associations. The validation of the effects awaits clinical 
trials or prospective studies, but our example illustrates how the drug-metabolite atlas can 
be used in combination with disease-metabolite studies to tease out drug and disease 
effects and generate testable hypothesis for future trials. We further showed that to some 
extent the statin-metabolite associations in a large-scale cross-sectional study can mimic 
that of longitudinal effect of statin administration, which are preferred from a 
methodological perspective. It is strengthened as the two studies are benchmarked by MR. 
These findings suggest that the atlas does yield informative associations that may be tested 
in future trials and follow-up studies.  
The third and by far the most exciting example integrates the atlas data into state-
of-the-art research questions. The finding that PPIs are associated with lower gut microbial 
diversity and a shift of the composition of the gut microbiome has been long 
recognized39,41,47. Interestingly, a recent study48 reported that non-diabetic obese patients 
with hepatic steatosis have low microbial gene richness and increased genetic potential for 
processing of dietary lipids and dysregulation of branched-chain amino acid (BCAA) 
metabolism, which is very much consistent with our findings. Zooming in into oral bacteria, 
genus Scardovia is found to be increased in the gut microbiome of PPI users39. This raises 
the hypothesis that due to the PPI related changes of the gastric acid secretion in stomach, 
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these microbiotas are reaching the gastrointestinal tract, very similar to the mechanism 
described in mice40 and in the study of human gut microbiome in patients with liver 
cirrhosis49. Genus Scardovia was most strongly and significantly associated with 
glycoprotein, which is an intriguing metabolite from a clinical and epidemiological 
perspective, as this acute phase glycoprotein is synthesized in the liver50 and associated to 
a wide spectrum of incident diseases51, such as cardiovascular disease52, type 2 diabetes53, 
cognition6 and all-cause mortality36. A key question to answer in future studies is to what 
extent glycoprotein plays a mediating role in the relation of gut microbiome and morbidity. 
Our analysis validated the previous findings that human gut microbiome is changed in 
patients with liver cirrhosis49 and withdrawal of PPIs in the cirrhosis patients decrease oral-
origin taxa38 in a general population study which has very low prevalence of severe diseases 
such as advanced liver or kidney disease (less than 3%). Our study also showed associations 
of PPIs with liver function variables, gut microbiota and metabolites in the blood circulation. 
Again, a longitudinal or intervention study is still required to examine this hypothesis.  
Another note of interest is that the experimental study of the effect of PPIs on the 
gut microbiome in patients with cirrhosis is based on omeprazole38. If we compared the 
different drugs that are included in the PPI category, we found that omeprazole is indeed 
associated to the metabolites identified in the drug category analysis (Extended Data Figure 
6). However, we also found that other drugs such as lansoprazole are even more strongly 
and significantly associated, while the association to rabeprazole and esomeprazole is less 
strong and non-significant. Also these are interesting findings to follow-up. 
This first comprehensive drug-metabolite atlas provides a basis for future 
exploration of drug-metabolite interactions, using the omics-based approach as we used or 
other (un)targeted experimental and longitudinal pharmaceutical research in the future. 
Our study includes examples of how to use the atlas which can be extended to other 
settings. We have limited the atlas to the most common drugs, but the atlas can be 
extended in the future for more rare drugs as such data for this platform are generated in 
larger cohorts such as UK Biobank. These “mega” cohorts would also allow studying the 
interaction of multiple drugs intake with sufficient statistical power systematically. On the 
other hand, the current atlas can be a starting point for the future researches which focus 
on certain limited number of drugs with metabolomics to check drug interactions. Another 
future challenge is to extend the atlas to a wider range of metabolites measured by other 
platforms (e.g. mass spectrometry) and tissues (e.g. urine). The use of MR is a strength of 
the current study, as it enables us to disentangle the effect of drugs and indicated diseases. 
However, we are not always able to capture strong instruments for the MR test, which may 
reduce the power of our analyses aiming to exclude the disease effects. Since our 
knowledge of the genes mimicking effects of drugs and diseases is rapidly growing, we are 
optimistic that more powerful genetic instrumental variables will be identified in the near 
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future, opening windows of opportunities to MR analyses in pharmacometabolomics 
research and in clinical trials. 
Our comprehensive in vivo reference atlas will empower future clinical and 
pharmacological research in a number of areas. These not only advance knowledge on the 
mechanisms of on-target drug effects as well as off-target drug effects but may also provide 
evidence for the discovery of novel therapeutic applications of known drugs. By making the 
atlas freely available through a web-based browser with downloadable datasets 
(http://bbmri.researchlumc.nl/atlas/), we hope to facilitate the use of the data by 
pharmacists, drug developers and clinical researchers on their drug or disease of interest.  
Methods 
Study population 
The research was performed within the BBMRI-NL. The study included 18,873 
individuals from 12 datasets of ten Dutch cohorts who had metabolites measured by 
Nightingale Health, drug information based on the Anatomical Therapeutic Chemical (ATC) 
Classification and clinical phenotypes which allow us to control for confounders. These 
cohorts included Rotterdam Study with three datasets (RS Dataset 1: n = 2,975, RS Dataset 
2: n = 729, RS Dataset 3: n = 1,487)54, Netherlands Twin Register (NTR, n = 3,563)55, 
Netherlands Study of Depression and Anxiety (NESDA, n = 2,914)56, Leiden Longevity Study 
(LLS, n = 1,873)57, LifeLines DEEP cohort (n = 1,435)58, Hoorn Diabetes Care System Cohort 
(Hoorn DCS, n = 995)59, Alpha Omega Cohort (n = 877)60, The Maastricht Study (TMS, n = 
854)61, Erasmus Rucphen Family study (ERF, n = 778)62 and Leiden University MIgraine 
Neuro-Analysis (LUMINA, n = 393)63.  
In the examples of application atlas, we additionally involved Netherlands 
Epidemiology of Obesity Study (NEO; n = 6,603)64, which is an obese cohort but have 
adjusted for BMI in type 2 diabetes-metabolite associations by inverse probability weighting 
on BMI to make the results comparable with the Dutch general population. Cohort 
descriptions, specific data processing and ethical compliance can be found in 
Supplementary Table 3. All studies have been approved by their respective Institutional 
Review Boards Local research ethics committees, and all participants have provided written 
informed consent to the original study. 
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Metabolite measurements 
The present study included 150 absolute-value-based metabolites measured by 
high-throughput 1H-NMR metabolomics (Brainshake Ltd./Nightingale Health, Helsinki, 
Finland). The explanation of the metabolites was shown in Supplementary Table 2. The 
metabolites include the quantitative molecular data on 14 lipoprotein subclasses, 
apolipoprotein A-I and B, multiple cholesterol and triglyceride measures, albumin, various 
fatty acids as well as on numerous low-molecular-weight metabolites, including amino 
acids, glycolysis-related measures and ketone bodies. The 14 lipoprotein subclasses 
included IDL, six VLDL subclasses, three LDL subclasses and four HDL subclasses based on 
the particle diameters. The components of these lipoprotein subclasses were quantified on 
total lipids (L), total cholesterol (C), particle concentration (P), phospholipids (PL), 
triglycerides (TG), free cholesterol (FC) and cholesterol esters (CE). The values of the 
representative coefficients of variations (CVs) for the metabolites ranged between 0.3% and 
19.5% (mean 4.5%) and most values are comparable to the clinical chemistry assays11,65.  
The blood samples of different cohorts have been centralized in Leiden University 
Medical Center (LUMC) and were shipped to and analyzed by Nightingale Health as part of 
a national initiative. A standardized protocol of metabolite measurement was applied for 
all the cohorts following the comprehensive quantitative platform generated by Nightingale 
Health and described originally by Soininen et al11,65,66. The protocol includes sample quality 
control and sample preparation, data storage and automated spectral analyses. The 
metabolite values which were suggested to be uncreditable in the quality control provided 
by Nightingale Health during the measurement procedure were treated as missing. Within 
the consortium, we checked and reported the distribution of zero values in our previous 
study by van den Akker, et al67. The quality control was unified and included an in-depth 
evaluation of the consistency of findings across datasets, a metabolite correlation matric 
and the principal component analysis on cohorts with different population structure. 
Pearson’s correlation test was used to check the pairwise correlation of the overall estimate 
values of drug-metabolite associations in model 1 between datasets. We also checked the 
correlation matrix of metabolites in a population-based cohort, Rotterdam study (n = 
5,191), by Pearson’s correlation and hierarchical cluster analysis, reporting that the distinct 
clustering groups were in accordance with the biochemical pathways ( Extended Data Figure 
1 and Supplementary Table 14). The effect of population structure on metabolite clustering 
was checked by principal component analysis using joint data from four cohorts that differ 
extremely in population: 1) one population-based study, Rotterdam Study54, 2) one family-
based study, ERF62, 3) one disease-based study, TMS61, which includes only patients with 
type 2 diabetes in the current dataset, and 4) a case-control study, Alpha Omega Cohort60, 
including patients with cardiovascular disease and non-disease controls (details in 
Supplementary Table 3). The obvious difference between Alpha Omega Cohort and TMS 
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underscore that meta-analysis should be performed instead of a joint analysis with pooled 
data (Extended Data Figure 7): the fixed-effect meta-analysis assumes a similar effect and 
structure over cohorts, while the random-effect meta-analysis allows for high heterogeneity 
across cohorts.  
As some distributions of metabolites were skewed, we transformed the metabolite 
values in each cohort to normal distribution. We first added the value of one to all the 
metabolites before doing the natural logarithm transformation, to include samples labeled 
zero that had metabolite levels below the detectable value. Then we scaled these 
transformed values to standard deviation units.  
Drug categories 
The drug information was classified by ATC codes in each cohort. In brief, the drug 
information per cohort was obtained either from the pharmacy records or from the 
questionnaires during the interview. Details on drug information of each cohort can be 
found in Supplementary Table 3. We used the drug category instead of the individual 
compound in all the analyses. We merged drugs with similar chemical, pharmacodynamics, 
pharmacokinetics and/or therapeutic characteristics into one category. For the ATC codes 
used for combinations of active ingredients, we categorized them into separate categories 
if possible. We excluded categories with five or fewer users in each cohort or less than 20 
users in total from all the cohorts. Thus, we ended up with 87 drug categories 
(Supplementary Table 1). The drug categorization was confirmed by two experienced 
pharmacologists: Lies Lahousse and Bruno H.C. Stricker. Throughout the text, the term drug 
category is further referred to drug. The individuals with metabolite and drug information 
available were included in the analysis.  
Statistical analysis  
All statistical analyses were performed using R statistical software and the two-
tailed test was considered.
Association between drug and metabolite 
To check for drug-metabolite associations, linear regression was performed in each 
cohort with drug use as an independent variable and metabolite as a dependent variable. 
Linear regression was used in the individual cohorts. The specific family relationship was 
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considered in the three family-based cohorts (see details in Supplementary Table 3). In the 
baseline analysis, we used age and sex as the covariates (model 1). we additionally adjusted 
for smoking (current smoking: yes/no) which is a major common risk factor of pathology68
and body mass index (BMI, kg/m2) which is a major determinant of circulating metabolites 
that captures the effects of diet and physical activity69 (model 2). Meta-analysis was 
performed with either the inverse-variance weighted fixed-effect model (no heterogeneity 
between cohorts) or a maximum likelihood random-effect model (significant heterogeneity 
between cohorts). The degree of heterogeneity was based on Cochran's Q test. The P-value 
threshold of both the Cochran's Q test and the meta-analysis was Bonferroni corrected with 
30 independent equivalents of the 150 metabolites and 87 drugs tested (P-value < 1.9 × 10-
5). Matrix Spectral Decomposition was used to calculate the number of independent 
equivalents70 in the largest population-based dataset: RS Dataset 1. R-package 'metafor" 
was used for the meta-analysis71.  
Effects of co-treatment: drugs prescribed together 
We next checked the potential confounding of drugs which were prescribed 
together (model 3) in each significant drug-metabolite pair. A co-treatment matrix with 
Spearman's correlation was made in the two population-based cohorts (Rotterdam Study 
and LifeLines DEEP, n = 6,631) separately and meta-analyzed. Potential confounding co-
treatment for each drug-metabolite pair was defined if: (1) a drug was positively correlated 
with the target drug (explained as prescribed together, Extended Data Figure 8 and 
Supplementary Table 15), and (2) this drug and the target drug were associated with the 
target metabolite in the same direction. We used the Bonferroni P-value correction with 85 
drugs available in the co-treatment matrix (P-value < 5.9 × 10-4). We then performed the 
same regression analysis as above in each dataset (12 datasets) and meta-analyzed with 
age, sex, BMI, smoking and all the available confounding co-treatments as covariates in each 
significant drug-metabolite pair (model 3). A sensitivity analysis was performed in the sub-
samples of patients who use one drug only (one-drug-users) and all-treatment-naive 
controls adjusting for age, sex, BMI and smoking. We used the Bonferroni P-value threshold 
by correcting the independent equivalents of the number of tested significant metabolites 
for each drug.  
Mendelian randomization to check the effect of indicated disease on metabolites 
We further focused on the drugs in the top 15 drug lists that had the largest 
number of related metabolites and the metabolite associations after adjustment for co-
treatments. We explored the confounding effect of the disease indicating the prescription 
of the drug by MR. MR is a statistical method which uses the effect of genetic variants 
determining an exposure and test its association with the outcome under study, based on 
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the assumption that the genetic variant is inherited independent of the confounding 
variables72. Thus, we tested whether the genetic determinants driving indicated diseases 
are also related to metabolites, using the genetic risk score of the disease as an instrumental 
variable of exposure. Genetic risk scores comprising > 5 genetic single nucleotide 
polymorphisms (SNPs) and explaining > 1% of variance in exposure were taken forward. For 
type 2 diabetes, we looked up the results from our previous well-organized MR research4, 
and 16 metabolites were found to be associated with either metformin or sulfonamides-
urea derivatives. In brief, this MR research was a two-sample bi-direction MR study checking 
the causation of metabolites and type 2 diabetes and fasting glucose, following by biological 
knowledge-based sensitivity analysis to control for the pleiotropic effect of the SNPs in the 
instrumental variables4. We currently used the results of the backward MR that was 
checking the association of the genetic score of type 2 diabetes and metabolites.  
For hypertension and depression, we performed two-sample MR based on the 
previous GWAS results on blood pressure73 (n = 317,754), major depression74 (n = 135,458 
cases and n = 344,901 controls) and NMR metabolite GWAS11 (n = 24,925). Among the 123 
metabolites associated with either antihypertensives, 96 metabolites were available to 
perform MR with systolic and diastolic blood pressure. We also performed MR of major 
depression with six metabolites associated with SSRIs. We did not perform MR of 
dyslipidemia over the statin-associated metabolites because most of the metabolites were 
lipoproteins which are part of the dyslipidemia definition.  
The R-package TwoSampleMR was used for the two-sample MR tests75. Genetic 
loci of major depression were extracted from previous paper as its original GWAS was not 
available74. The default pipeline in the TwoSampleMR package75 was used. In brief, the 
genetic score was based on the top genetic determinant SNPs (P-value < 5 × 10-8) with 
linkage disequilibrium (LD) R2 < 0.001 within 10,000bps clumping distance. Proxy SNPs were 
searched for if SNPs not available in the metabolite GWAS (R2 > 0.8). The palindromic SNPs 
with minor allele frequency less than 0.3 were excluded. It resulted in 161 independent 
SNPs for systolic blood pressure (R2 = 2.6%), 174 SNPs for diastolic blood pressure (R2 = 
2.8%) and 40 SNPs for major depression (R2 = 1.1%). Inverse variance weighted MR, 
Maximum likelihood MR, MR Egger analysis and median-based estimator were also 
performed to check the significant results75. We used the Bonferroni P-value threshold by 
correcting the independent equivalents of the number of tests per disease: P-value < 2.3 × 
10-3 for blood pressure, and P-value < 0.025 for depression. 
Indicated disease-metabolite associations: effect of indicated disease 
We associated the drug-related metabolites with the indicated disease in those 
who were not receiving the drug under study, i.e. the on-target-treatment-naive 
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population. This was focused on type 2 diabetes, dyslipidemia, hypertension and 
depression. The type 2 diabetes analyses were performed based on Rotterdam Study and 
NEO. Type 2 diabetes was defined as fasting glucose ≥7.0 mmol/L, and the cases who used 
glucose-lowering drugs were excluded in the analysis (815 cases and 10,619 non-diabetics 
controls in meta-analysis). We performed a regression model with type 2 diabetes status as 
an independent variable, glucose-lowering-drug-related metabolite as the dependent 
variable. Covariates included age, sex, BMI, smoking and lipid-modifying drugs.  
Dyslipidemia and hypertension were tested in ERF and Rotterdam Study. We tested 
the association of 87 lipid-modifying-drug-related metabolites and dyslipidemia. 
Dyslipidemia was defined according to the National Cholesterol Education Program-Adult 
Treatment Panel III as either total cholesterol ≥ 240 mg/dL, LDL-C ≥160 mg/dL, HDL-C < 40 
mg/dL, or triglyceride ≥200 mg/dL76 (2,451 cases and 2,956 controls in meta-analysis). We 
excluded the subjects with lipid-modifying drugs and adjusted for age, sex, BMI and smoking 
in the model. The associations of 123 antihypertensives-related metabolites and 
hypertension were performed. Hypertension was defined as either systolic blood pressure 
≥140 mmHg or diastolic blood pressure ≥90 mmHg (2,506 cases and n = 2,263 controls in 
meta-analysis). We excluded the subjects with antihypertensives and adjusted for age, sex, 
BMI, smoking and lipid-modifying drugs in the model. 
For depression, we tested the associations between the six SSRIs-related 
metabolites and depressed mood in the participants without any antidepressant drug (ATC 
code as N06A)77. Depressed mood was measured by either diagnostic interviews or 
validated depression questionnaires (3,966 cases and 8,887 controls in the meta-analysis). 
The detailed definition of cases and control in cohorts was descripted in our previous 
publication77. We adjusted for age, sex, fasting status, lipid-modifying drug and current 
smoking status.  
In addition, we checked the association of fasting glucose and glucose-lowering-
drug-related metabolites in the non-diabetes population (n = 5,871) and the association of 
systolic and diastolic blood pressure and antihypertensives-related metabolites in the non-
hypertension population (n = 2,263) in ERF and Rotterdam Study. The non-diabetes 
population were those fasting glucose ≤ 6.9 mg/dl and without any anti-diabetics 
treatment; the non-hypertension population were those systolic blood pressure less than 
140 mmHg, diastolic blood pressure less than 90 mmHg and without any antihypertensives. 
Linear regression was performed with adjustment for age, sex, BMI, smoking and lipid-
modifying drugs in the model. The P-value threshold for significance of associations was 
corrected for the number of independently tested metabolite equivalents per disease or 
endophenotype. Nominal significance between disease/endophenotype and metabolite 
was also considered (P-value < 0.05). 
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A comparison of cross-sectional and longitudinal studies and benchmarking findings by 
genetics: using statin as an example 
Forty-eight metabolites in the current cross-sectional study were also studied in 
the previous longitudinal study by Wurtz and co-workers which also quantified the 1H-NMR 
metabolic profiles in blood samples but focused on the change of metabolite concentrations 
of two time points: baseline and follow-up17. As the longitudinal study only adjusted for age 
and sex, we used the same model in the present cross-sectional study to allow a fair 
comparison. Since the effects of lipophilic statin and hydrophilic statin are similar in the 
current study, we used the results of lipophilic statin which had the largest sample size to 
do the comparison. The results of MR analysis, association of rs12916-T and metabolites, 
from Wurtz and co-workers were also used in the comparison17.  
We then compared the significant statin-metabolite associations in the current 
cross-sectional study with the associations of rs12916-T and metabolites. We used the 
GWAS results of the NMR metabolites from our previous paper which included 24,925 
individuals without lipid-modifying drug usage11. It resulted in 55 metabolites in the 
comparison.  
PPIs, circulating metabolite and liver function 
We studied biochemical variables in liver function test, i.e. ALT, AST, GGT, AST/ALT, 
total bilirubin and alkaline phosphatase, and hepatic steatosis. The liver function test used 
automatic enzymatic procedures (Roche Diagnostics GmbH, Mannheim, Germany)78. 
Abdominal ultrasonography was performed by a certified and experienced technician (Pavel 
Taimr) on Hitachi HI VISION 900 (Highland Heights, OH). Images were stored digitally and 
re-evaluated by a single hepatologist with more than ten years of experience in 
ultrasonography. The diagnosis of steatosis was determined by the ultrasound technician 
according to the protocol by Hamaguchi et al79.  
Linear regression was performed in Rotterdam Study (n = 3,436) with liver function 
measurements as an independent variable and metabolite levels as a dependent variable. 
The covariates included age, sex, BMI, smoking, lipid-modifying drugs, PPIs and alcohol 
intake per day calculated from questionnaires. The P-value threshold was Bonferroni 
corrected with 10 independent equivalents of 55 PPI-related metabolites and six 
independent equivalents of the seven liver function measurements (P-value < 8.3 × 10-4). 
We further checked the association of PPI use and liver function measurements by linear 
regression with adjustment for age, sex, BMI, smoking and alcohol intake per day (P-value 
< 8.3 × 10-3). 
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PPIs, circulating metabolites and gut microbiome 
We extracted the associations of PPIs with gut microbiota and (alpha) diversity 
from our previous paper by Imhann and co-workers39. Age, sex, BMI, antibiotics use and 
sequence read depth were corrected in the association analysis39. In total, 92 bacterial taxa 
abundance assessed by tag sequencing of the 16S rRNA gene58 and Shannon's diversity 
index (alpha diversity) were reported to be significantly different between PPI users and 
non-users (211 PPI users and 1,594 non-users, FDR < 0.05). Forty-five of the 92 bacterial 
taxa abundance and alpha diversity were also tested association with metabolites measured 
by Nightingale Health in our previous study80. In brief, it included 2,309 individuals who were 
not using antibiotics from Rotterdam Study (n = 1,390) and LifeLines DEEP (n = 915)47,58. Age, 
sex, BMI, technical covariates (time in mail and storage time) and medication use (lipid-
modifying drugs, metformin and PPIs) were adjusted in the association analysis. The P-value 
threshold for gut microbiota was Bonferroni corrected with 10 independent equivalents of 
55 PPI-related metabolites and 15 independent equivalents of the 45 gut microbiota (P-
value < 3.3 × 10-4). P-value threshold for alpha diversity was 5.0 × 10-3. 
References 
1. Patti, G.J., Yanes, O. & Siuzdak, G. Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev 
Mol Cell Biol 13, 263-269 (2012). 
2. Park, J.E., Lim, H.R., Kim, J.W. & Shin, K.H. Metabolite changes in risk of type 2 diabetes mellitus in 
cohort studies: A systematic review and meta-analysis. Diabetes Res Clin Pract 140, 216-227 (2018). 
3. McGarrah, R.W., Crown, S.B., Zhang, G.F., Shah, S.H. & Newgard, C.B. Cardiovascular Metabolomics. 
Circ Res 122, 1238-1258 (2018). 
4. Liu, J., et al. A Mendelian Randomization Study of Metabolite Profiles, Fasting Glucose, and Type 2 
Diabetes. Diabetes 66, 2915-2926 (2017). 
5. Wang, T.J., et al. Metabolite profiles and the risk of developing diabetes. Nat Med 17, 448-453 (2011). 
6. van der Lee, S.J., et al. Circulating metabolites and general cognitive ability and dementia: Evidence 
from 11 cohort studies. Alzheimers Dement 14, 707-722 (2018). 
7. Mapstone, M., et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat 
Med 20, 415-418 (2014). 
8. Thorburn, A.N., et al. Evidence that asthma is a developmental origin disease influenced by maternal 
diet and bacterial metabolites. Nat Commun 6, 7320 (2015). 
9. Mabalirajan, U., et al. Linoleic acid metabolite drives severe asthma by causing airway epithelial injury. 
Sci Rep 3, 1349 (2013). 
10. Illig, T., et al. A genome-wide perspective of genetic variation in human metabolism. Nat Genet 42, 137-
141 (2010). 
11. Kettunen, J., et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel 
systemic effects of LPA. Nat Commun 7, 11122 (2016). 
12. Draisma, H.H., et al. Genome-wide association study identifies novel genetic variants contributing to 
variation in blood metabolite levels. Nat Commun 6, 7208 (2015). 
13. Suhre, K., et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477, 
54-60 (2011). 
14. Beger, R.D., et al. Metabolomics enables precision medicine: "A White Paper, Community Perspective". 
Metabolomics 12, 149 (2016). 
Drug-metabolite atlas 
143 
C4.1 
15. Rappaport, S.M., Barupal, D.K., Wishart, D., Vineis, P. & Scalbert, A. The blood exposome and its role in 
discovering causes of disease. Environ Health Perspect 122, 769-774 (2014). 
16. Schutte, B.A., et al. The effect of standardized food intake on the association between BMI and (1)H-
NMR metabolites. Sci Rep 6, 38980 (2016). 
17. Wurtz, P., et al. Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase. J 
Am Coll Cardiol 67, 1200-1210 (2016). 
18. Altmaier, E., et al. Metabolomics approach reveals effects of antihypertensives and lipid-lowering drugs 
on the human metabolism. Eur J Epidemiol 29, 325-336 (2014). 
19. Elbadawi-Sidhu, M., et al. Pharmacometabolomic signature links simvastatin therapy and insulin 
resistance. Metabolomics 13(2017). 
20. Kaddurah-Daouk, R., et al. Lipidomic analysis of variation in response to simvastatin in the Cholesterol 
and Pharmacogenetics Study. Metabolomics 6, 191-201 (2010). 
21. Xu, T., et al. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 
diabetes. Diabetes Care 38, 1858-1867 (2015). 
22. t Hart, L.M., et al. Blood Metabolomic Measures Associate With Present and Future Glycemic Control 
in Type 2 Diabetes. J Clin Endocrinol Metab 103, 4569-4579 (2018). 
23. Moosavinasab, S., et al. 'RE:fine drugs': an interactive dashboard to access drug repurposing 
opportunities. Database (Oxford) 2016(2016). 
24. Voora, D. & Shah, S.H. Pharmacometabolomics meets genetics: a “natural” clinical trial of statin effects. 
(Journal of the American College of Cardiology, 2016). 
25. Wishart, D.S. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev 
Drug Discov 15, 473-484 (2016). 
26. Van Norman, G.A. Drugs, devices, and the FDA: Part 1: an overview of approval processes for drugs. 
JACC: Basic to Translational Science 1, 170-179 (2016). 
27. (FDA), U.S.F.D.A. 22 Case studies where phase 2 and phase 3 trials had divergent results 
https://www.fda.gov/ (2017). 
28. Brahma, D.K., Wahlang, J.B., Marak, M.D. & Ch Sangma, M. Adverse drug reactions in the elderly. J 
Pharmacol Pharmacother 4, 91-94 (2013). 
29. Wurtz, P., et al. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale 
Epidemiology: A Primer on -Omic Technologies. Am J Epidemiol 186, 1084-1096 (2017). 
30. Ahola-Olli, A.V., et al. Circulating metabolites and the risk of type 2 diabetes: a prospective study of 
11,896 young adults from four Finnish cohorts. Diabetologia (2019). 
31. Ference, B.A., et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants 
With Risk of Coronary Heart Disease. JAMA 321, 364-373 (2019). 
32. Holmes, M.V., et al. Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. 
J Am Coll Cardiol 71, 620-632 (2018). 
33. Onderwater, G.L.J., et al. Large-scale plasma metabolome analysis reveals alterations in HDL 
metabolism in migraine. Neurology 92, e1899-e1911 (2019). 
34. Struja, T., et al. Metabolomics for Prediction of Relapse in Graves' Disease: Observational Pilot Study. 
Front Endocrinol (Lausanne) 9, 623 (2018). 
35. Deelen, J., et al. A metabolic profile of all-cause mortality risk identified in an observational study of 
44,168 individuals. Nat Commun 10, 3346 (2019). 
36. Fischer, K., et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of 
all-cause mortality: an observational study of 17,345 persons. PLoS Med 11, e1001606 (2014). 
37. Teslovich, T.M., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 
707-713 (2010). 
38. Bajaj, J.S., et al. Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and 
Readmission Risk in Cirrhosis. Am J Gastroenterol 113, 1177-1186 (2018). 
39. Imhann, F., et al. Proton pump inhibitors affect the gut microbiome. Gut 65, 740-748 (2016). 
40. Llorente, C., et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of 
intestinal Enterococcus. Nat Commun 8, 837 (2017). 
41. Jackson, M.A., et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65, 749-
756 (2016). 
Drug-metabolite atlas 
144 
C4.1
42. Liu, R., et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss 
intervention. Nat Med 23, 859-868 (2017). 
43. Pedersen, H.K., et al. Human gut microbes impact host serum metabolome and insulin sensitivity. 
Nature 535, 376-381 (2016). 
44. Kontush, A. HDL particle number and size as predictors of cardiovascular disease. Front Pharmacol 6, 
218 (2015). 
45. Ahola-Olli, A.V., et al. Circulating metabolites and the risk of type 2 diabetes: a prospective study of 
11,896 young adults from four Finnish cohorts. BioRxiv, 513648 (2019). 
46. Mitchell, A.J., Vaze, A. & Rao, S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet
374, 609-619 (2009). 
47. Bajaj, J.S., et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant 
shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol 307, G951-
957 (2014). 
48. Hoyles, L., et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese 
women. Nat Med 24, 1070-1080 (2018). 
49. Qin, N., et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59-64 (2014). 
50. Bates, C., Adams, W. & Handschumacher, R. Control of the formation of uridine diphospho-N-acetyl-
hexosamine and glycoprotein synthesis in rat liver. Journal of Biological Chemistry 241, 1705-1712 
(1966). 
51. Kettunen, J., et al. Biomarker Glycoprotein Acetyls Is Associated With the Risk of a Wide Spectrum of 
Incident Diseases and Stratifies Mortality Risk in Angiography Patients. Circ Genom Precis Med 11, 
e002234 (2018). 
52. Akinkuolie, A.O., Buring, J.E., Ridker, P.M. & Mora, S. A novel protein glycan biomarker and future 
cardiovascular disease events. J Am Heart Assoc 3, e001221 (2014). 
53. Akinkuolie, A.O., Pradhan, A.D., Buring, J.E., Ridker, P.M. & Mora, S. Novel protein glycan side-chain 
biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 35, 1544-1550 
(2015). 
54. Ikram, M.A., et al. The Rotterdam Study: 2018 update on objectives, design and main results. Eur J 
Epidemiol 32, 807-850 (2017). 
55. Boomsma, D.I., et al. Netherlands Twin Register: from twins to twin families. Twin Res Hum Genet 9, 
849-857 (2006). 
56. Penninx, B.W., et al. The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives 
and methods. Int J Methods Psychiatr Res 17, 121-140 (2008). 
57. Schoenmaker, M., et al. Evidence of genetic enrichment for exceptional survival using a family 
approach: the Leiden Longevity Study. Eur J Hum Genet 14, 79-84 (2006). 
58. Tigchelaar, E.F., et al. Cohort profile: LifeLines DEEP, a prospective, general population cohort study in 
the northern Netherlands: study design and baseline characteristics. BMJ Open 5, e006772 (2015). 
59. van der Heijden, A.A., et al. The Hoorn Diabetes Care System (DCS) cohort. A prospective cohort of 
persons with type 2 diabetes treated in primary care in the Netherlands. BMJ Open 7, e015599 (2017). 
60. Geleijnse, J.M., et al. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-
myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. Am Heart 
J 159, 539-546 e532 (2010). 
61. Schram, M.T., et al. The Maastricht Study: an extensive phenotyping study on determinants of type 2 
diabetes, its complications and its comorbidities. Eur J Epidemiol 29, 439-451 (2014). 
62. Sayed-Tabatabaei, F.A., et al. Heritability of the function and structure of the arterial wall: findings of 
the Erasmus Rucphen Family (ERF) study. Stroke 36, 2351-2356 (2005). 
63. van Oosterhout, W.P., et al. Validation of the web-based LUMINA questionnaire for recruiting large 
cohorts of migraineurs. Cephalalgia 31, 1359-1367 (2011). 
64. de Mutsert, R., et al. The Netherlands Epidemiology of Obesity (NEO) study: study design and data 
collection. Eur J Epidemiol 28, 513-523 (2013). 
65. Soininen, P., Kangas, A.J., Wurtz, P., Suna, T. & Ala-Korpela, M. Quantitative serum nuclear magnetic 
resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet 8, 192-
206 (2015). 
66. Inouye, M., et al. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol 
Syst Biol 6, 441 (2010). 
Drug-metabolite atlas 
145 
C4.1 
67. van den Akker, E., et al. Predicting biological age based on the BBMRI-NL 1H-NMR metabolomics 
repository. bioRxiv, 632919 (2019). 
68. Sturm, R. The effects of obesity, smoking, and drinking on medical problems and costs. Health Aff 
(Millwood) 21, 245-253 (2002). 
69. Van Gaal, L.F., Mertens, I.L. & De Block, C.E. Mechanisms linking obesity with cardiovascular disease. 
Nature 444, 875-880 (2006). 
70. Li, J. & Ji, L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation 
matrix. Heredity (Edinb) 95, 221-227 (2005). 
71. Viechtbauer, W. Conducting meta-analyses in R with the metafor package. J Stat Softw 36, 1-48 
(2010). 
72. Lawlor, D.A., Harbord, R.M., Sterne, J.A., Timpson, N. & Davey Smith, G. Mendelian randomization: 
using genes as instruments for making causal inferences in epidemiology. Stat Med 27, 1133-1163 
(2008). 
73. lab, N. Details and considerations of the UK Biobank GWAS, available 10 Dec, 2018. 
http://www.nealelab.is/blog/2017/9/11/details-and-considerations-of-the-uk-biobank-gwas (2017). 
74. Wray, N.R., et al. Genome-wide association analyses identify 44 risk variants and refine the genetic 
architecture of major depression. Nat Genet 50, 668-681 (2018). 
75. Hemani, G., et al. The MR-Base platform supports systematic causal inference across the human 
phenome. Elife 7(2018). 
76. National Cholesterol Education Program Expert Panel on Detection, E. & Treatment of High Blood 
Cholesterol in, A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 
final report. Circulation 106, 3143-3421 (2002). 
77. Bot, M., et al. Metabolomics profile in depression: a pooled analysis of 230 metabolic markers in 
5,283 cases with depression and 10,145 controls. Biological Psychiatry (2019). 
78. Koehler, E.M., et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a 
general population: The Rotterdam study. Hepatology 63, 138-147 (2016). 
79. Hamaguchi, M., et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease 
reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 102, 2708-2715 
(2007). 
80. Dina Vojinovic, et al. Relationship between gut microbiota and circulating metabolites in population-
based cohorts. Nature communications In press(2019).

Chapter 5 
General discussion

General discussion 
149 
C5 
The aim of this thesis is to elucidate the pathogenesis and pathological progression 
of type 2 diabetes (T2D) and related traits including blood pressure, glucose and insulin 
metabolism. I have used a broad multiple molecular (omics) approaches, including 
genomics, epigenomics, transcriptomics and metabolomics. Building upon classical 
epidemiological and genetic approaches, I have explored a new avenue to integrate data 
from multi-omics levels for their use in prediction of future cases, as well as for their use in 
understanding the biology behind the disease. During the course of my PhD, it became 
evident that medication use is a major confounder in observational omics studies, with the 
exception of genomics. Without a doubt, drugs may confound omics studies. Therefore, as 
part of my thesis, I decided to develop a comprehensive atlas on drug and circulating 
metabolites association. This chapter summarizes the main findings of the thesis, discusses 
the implication towards the understanding of molecular processes and pathways and makes 
comments with regards to future research. 
Findings of this thesis 
Epigenomics of glucose and insulin homeostasis 
In Chapter 2, I study epigenetic effects related to glucose and insulin metabolism. 
Historically, epigenetics is considered to be the result of environmental interactions with 
the genome. However, thanks to methylation quantitative trait loci (meQTL) studies, the 
evidence is increasing that a large part of these effects is also under strong control from 
genetics. Chapter 2 focuses on identifying the DNA methylation sites associated with two 
endophenotypes of T2D, glucose and insulin homeostasis, and accounts for obesity. The 
chapter integrates the epigenomics findings by cross-omics analysis including a wealth of 
genomic and transcriptomic-based data. Although some previous studies reported 
differential DNA methylation in T2D and obesity1-5, our understanding of the role of 
differential methylation as a causal factor of T2D is very limited. A case study of a single 
individual whose global methylation pattern was measured at 57-time points spanning 36 
months reported changes in methylation preceding changes in glucose levels6. In addition, 
there is no evidence-based data to answer the question if the association of differential 
methylation and glucose and/or insulin metabolism is an irrelevant epiphenomenon that is 
related to obesity, the major determinant of T2D. Obesity has been associated with 187 
DNA methylation sites, including 62 of them which are also associated with T2D7. The 
disturbances in the obesity-related DNA methylation could also predict future type-2 
diabetes7. The earlier epigenome-wide association study (EWAS) research on T2D case-
control status2,8,9, established only one CpG locus in TXNIP replicated multiple times, and 
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the association is independent of BMI2,8,9. Along with limitation of power as a function of 
sample size, lack of replicable findings can be attributable to confounding factors namely 
obesity, medication and comorbidity among the cases which in theory can have a strong 
influence on differential methylation.  
As BMI is a major driver of both epigenetics and T2D7, I performed a blood-based 
epigenome-wide association study (GWAS) of fasting glucose and insulin, with and without 
body mass index (BMI) adjustment. The study was conducted in the context of the 
Biobanking and BioMolecular Infrastructure of the Netherlands (BBMRI-NL), in which 4,084 
participants of three studies were characterized for the Illumina© Human Methylation450 
array and included in the discovery phase of the current study, and a total of 3,841 
participants underwent RNA sequencing and were included in the previous studies10,11. For 
all participants genome-wide data for common genetic variants was also available. 
Meanwhile, the T2D working group of the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) served as a control including 11,750 participants. To exclude that 
the epigenetic effects were the consequence of the T2D or its treatment, analysts from each 
center studied only participants without diabetes. By meta-analysing the discovery cohorts 
and replicating the findings, I identified and successfully replicated nine CpGs not implicated 
in T2D and/or related traits previously and validated 11 known loci. The newly identified 
CpGs in LETM1, RBM20, IRS2, MAN2A2 and the 1q25.3 region are associated with fasting 
insulin, the ones in FCRL6, SLAMF1, APOBEC3H and the 15q26.1 region are with fasting 
glucose. Three CpG sites (in SLAMF1, APOBEC3H and the 15q26.1 region) were associated 
with fasting glucose only after adjustment for BMI.  
Overall, obesity has been associated with over 11 out of 20 identified CpGs, 
remarkably all associated with insulin. After a closer look at these associations, I found that 
differential methylation of the insulin-related CpG sites explained up to 16.9% of the 
association between obesity and insulin levels. These findings are in line with the report on 
the EWAS of BMI that found that the methylation patterns in blood predict future diabetes8
and suggest that BMI may be the driver of differential methylation which subsequently 
raises insulin level in the circulation. Meanwhile, the fasting glucose-related methylation 
loci are either enriched in immune function and innate immune response (SLAMF1 and 
APOBC3H) or have genetic determinants in the immune-related HLA region (FCRL6, 15q26.1 
and SLAMF1). These findings provide us with strong epigenetic signals of the immune 
system on glucose metabolism in the population of non-diabetic individuals. 
Of further note is that the well-established locus, TXNIP, which has been 
repeatedly associated with T2D in multiple EWAS researches2,8,9was also associated with 
the fasting glucose in the non-diabetic population (P-value = 7.6 × 10-7 in the BMI adjustment 
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model) in our discovery setting, indicating that the differential methylation in TXNIP already 
takes place before the onset of diabetes. Although we have conducted the largest study to 
date and have doubled the number of CpGs, the power of the present study is still limited. 
At present, we are collaborating on an analysis of the CHARGE consortium. This analysis 
includes 13,500 non-diabetes participants and has identified 43 CpGs associated with 
fasting glucose and 89 associated with fasting insulin, suggesting that we are not facing the 
end of the discovery of epigenetic loci implicated in T2D.  
It is also of note that tissue-specific experiments are important for the omics 
analysis but hard to achieve. In Chapter 2, I systematically integrated the multi-omics 
(genomics, epigenomics and transcriptomics) based on the selected glycaemic related CpGs. 
However, most of the data was based on the concentration in blood circulation. Blood is 
not the main relevant tissue involved in the pathogenesis of T2D but is the easiest sample 
to obtain. Given consideration for the relatively high statistic power in large-scale 
population, and the correlation of CpG levels and gene expression between blood and 
tissues, using blood data to screen the target loci and then validating them in a smaller 
sample size with specific-tissue-based experiments can be a cost-effective method to find 
targets and investigate the mechanism of T2D. I thus call for future studies in tissue-specific 
methylation and expression to fill in the current integration framework in Chapter 2. 
Metabolomics in T2D 
In Chapter 3, I focused on the associations of metabolites and T2D or its 
endophenotypes and directionality of possible causal effects. To start with, in Chapter 3.1, 
I investigated the predictive performance of metabolomics on future T2D and compared it 
with the well-known predictor, fasting glucose, in the whole population, but also in 
subgroups stratified by the traditional risk factors of T2D. I analysed 261 metabolites in 
2,776 participants from the Erasmus Rucphen Family study (ERF) in the baseline and 1,571 
diabetes-free individuals who were followed for 14-years. Using the Least Absolute 
Shrinkage and Selection Operator (LASSO) regression, I selected 24 metabolites, i.e. high-
density lipoprotein (HDL), low-density lipoprotein (LDL) and very-low-density lipoprotein 
(VLDL) sub-fractions, certain triglycerides, amino acids, and small intermediate compounds, 
as the T2D markers in the baseline data. These markers together can predict future T2D 
independently with an area under the curve (AUC) of 0.81. Together with the traditional 
risk factor and previous reported BCAA, the AUC can be maximized to 0.89. I also found that 
in the young (age < 50 years) and lean (BMI < 25 kg/m2) female group of participants, the 
predictive performance of the metabolites is significantly better than fasting glucose 
compared with the old and overweight male groups. In Chapter 3.1, I generated a novel 
prediction model that increases the long-term predictive performance, and brings a higher 
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resolution over the complexity of the lipoprotein component. I provided evidence that 
metabolomics has better utility for T2D prediction specifically in the young, the female and 
the lean population with the stratification analysis based on age, gender and overweight 
status. Although our knowledge of the metabolic signature of T2D is far from complete, 
Chapter 3.1 suggests that metabolomics may help to address the pathways underlying 
metabolically unhealthy normal weight (MUHNW) and metabolically healthy obese (MHO) 
phenotypes12. Recent research from the PREDIMED cohort study13 also reported improved 
predictive ability by a selection of metabolites for high HOMA-IR levels after 1, 2 and 3-year 
follow-up with a maximum AUC of 0.81 when compared to classical risk factors alone (AUC 
of 0.69). The same metabolite risk score associated with significantly increased T2D risk with 
a hazard ratio of 2.00 for each SD of the multi-metabolite risk score in the analysis of 152 
incident cases and 548 control participants (median follow-up: 3.8 years)13.  
In Chapter 3.2, I explored the evidence for causation of the association between 
metabolites and T2D or fasting glucose. To this end, I conducted a bi-directional two-sample 
Mendelian randomization (MR) study. As described in Chapter 1 and Chapter 3.2, MR uses 
the additive effects of genetic variants as instrumental variables for exposure. The basic 
rationale is that if exposure is causally related to T2D, the genetic variants that are 
associated with the exposure (as instrumental variables) should also show association to 
the disease. We tested the following hypothesis:  
1. Do the genes that determine the metabolite levels in the blood circulation also 
associate with T2D, implying these metabolites are causally associated with T2D. 
2. Do the genes that determine T2D risk also determine circulating metabolites, 
implying that the metabolites are a consequence of the disease process or 
progression (or medication). 
Although MR has been successfully used for elucidating directionality in several 
disorders 14-17, a major assumption is that the genetic variants do not have pleiotropic 
effects. As described in Chapter 1, this is quite an assumption for complex disorders such as 
T2D, which is driven by common genetic variants which are typically involved in multiple 
processes and thus have pleiotropic effects. In Chapter 3.2, I therefore carefully evaluated 
pleiotropic effects based on the biological pathway-based sensitivity analysis. I detected 14 
candidate causal associations: ten metabolites influencing fasting glucose, one influencing 
T2D and three influenced by T2D. Firstly, genetically increased cholesterol, free cholesterol 
and phospholipid content of circulating XL-HDL and L-HDL particles together with XS-VLDL-
phospholipids associated with decreased plasma glucose level. Secondly, triglyceride 
content of S-HDL and S-VLDL particles as well as total plasma triglycerides increase plasma 
glucose. Thirdly, total triglycerides increase the risk of T2D. Finally, genetic variants 
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implicated in T2D are found to be associated with lower levels of two alkyl-acyl 
phosphatidylcholines (PC) and a higher level of alanine, suggesting the change in levels of 
these metabolites are a consequence of the disease process. The findings add information 
to the previous MR results that increased LDL-cholesterol, HDL-cholesterol, and possibly TG 
levels are associated with a lower risk of diabetes18,19. Chapter 3.2 shows that a higher 
resolution metabolic phenotypes can be achieved in a cost-effective way and demonstrates 
that the decreasing effect of HDL-cholesterol on fasting glucose is specific to the L-HDL or 
XL-HDL subclasses since the effect of genetic risk scores of L-HDL or XL-HDL subclasses 
(cholesterol, free cholesterol, phospholipids) have larger weighted effect than the HDL-
cholesterol, while no significant negative association was found with M-HDL, S-HDL or XS-
HDL particles. These results advocate for further metabolic studies in order to improve our 
understanding of the pathogenesis of T2D and glucose metabolism. 
Hypertension is a key feature of metabolic syndrome (Chapter 1), which is strongly 
related to the obesity epidemic and one of the main drivers of cardiovascular disease (see 
Chapter 1). While there have been numerous studies of the metabolomics in obesity, type 
2 diabetes and cardiovascular disease20,21, a few have studied blood pressure and 
hypertension, especially for the detailed characterized phospholipids. In Chapter 3.3, I 
examined the association of the plasma phospholipids that are characterized with systolic 
and diastolic blood pressure. I discovered and replicated five associations between 
metabolites and systolic blood pressure (PC 32:1, PC 40:5, phosphatidylethanolamines (PE) 
38:3, PE 40:5, and PE 40:6), as well as six associations between metabolites and diastolic 
blood pressure (PE 38:3, PE:38:4, PE38:6, PE 40:4, PE:40:5 and PE 40:6). Ten of the 
associations were validated in a third sample by data-mining. The multi-metabolic blood 
pressure profile only added a small increase on top of the traditional risk score for incident 
hypertension. However, from a biological point of view as tested by MR, blood pressure 
seems to be causal in elevating the level of a distinct fatty acid type phospholipids PE 40:5, 
yet the pathways responsible for this effect still need to be understood. The multi-
metabolomic blood pressure profile clustered with both triglycerides and other 
cardiometabolic traits, and are likely to share genetic determinants of other lipoproteins, 
blood cell counts and pulse rate. The associations with medication use is interesting, 
however needs to be separately investigated in a larger omics framework which we 
established in Chapter 4 of this thesis.  
Drug-metabolite atlas 
One of the major problems encountered in observational clinical and 
epidemiological metabolic studies is the use of medication by the study participants. The 
drug may be prescribed in relation to the disease under study, to a related disorder, e.g. 
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patients with diabetes or hypertension are often co-medicated to dyslipidaemia, or co-
occurring disease, e.g. elder patients often suffer from multi-morbidity. Within the BBMRI 
Metabolomics Consortium22, confounding by unknown medication was identified as a major 
issue. The BBMRI Metabolomics Consortium has conducted a joint metabolomics study 
involving 25 cohorts and over 25,000 participants. As comprehensive data involving all 
medication used by a participant is not always available in the cohorts studied, joint analysis 
of data was hampered by the fact that results may be confounded by medication not 
registered by cohorts.  
To overcome this problem, in Chapter 4, I have constructed an atlas of the 
metabolic effects of drugs prescribed in T2D and other disorders. I uncovered 1,071 drug-
metabolite associations after evaluating confounding including age, sex, BMI, smoking and 
co-treatment, covering a wide range of drug-metabolite associations which were not 
studied before. As the atlas is based on well-characterized cohorts, I was able to adjust for 
confounders of the drug-metabolite association. I found that BMI and smoking accounted 
for 21.4% of the significant associations between the drug and the metabolites, indicating 
that these two factors should be considered when studying such associations.  
The major problem of developing a drug-metabolite atlas is that the target disease 
for which the drug is prescribed may explain the drug association. For instance, up to 100% 
of the metabolic associations with sulfonamides-urea derivatives and 84.1% with 
metformin are partially or fully explained by T2D. From the previous T2D study in BBMRI 
Metabolomics Consortium, 24 of the 26 metabolites significantly associated with either 
glucose-lowering drug in the T2D patients are also associated with HbA1c level23. The study 
also reported that the metabolic associations with insufficient glycaemic control were 
similar between different treatment groups23. However, if the association of metabolites 
and HbA1c/insufficient glycaemic control is explained by T2D or by the drug effects cannot 
be concluded in their study.  
In addition to being a toolbox to explore drug metabolites associations, the atlas 
can also be used to explore on-target and off-target effects of drugs. However, the 
relationships in the atlas are based on cross-sectional data. An important finding of Chapter 
4 is that the statin findings in a large-scale cross-sectional study are very similar to that of 
longitudinal study for pharmacometabolomics research. More importantly, we could 
benchmark the similarity of the study design by using MR. This finding in statins does not 
warrant that we can extrapolate the similar associations between cross-sectional data and 
longitudinal data to other drugs. But, our results at least show that cross-sectional atlas data 
can yield information on future drug effects, which can be a starting point for proper 
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prospective studies and trials. As such, the atlas opens avenues to the 
pharmacometabolomics studies in large epidemiological biobanks.  
Exploring off-target effects, I also found a similar metabolic association pattern 
among proton pump inhibitors (PPIs), certain biochemical liver-parameters, hepatic 
steatosis, diversity of gut microbiome and specific gut microbiota. Again, this yields a 
starting point for future research on the mechanism through which the metabolites 
associated with PPI are associated with liver function, hepatic steatosis and gut microbiome. 
To make the data available to the wider community, we have created an analysis tool via a 
web browser http://bbmri.researchlumc.nl/atlas/.  
Challenges and future developments 
Challenges in large biobank studies 
My thesis has been one of the first unique examples of integration of biobank data 
with data mining in genetic epidemiology, going beyond the golden standard “meta-
analysis-discovery-replication-validation” path. By the help of new biobanks and unique 
omics datasets emerging, exponentially increasing a number of similar research studies in 
epidemiology is inevitable. One of the growing biobank resources, BBMRI-NL, has been 
founded with the mission to maximize the use of biosamples, images and data for health 
research on the prevention, diagnosis and treatment of diseases24. BBMRI-NL has provided 
researchers access to biosamples, images and data, tools to capture, integrate and analyse 
data, as well as support on ethical, legal and societal implications. Another remarkable 
biobank that has recently emerged is the UK Biobank, which has been a pillar in modern 
epidemiological research not only by its sample size (N = 500,000) but also by the 
accessibility of its wide-range of phenotypes, including questionnaires (diet, cognitive 
function, work history and digestive health), image (brain, heart, abdomen, bones & carotid 
artery), electronic health records (cancer, death, hospital episodes, general practice), blood 
biochemistry and genetic data25. Moreover, the GWAS of selected lists of traits from the UK 
Biobank which were analysed by independent research groups and summary statistic files 
were then deposited in public repositories such as PheWeb26 thus allowing me to perform 
phenome-wide association studies (PheWAS), exploring which phenotypes are associated 
with a genetic variant (SNP). However, the amount of readily analysed/collected data comes 
with a price. One and perhaps the only major problem with these types of publicly available 
bulk amount of data is the quality of the phenotypic data collected/analysed. Although a 
standard genotyping quality check (QC) would be sufficient to filter out outlying individuals, 
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detect contaminated samples and unknown familial relatedness, for the phenotypic data 
especially when analysed according to “one solution fits all” manner, no such quality 
criterion exists. This is in line with the fact that we are living in a decade where scientific 
activities produce more data than can be QCed and analysed by qualified researchers. This 
fact, therefore, emerges as a growing challenge in epidemiological research that currently 
has no solution.  
Opportunities and challenges in MR 
Since MR methodology was published by Smith, et al. in 200327, it has provided an 
exciting promise for epidemiological studies of gene-disease associations especially with the 
continuing success of large scale GWAS in identifying robust genetic associations and 
development of multiple MR methods utilizing GWAS summary data. These multi-
instrument MR methods aggregate estimates from multiple instrumental variables, testing 
for a causal relationship between a given exposure and outcome in a linear regression 
framework in which the variants’ effects on the outcome are regressed on the same 
variants’ effects on the exposure28,29. 
In the last five years, using keywords (Mendelian randomization) OR ‘Mendelian 
randomization’ while searching in PubMed, the number of MR papers has increased from 
63 in 2014 to 369 in 2018. By July 2019, the number has reached 304 (Figure 1). An 
automated MR, called MR-base with a web interface was even developed for non-
specialists30. MR-base uses a strategy known as two-sample Mendelian randomization 
(2SMR), bypassing the need for individual-level data. The software includes several 
sensitivity analyses for assessing the impact of horizontal pleiotropy and other violations of 
assumptions30. Ruling out horizontal pleiotropy is the fundamental assumption of MR which 
requires that the instrumental variable acts on the target outcome exclusively through the 
exposure31. Horizontal pleiotropy occurs when the variant has an effect on other traits 
outside of the pathway of the impact of exposure on the target outcome, or when the 
variant has a direct effect on the target outcome32. Horizontal pleiotropy can lead to 
inaccurate causal estimates, loss of statistical power and potential false-positive causal 
relationships. There are several methods to detect this33: the MR-PRESSO global test, Q 
test34,35, Q (modified) test36, Q’ test34,35, Q’ (modified) test36 and several methods to correct 
for it, including MR-Egger regression37,38 and multi-variable MR39,40. However, PheWAS and 
genetic correlation results of large epidemiological studies proved that pleiotropy is the rule 
rather than the exception and accounted for over 48% of significant causal relationships in 
MR32.  
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Altogether, automated MR results should be interpreted with caution after careful 
consideration of conditions of MR as we mentioned earlier in Chapter 1. For instance, some 
of the associations between metabolites and fasting glucose in the MR-base have 
inconsistent results when compared with the results from our study presented in Chapter 
2.3. The knowledge of gene function and pleiotropic effects are limited, and the association 
of SNPs in the instrument and confounders between exposure and outcome is not always 
very clear.  
Meanwhile, MR is often described as naturally occurring randomized trials as the 
genetic factors are randomly assigned by nature41. But the frequently made analogy 
between MR studies and randomized trails also has key threats which should be considered 
during the MR study design. These threats include: (1) the population stratification and 
linkage disequilibrium make the case and control groups not as exchangeable as in the 
randomized trials, (2) the MR studies have no clear definition of the time for setting 
eligibility criteria as in the randomized trials, (3) the genetic variant is not always causal 
indicating that the measurement of treatment is not always correct, (4) the “adherence” in 
the MR is not clear, for instance, not all the persons with the mutation of FTO gene get 
obesity. 
The development of MR methodology is challenging, but it is the preferred 
epidemiological source for estimating the causation of traits when the trial data is not 
available, such as in metabolomics and proteomics. MR opens up opportunities to 
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investigate the causation in and between the omics data as there is a lot that is known of 
the genomic drivers of metabolome and proteome. However, a weak instrument may lead 
to a false negative association in the MR studies, especially when the identified genetic 
associations of metabolome and proteome are limited and only explain a small variance of 
the exposure because of the small sample size function in the GWAS. Some of the 
metabolite GWAS have reached a sample size as large as 25,00042 in one platform to 
80,00043 in combined multiple platforms. However, the sample size of the GWAS of the 
proteome is much lower. The largest one was done in 8,293 Finns of 48 cytokines44. High-
throughput, multiplex and high sensitivity proteomics technology has developed fast in the 
last five years. For instance, SOMAScan® array can measure 5,000 proteins across eight 
orders of magnitude of abundance and converts protein measurements as straightforward 
as DNA measurement45. On the other hand, Olink® can measure 350 human proteins46. 
These proteomics platforms have been used in large epidemiological studies such as 
INTERVAL47, the Cooperative Health Research in the Region of Augsburg (KORA) F4 study48
and Framingham Heart Study (FHS)48, suggesting a bright future in identifing genetic drivers 
of high resolution proteins while supporting less weak instrument in the MR studies of 
proteomics.  
Tissue specificity of methylome and transcriptome  
One of the scientific challenges we face today in a large biobank is the choice of 
tissue for the omics research to be conducted. This is perhaps a lesser problem for 
metabolomics as liver, the metabolite conversion warehouse of the body, is directly 
connected to the bloodstream, as compared to the gene methylation and transcriptomics 
studies. This is a major challenge for the interpretation of transcriptomics and methylation 
studies as gene expression and methylation are not only age and environment-dependent, 
but also tissue-specific. On one hand, the most pragmatic solution is to assay these type of 
omics data and to use accessible tissue biobanks such as circulating white blood cells, 
maximizing the sample size for all cohorts, as it is currently done today. On the other hand, 
the research results are more difficult to interpret in the biological context when the 
involved tissue is other than blood such as brain or liver. While GTEX project database which 
provides gene expression profiles from several tissues and related genetically regulated 
expression prediction tools, can predict the genetic component of variance in human 
transcriptome49,50, the methods have the obvious limitation in that they are independent of 
aging, gender and environmental factors which are also contributors of diseases. Therefore, 
such predictions would be weak when modelling the effect of environmental factors on 
diseases; in such scenarios, environment affects the gene expression which in turn leads to 
disease. Additionally, to our knowledge, the same scale training set for genome-wide 
methylation does not exists, hampering research of tissue-specific methylation patterns in 
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different outcomes. Methods harvesting omics information from single cells are also very 
promising in terms of biological validity. However, how they will be placed in a population-
based biobanking is a good question as these types of trends obviously will come with their 
own technical challenges in both material collection and quality control as well as price.  
Metabolomics platforms to date 
Ten years after the first report on population-based metabolomics research51, a 
handful of platforms are validated and widely used in biobanks, utilising either Mass-
Spectrometry (MS) or Nuclear Magnetic Resonance (NMR) Spectrometry. The well-knowns 
among them include (1) detailed analysis of circulating lipoprotein particles as developed 
by Bruker® and Nightingale® companies, (2) phospholipids and carnitine assays that were 
mainly developed by Biocrates® but also by numerous in-house frameworks, (3) and finally, 
the so-called “complete metabolomic” assays, initially developed by Metabolon® which 
focuses on the products of enzymatic reactions. Although all three types of platforms 
significantly contributed to gene discovery by their GWASs42,52-55, their value in disease 
prediction and aetiology research has been particularly limited to certain disease groups. 
For example, the lipoprotein particle analysis has great potential to replace the classical 
cholesterol measurements in the clinic and complement routine biochemistry tests leading 
to improvement in precision medicine56. On the other hand, platforms enriched in 
membrane lipid particles have potential for neurologic and psychiatric phenotypes such as 
Alzheimer disease and depressive disorders57,58. Although their predictive and diagnostic 
ability can be high, these platforms measure rather complex molecules which were 
technologically defined rather than biologically and which makes it very difficult to plug 
them into enzymatic pathways and elementary flux models. The third and final platform 
advancing MS can profile up to 1,000 metabolites with less than 5% process variability and 
has been a success59 but the availability for biobanks is rather low due to the high costs of 
the experiments.  
Microbiome 
My personal interest in the microbiome and its relationship to metabolites in the 
circulation and organs and their effects on health has grown. In particular, the gut 
microbiome is large and includes more than 1014 bacteria that reside in the gut. It has even 
larger genetic material than human genome and is referred to as the second genome of 
human body60. As a fast-growing field, the human microbiome is enormously complex. 
Genome is static, while microbiome is dynamic. The composition of microbiota during the 
course of a human life is different and dynamic, depending on age, birth and development, 
diet, disease and other environmental factors. Some previous studies on gut microbiome 
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and T2D or glucose have reported various potential mechanisms of T2D, ranging from 
endocrine and metabolic pathways to mechanisms on a cellular and genetic level through 
gut microbiome61. Well-designed targeted diet can regulate the structure of gut 
microbiome62 and supplementation of beneficial bacteria such as Akkermansia muciniphila
was shown to decrease insulin resistance and cause weight loss in obese volunteers63. 
Although the expectations from gut microbiota research have been very high for 
cardiometabolic diseases, population-based meta-analysis studies suffer from inconsistent 
association and the replication rate is very low64. This is due to the very heterogeneous 
nature and per-individual complexity of the gut microbiome under continuous control of 
the exposome. Unexplored areas such as microbiome and genome-wide 
methylation/transcriptome in time-matched samples will help to elucidate the exposomal 
pathways in which human gut microbiota take place. However, strong confounding factors 
such as medication and diet need to be controlled, requiring well-characterized 
populations. Recent MR research on microbiome uncovered some short fatty acid chains 
related to causal effects between the microbiome and metabolic diseases65, but overall MR 
of microbiome is still underpowered due to the weak instrumental variables for the 
microbiota exposure. 
Concluding Remarks 
In this thesis, I have used multi-omics data to provide insight into the 
pathophysiology of T2D and its related traits and therapeutics information. I have 
integrated cross-omics to discover novel biomarkers and pathways of T2D, elucidate the 
causality of them and link the information to therapeutics. As the high-throughput era in 
omics is progressing, integration of multi-omics will be much more popular and effective, 
yielding insights into the pathophysiology, prevention and treatment of T2D and related 
disorders. 
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Summary 
A substantial burden of mortality and disability worldwide is caused by diabetes 
and its complications, including cardiovascular diseases, retinopathy, nephropathy and 
neuropathy. Among the diabetic patients, 90-95% are suffering type 2 diabetes (T2D), which 
is age-related and determined by a combination of genetic, epigenetic and environmental 
factors, including overweight, obesity, diet, physical activity, smoking and other factors. 
Meanwhile, T2D is also highly co-occurrent with the components of metabolic syndrome, 
including high blood pressure, lipid dyslipidaemia and abdominal obesity. However, the 
molecular processes and pathways underlying T2D and these related risk factors and its 
endophenotypes are still not clear. Understanding the pathophysiology of T2D and 
glycaemic traits can help to facilitate the prevention and treatment strategies. In this thesis, 
I aim to provide novel insights into the pathophysiology of T2D by several omics approaches 
and integration of multi-omics, centering on genomics, epigenomics and metabolomics.  
In Chapter 2, I found nine novel differential DNA methylation loci associated with 
fasting glucose and insulin by a large-scale epigenome-wide association study (EWAS) and 
its replication, which greatly complemented the previous knowledge on epigenomics of 
T2D. I also validated 11 loci which was previously reported. After following our pipeline of 
multi-omics integration, 29 genetic determinants of the glycaemic related methylation sites 
were identified. Two novel pathways in FCRL6 and SLAMF1 under the pipeline involving 
genomics, epigenomics, transcriptomics and fasting glucose were identified. Strong signals 
of adaptive immune system on glucose metabolism was surfaced in this chapter. 
Meanwhile, I also found that the insulin-related methylation sites would explain 17% of the 
association of obesity and fasting insulin.  
Chapter 3 focused on the association of metabolomics and T2D or related traits. In 
Chapter 3.1, I found a combination of 24 glucose-related circulating metabolites can 
effectively predict the future T2D with a high predictive performance (the area under the 
curve (AUC) up to 0.81). Adding them to the traditional risk factors of T2D significantly 
improved the predictive performance to 0.89. Notably, in the low risk groups, the predictive 
performance of the metabolites alone is even better than the baseline fasting glucose. In 
Chapter 3.2, a bi-direction two-sample Mendelian randomization (MR) was performed to 
explore the causality of circulating metabolites and T2D and glucose. I detected 14 
candidate causal associations: ten metabolites influencing fasting glucose, one influencing 
T2D and three influenced by T2D: increased total cholesterol, L-HDL-cholesterol, XL-HDL-
cholesterol, L-HDL-free cholesterol, XL-HDL-free cholesterol, L-HDL-phospholipid and XL-
HDL-phospholipid and XS-VLDL-phospholipids effect decreased glucose level; S-VLDL-
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triglycerides, S-HDL-triglycerides and plasma triglycerides increase the fasting glucose; 
lower levels of two alkyl-acyl phosphatidylcholines and higher level of alanine are probably 
the consequence of T2D. In Chapter 3.3, we identified eight circulating phospholipid 
molecules which associated with blood pressure and have a predictive value for incident 
hypertension. There is a very strong association of the selected phospholipids and 
triglycerides, waist, waist-hip ratio, glucose, total fat percentage, BMI and leptin. The 
genetically increased systolic blood pressure level associate with the increase of circulating 
PE 40:5 and PE 38:3. The genetic variants of the selected phospholipids are also strongly 
linked to HDL-cholesterol, subfractions and diameter, blood cell counts (white, red and 
platelet) and pulse rate. 
Finally, in Chapter 4, I built a comprehensive drug-metabolite atlas, involving on-
target and off-target effects of drugs prescribed in T2D and other disorders. It remained 
1071 drug-metabolite associations after evaluating the effect of age, sex, body mass index 
(BMI), smoking and co-treatment. With the genomics approach, I provided evidence that 
cross-sectional atlas data can yield information on future statin effects. I further linked 
proton pump inhibitors to circulating metabolites, liver function related variables, hepatic 
steatosis and the gut microbiome with data integration. A web-based resource for 
visualization of the atlas (http://bbmri.researchlumc.nl/atlas/) was also established.
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Een aanzienlijke sterfte- en invaliditeitslast wereldwijd wordt veroorzaakt door 
diabetes en de complicaties ervan, waaronder hart- en vaatziekten, retinopathie, 
nefropathie en neuropathie. Van de diabetespatiënten heeft 90-95% diabetes type 2 (T2D), 
dat leeftijdsgebonden is en wordt bepaald door een combinatie van genetische, 
epigenetische en omgevingsfactoren, waaronder overgewicht, obesitas, voeding, fysieke 
activiteit, roken en andere factoren. Ondertussen is T2D ook in hoge mate gelijktijdig 
aanwezig met de componenten van het metabool syndroom, waaronder hoge bloeddruk, 
lipidedyslipidemie en abdominale obesitas. De moleculaire processen en routes die ten 
grondslag liggen aan T2D en deze gerelateerde risicofactoren en de endofenotypen ervan 
zijn echter nog steeds niet duidelijk. Het begrijpen van de pathofysiologie van T2D en 
glycemische eigenschappen kan de preventie- en behandelingsstrategieën helpen 
vergemakkelijken. In dit proefschrift probeer ik nieuwe inzichten te verschaffen in de 
pathofysiologie van T2D door verschillende omics-benaderingen en integratie van multi-
omics, met de nadruk op genomics, epigenomics en metabolomics. 
In Hoofdstuk 2 vond ik negen nieuwe differentiële DNA-methylatie-loci 
geassocieerd met nuchter glucose en insuline door een grootschalige epigenoombrede 
associatiestudie (EWAS) en de replicatie ervan, die in grote mate de eerdere kennis over 
epigenomica van T2D aanvulde. Ik valideerde ook 11 loci die eerder werden gerapporteerd. 
Na het volgen van onze pijplijn van multi-omics integratie, werden 29 genetische 
determinanten van de glycemisch gerelateerde methylatieplaatsen geïdentificeerd. Twee 
nieuwe routes in FCRL6 en SLAMF1 onder de pijplijn met genomica, epigenomica, 
transcriptomics en nuchtere glucose werden geïdentificeerd. In dit hoofdstuk zijn sterke 
signalen van adaptief immuunsysteem op het glucosemetabolisme naar voren gekomen. 
Ondertussen vond ik ook dat de aan insuline gerelateerde methylatieplaatsen 17% van de 
associatie van obesitas en nuchter insuline zouden verklaren. 
Hoofdstuk 3 concentreerde zich op de associatie van metabolomics en T2D of 
gerelateerde kenmerken. In Hoofdstuk 3.1 vond ik dat een combinatie van 24 
glucosegerelateerde circulerende metabolieten de toekomstige T2D met een hoge 
voorspellende prestatie (het oppervlak onder de curve (AUC) tot 0,81) effectief kan 
voorspellen. Door ze toe te voegen aan de traditionele risicofactoren van T2D is de 
voorspellende prestatie aanzienlijk verbeterd tot 0,89. Met name in de groepen met een 
laag risico is de voorspellende werking van de metabolieten alleen nog beter dan de basislijn 
nuchtere glucose. In Hoofdstuk 3.2 is een tweerichtings Mendeliaanse randomisatie (MR) 
in twee richtingen uitgevoerd om de causaliteit van circulerende metabolieten en T2D en 
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glucose te onderzoeken. Ik ontdekte 14 mogelijke causale associaties: tien metabolieten 
beïnvloeden nuchtere glucose, één beïnvloedde T2D en drie beïnvloedden door T2D: 
verhoogd totaal cholesterol, L-HDL-cholesterol, XL-HDL-cholesterol, L-HDL-vrij cholesterol, 
XL-HDL-vrij cholesterol, L-HDL-fosfolipide en XL-HDL-fosfolipide en XS-VLDL-fosfolipiden 
hebben een verlaagd glucosegehalte; S-VLDL-triglyceriden, S-HDL-triglyceriden en plasma-
triglyceriden verhogen de nuchtere glucose; lagere niveaus van twee alkyl-acyl 
fosfatidylcholines en een hoger niveau van alanine zijn waarschijnlijk het gevolg van T2D. In 
hoofdstuk 3.3 hebben we acht circulerende fosfolipidemoleculen geïdentificeerd die 
geassocieerd zijn met bloeddruk en een voorspellende waarde hebben voor incidente 
hypertensie. Er is een zeer sterke associatie van de geselecteerde fosfolipiden en 
triglyceriden, taille, taille-heupratio, glucose, totaal vetpercentage, BMI en leptine. Het 
genetisch verhoogde systolische bloeddrukniveau hangt samen met de toename van 
circulerend PE 40: 5 en PE 38: 3. De genetische varianten van de geselecteerde fosfolipiden 
zijn ook sterk gekoppeld aan HDL-cholesterol, subfracties en diameter, bloedcelaantallen 
(wit, rood en bloedplaatjes) en polsslag. 
Ten slotte heb ik in Hoofdstuk 4 een uitgebreide drug-metaboliet atlas gebouwd, 
met on-target en off-target effecten van medicijnen voorgeschreven in T2D en andere 
aandoeningen. Het bleef 1071 drug-metaboliet associaties na evaluatie van het effect van 
leeftijd, geslacht, body mass index (BMI), roken en co-behandeling. Met de genomics-
aanpak heb ik aangetoond dat cross-sectionele atlasgegevens informatie over toekomstige 
statine-effecten kunnen opleveren. Verder heb ik protonpompremmers gekoppeld aan 
circulerende metabolieten, leverfunctie gerelateerde variabelen, hepatische steatosis en 
het darmmicrobioom met data-integratie. Een web-gebaseerde bron voor visualisatie van 
de atlas (http://bbmri.researchlumc.nl/atlas/) werd ook opgericht.
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